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INTRODUCTION 
Osteoporosis is defined, by consensus, as a systemic skeletal disease. characterized by low 
bone mass and microarchitectural deterioration of bone tissue with a consequent increase 
in bone fragility and susceptibility to fracture,' It is well known that there is an important 
age-related decrease in bone mass and bone strength as witnessed by the exponential 
increase of hip fractures with age.2 Osteoporosis is primarily described in post-
menopausal women but men arc not free from it. and a quarter of the hip fractures 
occurs in men.3 
Osteoporosis and its direct consequences, fractures, are major concerns for public health 
since they arc associated with increased death rates and with substantial disability. 
:Moreover, they represent an important cost for the public health budget. 'TIle European 
Commission estimated in a recent report the cost of osteoporosis in the countries of the 
European Union at € 3.5 billion annually for hospital health care alone,4 and an American 
study estimated the total health care expenditure attributable to osteoporotic fractures in 
the United States at USS 13.8 billion (€ 12.4 billion) in 1995.' Without intervention, the 
improved life expectancy and the demographic evolution will cause the number of hip 
fractures worldwide to increase from around 1.7 million in 1990 to over 6 million in 
2050.6 Therefore, it can be expected that medical expenditure will also increase in the 
coming decades. 
Osteoporosis, defined as a reduction in bone mass below a specified threshold, has been 
shown to be a major determinant of fracture risk.7 Bone mass can be measured with 
sufficient accuracy and precision and it is currently the best available indicator of fracture 
risk, other than age and gender. There is, however, a considerable overlap of bone 
density values between people who develop fractures and people who do not.2 
The central goal of this thesis is to study the cost of osteoporosis and fractures in the 
Netherlands and to develop mathematical models for estimating fracture risk based on 
Dutch epidemiological data. These models are then used in simulations to analyze the 
effects of potential preventive measures against osteoporotic fractures. 'The most 
disabling of these is the hip fracture, but also wrist fractures and fractures of the 
vertebrae are considered as osteoporotic fractures. 8 Also from a cost perspective the 
importance of hip fractures appears to be overwhelming, and therefore the models focus 
is on hip fractures. 
Several treatments are currently available,2 but to design effective and cost~effective 
intervention strategies it is important to know who needs to be treated and when this 
should be done. Ideally, we would like to have long-term data from intervention studies 
to assess the effectiveness of different intervention strategies, but those studies would be 
unacceptably long especially when conside~ing hip fractures. :tv!oreover, when the results 
would finally be available they would most likely not be of interest anymore, since by 
then new prevention techniques would be more appropriate. 
For the development of clinical guidelines, decisions need to be taken now. To handle 
the existing uncertainties we choose a modeling approach . .i\tlodeling allows for the 
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simulation of reality but should be used with caution. It is important that the 
assumptions used arc reasonable and supported by the best available evidence. 
l."fost of the data used in the models described in this thesis were derived from the 
Rotterdam study, a large population based prospective cohort study of the occurrence 
and determinants of disease and disability in the elderly.9111e stud)' is conducted in 
Ommoord, a suburb of Rotterdam. It began in 1990, and 7983 men and women aged 55 
years and over underwent baseline assessments and arc followed-up longitudinally for 
several disease outcomes including fractures. In the domain of osteoporosis it is one of 
largest studies in the world, and one of the few that also include men. Additionail)" we 
have used information from other sources, including Dutch registration data, and data 
from literature. 
Part 1 of this thesis focuses on the basic epidemiological information and on information 
about the cost of osteoporosis and fractures. Chapter 1.1 is mainly a review of the 
information on the epidemiology and cost of osteoporosis and fractures that was 
available at the start of this research project in 1995. 
Chapter 1.2 takes a closer look at the impact of different fractures on the cost, and it 
gives some indications on how a more adequate discharge strategy might be a direct way 
for cost-containment. Additionally it discusses the potential impact of different 
intervention strategies. 
Chapter 1.3 describes a cost study that was performed within the Rotterdam Stud}' 
population. The aim of this study was to estimate incremental cost of medical care after 
hip fracture and first vertebral fracture. This was done in a nested case cohort design 
comparing the health expenditure in fracture patients to the costs generated in a control 
group that was comparable at baseline. 
Part 2 is devoted to the development and validation of risk estimation models for hip 
fractures. TIle conventional method of evaluating fracture risk is by bone densitometry, 
and the \'7orld Health Organization has even defined osteoporosis as a bone mineral 
density that is more than 2.5 standard deviations belo\v the average for young adults. \0 
Therefore, the models will be based on bone mineral density, age and gender. 
In chapter 2.1 a risk model is theoreticallr derived, mainly based on Dutch data. Such a 
model needs validation, and dus is done in chapter 2.2. Here, the risk model is validated 
for its use as a general risk stratification tool, using the fracture follow-up data from the 
Rotterdam Study. 
Finally, in chapter 2.3 the performance of this risk model is evaluated as a prognostic test 
for the prediction of hip fractures in the individual. The performance of the risk function 
is compared to the mere prediction by age and gender, and to the use of the conventional 
T-score and Z-score B}'JD thresholds. 
In Part 3, the previously developed short-term risk estimates for hip fracture are 
extrapolated to model the long-term hip fracture risk and the potential effects of 
inten'cntions to reduce this risk. For the purpose of this thesis, this was done for women, 
but obviously the modcls could also be applied to men. 
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In chapter 3.1, the short-term risk estimates are extrapolated to long-term and lifetime 
risks at different ages. In this chapter the design of the models and the input assumptions 
are discussed, and special emphasis is given to the uncertainties surrounding future bone 
mineral density in the individual. 
Finally, in chapter 3.2 theoretical intervention scenarios that aim at reducing the long-
term risk are modeled. Screening strategies are compared to a population approach 
considering effectiveness, but also with a focus on cost-effectiveness and the burden 
related to screening. By comparing different interventions, changing the age of 
intervention and taking into account the uncertainties about long-term bone mineral 
density evolution, the expected dynamics of the interventions are analyzed. This finaJl}' 
leads to a series of conclusions that define the context in which prevention strategies can 
become both effective and cost-effective. 
Part 4 concludes this thesis with a general discussion of the results, including suggestions 
for further research. 
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PART 1 
BURDEN OF ILLNESS OF OSTEOPOROSIS 

1.1 OSTEOPOROSIS IN THE NETHERLANDS: BURDEN OF 
ILLNESS 
This (hapter is al1 abbrew'aled I.'enion 0/ a report thaI/wI! pllblished as: De I.afl CEDH, Vall HOIII 
BA, Pols HAP Osteoporosis ill/he Nether/ollr/si A burden ojIllneS! sllf4Y. 1996 Ills/illlle for AIedka! 
Techn%J!)' AssfSJllJtnt, ROllerdalll. It was fe-edited for Ihis thesis dnd redundant details were omitted. 
The fitlf resH/ls (all be folll1d iii the origillal report. 
1.1.1 INTRODUCTION 
In this chapter, we an ovenTicw is given of the publicly available quantitative information 
about osteoporosis in the Netherlands, and of the costs associated with it. It is based on 
information that was available at the start of our research in 1995. Although the main 
subject is osteoporosis, the focus is on fractures, as these are clinically the most relevant 
outcome events. The data were collected from publicly available data sources and from 
international literature, Information is mostly about the year 1993 (the rejereJIre ),ear), but 
on a few occasions information from other years had to be used, \"'{!hen this is so, it is 
clearly indicated, No primary data collection was carried out for this chapter, except for 
the section on bone mineral density where recent data from the Rotterdam Study were 
used, Conversion of cost from Dutch guilders to Euro was done using the official 
conversion coefficient (2,20371 guilders for € 1), 
The information in this chapter was collected from the following data sources: 
Central Burea" for Statistics (CBS) 
The CBS l ,2 (Centraal Bureau voor de Statistiek) is the official Dutch organization that 
covers the national registration of a wide variety of statistics, including demography. 
registration of causes of death, etc, Some of this information is published in yearly and 
monthly publications, Other information, such as causes of death related to osteoporosis 
was specifically obtained from CBS for this study, 
Fo/wdaliol1 for Health Care Inforlllatioll (SIG) 
TIle SIGJ (Stichting Informatiecentrum voor de Gezondheidszorg) is a national registry 
collecting various health care related data, All of the hospital admissions in academic and 
general hospitals within the Netherlands are included in this registration as is most of the 
nursing home information, Both published information and files specifically obtained 
from SIG for the purpose of this study were used, 
Illftitlite for Medical 5 tat,""s (IMS) 
IMS4 is a company that collects data on health care use by sampling General Practitioners 
and 1kdical Specialists and asking them about the patient contacts they had within a 
given week. The reason for encounter, diagnosis, patient demographics, and therapy was 
recorded. Furthermore, data from pharmacies were sampled to estimate the actual sales 
of drugs, It is clear that, due to this sampling technique, this information can be expected 
to be less precise than the information from the previous data sources, 
7 
Osteoporosis and fracture prevention 
HOllie Health Care SerJlice Rotterdalll 
The Home Health Care Service Rotterdam5 (Ibuiszorg Rotterdam) collects information 
on all home health care activities in the city of Rotterdam. 1111S registration was used to 
estimate the use of home health care in the Netherlands, assuming that data from 
Rotterdam could be extrapolated to the whole of the Netherlands. 
Literature 
\Vhenever specific data for the Netherlands were lacking, data from the international 
literature were used for formulating assumptions. \\lhenever this is done, it will be clearly 
indicated in the text. 
In section 1.1.2 the epidemiology of osteoporosis and fractures will be described. In the 
subsequent sections, the use of health care, the mortality and the medical cost of the 
treatment of osteoporosis and fractures \vill be covered. To take into account the 
uncertainties surrounding the cost estimates, we \'\-rill present a minimal and a maximal 
estimate. \'('hen, due to the unavailability of data, assumptions were made in the original 
report that could be compared to data that became available afterwards, this will also be 
mentioned. 
1.1.2 THE EPIDEMIOLOGY OF OSTEOPOROSIS AND FRAcruRES 
Delllograpl!) 
As in most \'{festern countries, the population of the Netherlands is aging. TIle size of the 
population increased from 10 million to 15 million in the period 1950-1990 mainly due to 
the post-war baby boom. At the same time there was a gradual increase in the proportion 
of elderly people. Over the next decades this latter trend will continue. The Dutch 
population is primarily white Caucasian, and the incidence of osteoporosis is known to 
be different in other races. No ethnic specific information about osteoporosis is available 
for the Netherlands. 
The Netherlands Central Bureau of Statistics (CBS) produces, on a regular basis, 
forecasts to predict the future composition of the population. Those forecasts are known 
as the high, medium and low variant, but their basic assumption is that there will be no 
drastic changes in neither behavior, policy, (medical) technology and that there \\rill be no 
major catastrophes. It is what is called a Jlllpn'Jelree forecast. The forecasts are based on the 
trends from the near past. 'TIle CBS forecasts are updated each year, on the basis of the 
latest developments. For this chapter, we used the 1994-2050 forecast. 6 
Different variants of these forecasts are published. TIle medium variant is the most likely 
development. In the low variant birth rates as well as immigration and divorce rates are 
lower, while mortality, emigration and marriage rates are higher. Opposite assumptions 
are used in the high variant. In the elderly population of interest in this chapter, however, 
the difference between the several variants is very small. These persons are born, and 
only changes in mortality rates and migration effects their numbers. 
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BOlle llJineral de11Sily and the defillition of osteoporosis 
TIle bone mineral density (B~JD) reference data in this chapter come from the first 
phase of the Rotterdam Study that was conducted between 1990 and 1993. Baseline 
B~'ID measurements (Lunar DPX-L densitometer) were performed in 5814 ambulatory 
subjects (2446 men) aged 55 years and more. 70S 
Osteoporosis was defined by the \'\forld Health Organization as a bone mineral density 
(BMD) of 2.5 SD below the mean for young adults,? while a BMD between -2.5 SD and 
-l SD was defined as osteopenia. This number of standard deviations under the mean 
for young adults is referred to as the T-score. To determine the reference BNID for young 
adult women, we used a study on BMD and age in Dutch women by Erdtsieck et aI .. 10 In 
this relatively small study, the average B~'ID was 1.01 g/ cm2 for women aged 20-40 years 
of age. \\Iith a SD =0.134 g/ cm2 that is the same at all ages,S threshold values are 0.675 
g/cm2 for osteoporosis, and 0.876 g/cm2 for osteopenia. 
Table 1 lists the prevalence of osteoporosis and osteopenia at different ages when these 
threshold values are applied to the Rotterdam Study. For men, no corresponding Dutch 
reference values were available. Therefore, the same threshold values were used, since it 
was felt that the absolute HMD level is more important for fracture risk than the relative 
level. 
Table 1: Pretla/mce of osteoporosis and osteopenia at difftrmt ages ill the RotterdallJ Stfl{fy 
Women 55-59 60-64 65-69 70-74 75-79 80-84 >85 
Osteopenia 42% 47% 50% 53% 53% 53% 50% 
Osteoporosis 7% 10% 13% 18% 23% 29% 37% 
Men 
Osteopenia 
Osteoporosis 
32% 
3% 
35% 
4% 
38% 
5% 
41% 
6% 
43% 
7% 
46% 
9% 
48% 
ll% 
It should be remembered that these threshold values are arbitrary. {,,{oreover, the bone 
densitometers are shipped with manufacturer specific reference values. In the Lunar 
DPX-L densitometer, the default reference values are those for the USA Femur 
Reference Population, ages 20-45. Here, a T-score of -2.5 corresponds to 0.681 g/cm2 
for women, which is very similar to our estimate, but to a threshold of 0.769 g/cm2 for 
men, which is much higher. Using those values, similar results are obtained for women 
but for men the prevalence rates are much higher (table 2). 
TabJe 2: PrcwtleIJce of osteoporosis alld osteopellia in /JIeIJ at dif/erellt ages IIsillg the tbresholds fro/JI the 
Lllllar DPX-L, USA H.e(erelJce popu/atioll in the Rotterdam St/ldy 
Men 55-59 60-64 65-69 70-74 75-79 80-84 
Osteopenia 
Osteoporosis 
Hip fractllres 
47% 
15% 
48% 
18% 
49% 
21% 
50% 
24% 
50% 
28% 
49% 
32% 
>85 
48% 
36% 
In the Netherlands, virtually all persons with hip fractures are treated clinically. 
Therefore, hospital data give an accurate view of the incidence of hip fractures. Data for 
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hip fractures in 1993 were collected from SIG hospital registration data. A specific file of 
all hospital admissions for hip fracture was obtained and analyzed. 
In 1993 there were 15.107 hospital admission for hip fracture in the Netherlands (3882 in 
men). In figure 1. these absolute numbers of fractures were combined with the age and 
gender distribution of the 1993 Dutch population to calculate the hip fracture incidence 
in men and women.2 
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.:; 4000 0 
..... 
...... 
., 
3000 --Women <.i 
= ~ --Men 
.~ 
<.i 
.S 2000 
... 
'" ~ 1000 
i!l 
0 0 
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Figure 1: Hip fm(/"re i"rideJJ(e i/J the Ne/her/(mds i/J 1993 per 100.000 
Hip fracture incidence data from 1972 till 1987 for the Netherlands were published for 
men and women aged 50 years and older. lI Those data were based on the same (SIG) 
hospital registration source. Hip fracture incidence was age-adjusted by direct 
standardization. To compare the 1993 data with the published data. we obtained the 
standard population for the standardization in the same way as in this study by 
Boereboom et al. (summation of the Dutch population for the calendar years 1972-1987). 
W/hen we added the 1993 data to the previous analysis the significant upward trend that 
was described previollsly was confirmed. In women. the age standardized hip fracture 
incidence, that increased from 249/100.000 in 1972 to 345/100.000 in 1987, reached 
371/100.000 in 1993. For men, the increase was from 105/100.000 in 1972 over 
150/100.000 in 1978 to 168/100.000 in 1993. This trend was highl), significant in both 
men and women (p<O.OOI). Trends in age-adjusted hip fracture incidence in the 
Netherlands in men and women aged 50 years and older are given in figure 2. The 
strange peak in the 1979 data remains unexplained, and may be due to a data artifact in 
that year. 
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Figure 2: Trmd ill age (l(!Jilfted hip jrartllrf il/cidence i1l the Nether/al/ds per 100.000 
Apart from this important age-adjusted upward trend, it is expected that the total number 
of hip frachlres in the Netherlands will also increase due to the demographic changes 
with the aging of the population. In figure 3 the current age specific hip fracture rates 
were applied to the population forecast figures, showing that the total number of hip 
fractures ,vill double by the year 2050 due to demography alone. 
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Figure 3: Expected )'earfy !lilli/bel' 0/ Np jrartlll'fS i11 the Netlml(wds dtle to demographic ch(lI/gn 
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Other fracttlres 
Dlflrh data for other/ractlfres 
Although hip fractures are the most serious consequences of osteoporosis, other 
fractures also occur. Those arc mainly fractures of the vertebrae and the forearm.1 2 1\:10st 
frequently, those fractures do not require a hospital admission and are treated either in an 
outpatient setting or, in the case of vertebral fractures, arc often not treated at all. \V'hen 
looking at the hospital admissions for fractures other than the hip, we observed smaller 
numbers and we miss the typicalJ}1 high percentage of persons over 65 years of age. 
Furthermore, we did not observe the typically high female/male ratio of fractures. 
Therefore, it seems that those hospital admission data are not reflecting the osteoporosis 
related fractures, and that they cannot be lIsed to estimate the incidence of osteoporosis 
related non-hip fractures. 
Since, at the moment of writing this report in 1995, no reliable data for osteoporosis 
related non-hip fractures in the Netherlands \vere available, we were forced to use data 
from the international literature. In 1998, hO\vever, incidence data for wrist fractures 
became available from the Rotterdam Study. U 1110se data largely confirmed the 
assumptions that were made here based on American incidence data. 
Iu/cma/iolJai data for other/rae/lfres 
j\Ielton et al., in an 1992 oven,iew article,14 presented incidencc figures for hip, wrist, and 
vertebral fractures in men and \vomen in Rochester, ~Jjnnesota. Although those data 
should be used with caution, since the incidences refer to different time periods and the 
vertebral fractures only refer to clinically diagnosed fractures, they appeared to be the 
best available estimates. \Y/e choose to use clinically diagnosed vertebral fractures, since 
there is some debate about how to define radiographic vertebral deformities. Different 
techniques of measurement and different criteria can produce varying results and varying 
frachlre rates. 15,16 Additionally, clinically diagnosed vertebral fractures can be expected to 
be morc relevant to cost. 
\X'hen we compared the Rochester incidence data for hip fractures with the registration 
data for the Netherlands in 1993, they appeared to be remarkably similar. Therefore, \ve 
assumed that we could also usc these Rochester data to estimate the number of non-hip 
fractures in the Netherlands, although we arc aware that time trend, and incidence might 
be different. TIle upward time trend in the hip fracture incidence for example appears to 
have stopped in several countries, including the US. 17 
Based on this information we estimated for the Netherlands an annual number of 14.500 
wrist fractures, and 15.000 vertebral fractures that came to clinical attention, 
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1.1.3 HEALTH CARE UTILISATION ASSOCIATED WITH OSTEOPOROSIS 
AND FRACTURES 
PharlJlacotherapy 
The use of drugs for the treatment and prevention of osteoporosis was estimated based 
on IMS data. lbe total figures were adjusted for the estimated proportion of the drug 
that was used for osteoporosis. Since presentation and dosage can differ from one 
prescription to another, data were recalculated to estimate patient-years of treatment. The 
cost of pharmacotherapy is included in the bottom-up cost assessment given in section 
1.1.5. 
Hosp;ta! ad/l/;ss;ol/f for hip fmctllres 
Hospital admission data were collected from the SIG hospital registration dat."1. \V,le used 
the same file of hospit.'11 admissions as used for estimating the hip frachlre incidence. 
The mean length of stay (LOS) was 26.03 days, with a standard deviation of 29 days. The 
distribution of the LOS was highly skewed and an association with age and gender was 
observed. Mean LOS in men was 23.7 days; mean LOS in women was 26.8 days 
(p<O.OOl). l ... Iedian LOS was 16 days for men and 19 days for women. 
After the acute episode, women were discharged more often to a home for the elderly or 
to a nursing home than men. Some of these patients were probably already a nursing 
home resident at the moment they suffered a hip fracture. but no infonnation is available 
about this. In men the crude in-hospital mortality was almost twice that of women. The 
trends in discharge status are also strongly age dependent as can be seen in figures 4 and 
5. 
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Hospilal admissioJls for olherjractllJ'CS 
For other fractures, only data for 1992 were readily available. IS As mentioned before, we 
need to be cautious while interpreting those data. These hospital admissions do not seem 
to reflect the typical osteoporosis related fracture pattern such as a high female/male 
ratio, and might be more related with high energy trauma. J\.[ost people with those 
fractures were indeed treated as out~patients. Therefore, the cost associated with those 
hospital admission will only be included in the ma..ximum cost estimate in section 1.1.5 
T\TllniJlg hOllJe can (fIJII care alld dc!) care) 
Data for nursing home care were obL'lined from the SIG data source. Data were 
collected for both full care as for day care in nursing homes. Data collection was 
relatively complete but less so than for the hospital admission data. Infotmation was 
available for 89.9 % of nursing homes, cotTesponding to 92.8 % of the 'solllatic' beds and 
91.2 % of the 'p[),chotPiatJic' beds. Overall information was available from 92 % of the 
nursing home beds,19 'Jnd patients with fractures were mainly (98%) treated in the 
somatic nursing home wards. To obtain a more accurate estimate of the absolute 
numbers for the Netherlands, we adjusted for this. In addition to the published data, files 
of all 1993 discharges (full care and day care) with admission diagnosis of hip- or other 
fractures were obtained and analyzed. 
Full care 
\,\'hen antllyzing the total population of people in nursing homes, the proportion of 
people with admission diagnose of fracture seems to be relatively stable. Two cross-
sectional views at specific da}'s were compared; one from our data analysis, the other 
from the published data. Admissions due to fractures accounted for 8.7 % of the 
population of nursing homes. Over 80 % of these were admitted for hip fractures and its 
sequels. 
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\Yie estimated that in 1993,4588 persons were treated every day in nursing homes for all-
fractures. Of those, 3702 were treated for hip-fractures and its sequels. 
It \vas important however to consider that some of the patients might also have been 
admitted without a hip fracture because of co-morbidity, while the hip fracture event was 
only the precipitating factor. Therefore, we analyzed the length of stay and the discharge 
status. 
The average length of stay was approximately the same for both genders: 238 days 
(SO=553) for men and 241 days (SO=553) for women (p=0.85). Median LOS was 67 
days for men and 70 days for women. The high mean LOS and its high standard 
deviation were explained by the relatively large group of people that stayed extremely 
long (up to 21 years). It was hypothesized that those long stays in nursing homes cannot 
solely be attributed to the hip-fracture but must largely be due to co-morbidity leading to 
a more dependent state. 
The majority of patients \vere discharged within 3 months. \\;then those people that 
stayed up to 3 months in the nursing home were considered separately, the average LOS 
were 41.6 days (SO=23.6) for men, and 44.0 days (SO=22.4) for women (p=0.02). 
\'\'hen looking at discharge status, we again analyzed those people that stayed for a 
shorter period separately from those that stayed longer. The majority ofpeople that 
stayed more than one year in a nursing home, stayed there until they died (over 80 % in 
both men and women and for all diagnosis groups). 
Those persons who stayed for less than one year had a completely different discharge 
pattern. In general, about 60 % of the people admitted to a nursing home stayed there 
for a maximum of 3 months. Over 70 % of those returned home afterwards, 8.6 % died 
in the nursing home. The rest went primarily to homes for the elderly, or to a lesser 
degree to day care. 
Por longer stays, the discharge status changed: gradually more people were dying and less 
people were going home. At 4 months LOS the percentage going home dropped to 54.8 
%, after 5 months to 34.6 %. These persons with longer stays clearly represented a more 
dependent group of people, with more concomitant illnesses. Based of the length of stay 
and discharge patterns, we hypothesized that only the first few months of stay in a 
nursing home represented the direct effect of osteoporosis and fractures. TIlerefore, we 
included only the cost of the first three months of stay in the nursing home in the 
calculation of costs in section 1. I .5. 
Day care 
\\Ihen analyzing the total population of people in day care, the proportion of people with 
admission diagnosis of fracture again seemed relatively stable. Two cross-sectional views 
were compared, one from our data analysis, the other from published data. I '} Admissions 
due to fractures accounted for 3.1 % of the population in day care. About 85 % of these 
admissions were for hip fractures and its sequels. 
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Applying the same adjustment as before, we estimated that in 1993, 239 persons per day 
were treated in day care for fractures, and 201 for hip-fractures and its sequels. 
The average length of stay was 20 I days (SD=416) for men and 151 days (SD=215) for 
women (p=O.27). i\kdian LOS \vas 86 days for men and 97 days for women. The high 
averages combined with a high standard deviation (especially in men), were explained by 
the relativel)T large group of people that stayed long in day care. 
Again, we estimated the total number of day care days on the basis of the registered 
nursing home days and by applying the same adjustment as before. 
Olltpatiellt care 
Outpatient care was not systematically registered in the Netherlands. For General 
Practitioners, there arc series of surveys, but those deal primarily with the typical GP 
pathology and they do not allow to estimate the fracture- or osteoporosis-related number 
of contacts. For the assessment of thc direct cost of outpatient care, we used published 
. " cost estimates. 
HOllie health care 
'I11e number of clients of home health care and the number of contacts was estimated on 
the basis of data available for the Rotterdam district. No specific information was 
available on clinical indication for home health care. To estimate the maximum possible 
home health care consumption for hip fractures in the Netherlands, we used the number 
of patients that went home after discharge from hospital. Next we assumed that they all 
needed home health carc. \Vie concluded that at the maximum about 5 % of the total 
home health care cost could be allocated to hip fractures. 
1.1.4 MORTALITY ASSOCIATED WITH OSTEOPOROSIS At'JD FRACTURES 
Osteoporosis related mortality is due to fractures, mainly hip fractures, and mortality 
following hip fractures is indeed high and age dependent.21 Attributing death to fractures, 
hO\vever, is not easy. Hip fractures may be associated with death in various ways and 
official death certification does not necessarily reflect the underlying cause. 'nlerefore, 
official death certification is not sufficient to indicate the real death toll of osteoporosis. 
In fact, the numbers from official death certification, combined with the number of hip 
fractures in the Netherlands, even show a lower mortality rate after hip fracture than in 
the population at large. Therefore, we also used our data about in-hospital mortality and 
published mortality data from a follow-up study in the Netherlands.22 
\\!e absenTed an overall in-hospital mortality of 10.1 % for men and 5.9 % for ,vomen. 
This in-hospital mortality was strongly age dependent, rising from almost non-existent at 
younger ages to 22% for men and 10 % for women in the highest age group. rvlortality in 
men was twice as high as in women for all age groups. 
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\Y/e cannot correctly assess mortality after the hospital stay from our data, although we 
do present some information on mortality in nursing homes. For a better idea of dle 
mortality after hip fracture, we need follow-up data. Boereboom et a1. studied 493 
patients with a hip fracture during the period 1982-1984 in three hospitals in Utrecht.22 
In-hospital mortality \vas similar to our findings with 9.1 % of the patients dying during 
hospital admission. One year after the hip fracture, 23.6 % of the women and 33 % of 
the men had died. 
111is study also showed that mortality was highest during the first 8 weeks after the hip 
fracture and strongly age and gender dependent. The relative risk of dying for men was 
1.9 (95% CI 1.4-2.5) compared to women. Concomitant illness and hospital 
complications were also related to mortality. \X!hen looking at the official cause of death 
mentioned on the death certificate, it was found that in only 19 % of the women and 25 
% of the men, hip fracture \vas mentioned as cause of death. Although mortality after hip 
fracture was strongly increased in the months following the event, especially in men, one 
should be careful not to attribute all of this excess mortality exclusively to the hip 
fractures, Patients with a hip fracture often had concomitant illnesses and a poor general 
condition. This condition in itself can increase the risk of falling and the perioperative 
risk. 
J.1.5I1lEDICAL COSTS ASSOCIATED WITH THE TREATEMENT or-
OSTEOPOROSIS AND FRACTURES 
To assess the medical cost of osteoporosis and fractures, we used two separate 
approaches. In the first (top-down approach) we used published Dutch cost estimates for 
hip, forearm and vertebral fractures. Those estimates were combined with our incidence 
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figures. In a second approach (bottom-up), the detailed costs of medical consumption 
related to osteoporosis and fractures were calculated, based on the medical consumption 
described in this chapter. 
Top-dom} approach 
In a 1993 i:r.-1TA report, Al et al. estimated the cost of hip, vertebral and forearm 
fractures. 2o Costs for hospital treatment, complications, home care, physiotherapy and 
GP visits were estimated, and these cost estimates are listed in table 3. Nursing home 
care, hO\vever, \vas not included in this estimate, since it was argued that the fracture very 
often was the trigger, rather than the cause of the admission to a nursing home. 'TIle 
demand for home health care was used as a proxy for the additional help needed. For 
vertebral fractures, we used the cost for cHnicallr diagnosed fractures, since the incidence 
figures only reflected this category of vertebral fractures. 
Table 3: Estimated costs of fractll!t'S in the Netherland?] 
Hip fracture € 100400 
Vertebral fracture € 1.041 
Forearm fracture 
€ 844 
These costs were applied to the estimated 1993 incidence figures for the Netherlands. 
For this part of the analysis, only fractures at the age of 50 and older were considered, 
the age of 50 being an arbitrary cut-off point for osteoporotic fractures. The resulting 
global estimates arc given in table 4. 
Table 4: Global esfliJlated )'ear!y costs for hip, t'utebml and forem"IJI jract/IJ"fS ill the l\Telher/(wds 
(million €) 
Hip fracture 
Vertebral fracture 
Forearm fracture 
Total 
Bottom-lip approach 
149.52 
15.81 
12.23 
177.56 
In this bottom-up approach, the analysis was again limited to individuals aged 50 years 
and older. The choice of the costs corresponding to one day of hospital stay, one 
contact, etc. \vas based on the Dutch guidelines for cost calculations in health care.:n 
Pharmacotherapy 
The cost per person-year was calculated based on cost information in the 
Pharmacothempwtisch kompm,24 and on the recommended dosage. 
Hospital admissions for hip fractures 
To assess the direct cost of hip fracture hospital admission, the number of hospitalization 
days for persons over age 50, were combined with an average daily price for 
hospitalization of € 351. 
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Hospital admissions for other fractures 
Hospital admission for other fractures can only be estimated from 1992 data. ls \X'e only 
had the proportion of people aged 65 and older. Thereby, we disregarded the patients 
aged between 50 and 64 leading to an underestimation. On the other hand, these data 
also included fractures that where not osteoporosis~related, leading to an overestimation. 
For the reasons mentioned in the corresponding section, it is unclear whether or not 
those figures should be included in an estimate of the cost of osteoporosis. \'\'e included 
them here for reasons of completeness in the maximum cost estimate. 
Average length of stay in 1992 for those fractures that led to a hospital admission was 5.7 
days for forearm fractures and 17.2 days for vertebral fractures. 211 
Nursing home care (full care) 
Including all nursing home patient days after a fracture would lead to an overestimation 
of costs. A fracture can be the trigger that changes a borderline independent state into a 
dependent state of life, for people who \vould anyhow be admitted into nursing home 
care. As argued in the chapter on nursing homes, we only considered the first three 
months of stay in a nursing home in the calculation of the cost. It should be clear that 
using the cut-off point of 3 months was an arbitrary choice based upon the arguments 
developed in the discussion on length of stay and discharge status. 
An average daily price for nursing home care of € 95 was used. 
Nursing home care (day care) 
For the same reason as with the nursing homes, only the first 3 months of day care were 
included in the calculation of the cost. An average daily price for day care of € 55 was 
used. 
Outpatient care 
No hard data on the outpatient care for osteoporosis related fractures were available for 
the Netherlands. In the absence of those data we used the assumptions for outpatient 
care from Al et a1.20 that \verc also used in the top-down approach. 
For hip fractures, it was assumed that patients had on the average 2 GP visits after the 
discharge from hospital and that 50 % of the patients had an average of 12 trcaUnent 
sessions by a physiotherapist. 111is leads to a global outpatient care price of € 145 per hip 
fracture. 
For l'tltebral fractllres, it was assumed that 5 out of 6 of the total number of clinically 
diagnosed patients were treated by the GP. 5 GP visits, one specialist visit (including an 
X ray) and 12 treatment sessions by a physiotherapist were assumed with a total cost of 
€ 546, leading to an outpatient cost of € 455 per vertebral fracture. 
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For forearm jrflctlll"eS, it was assumed that 95 % of patients were treated in the outpatient 
clinic with a total cost of € 752. This leads to a cost per forearm fracture of € 715. 
Home health care 
Based on the assumptions made in the chapter on Home health care, we calculated the 
lIJaxillJ/flJl possible cost for home health care related to hip fractures. In order to do so, 
we used a price of € 25 per contact. 
Overview of the bottom-up approach 
In table 5, we present an overview of the estimated yearly cost, with and \vithout the 
maximum estimates, using this bottom-up approach. 
Table 5: Detailed 0/"e11liell' cf the estillJated cost cf osteoporosis and the treatllJeJJt cf jrarlllres il1 the 
Nether/ands ill 1993 (lIJillion €) 
Pharmacotherapy 
Hospitalisations hip fractures 
Non-hospital inpatient care (full care) 
Day care 
Outpatient care 
Total (excluding maximum estimates) 
I-lospitalisatiollS otherjmrtlllrs (maXiIJlfllll estimate) 
HOlIJe health (are (tJJaxlilJlIIlJ estillJate) 
Total (inclllding lIJaximulIJ estiJlJates) 
1.1.6 CONCLUSIONS 
EpidellJiology 
Estimated yearly 
cost 
7.09 
133.77 
36.80 
1.66 
19.36 
198.68 
7.10 
5.17 
212.15 
Osteoporosis and fractures are a major source of illness and health care costs in the 
elderly, both today as in the foreseeable future. Especially the most serious consequence, 
hip fracture, is frequent and the incidence is increasing. Both in men and \VotIlen, the 
incidence increases exponentially with age. r..kn reach the same hip fracture incidence at 
an age 5-6 year older than women, and for instance a 30-year-old male has the same hip 
fracture risk as a 75-year-old female. 
The total number of hip fractures will inevitably rise if no serious preventive strategies 
are developed. An upward time trend in age-adjusted hip fracture rates, as well as the 
aging of the population are responsible for this. Several possible explanations for the 
upward trend have been suggested, such as the decreasing physical activity and sedentary 
lifestyle, nutrition, or even the fact that people are growing tailcr than before. In the US, 
Sweden, and thc UK, this upward trend of age~adjusted hip fractures seems to have 
leveled off,I7 In other regions such as Hong Kong and, as we showed, also in the 
Netherlands, the rates are still increasing. \X/hile it is difficult to predict the further 
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evolution of this trend, the aging of the population is certain. Even when current 
incidence rates remain stable in the future, the total number of hip fractures in the 
Netherlands will double by the year 2050 to over 30.000 per year. \\lhen the current 
upward trend continues, this number will be even higher. 
\\le did not have Dutch incidence data of other fractures, and \ve derived incidence rates 
from international data. The accuracy of these estimates is likely to be poorer, but, since 
we focus on cost and personal illness burden, these fractures appear to be less relevant in 
this context. Recent incidence data from the Rotterdam Study, however, are similar to 
the estimates used in this chapter. 
Health care IItilizatioJl 
Osteoporosis and fractures arc an important cause of health care consumption. Hip 
fractures lead to long hospital stays with a mean length of stay of 26 days. Forearm and 
vertebral fractures are most frequently treated in an outpatient setting. People over age 
85, representing less than 2 % of the population nevertheless are responsible for over 
one third of the hospitalization days for hip fractures. This is due both to the exponential 
increase of hip fracture with age, and to the longer length of stay. \\lith an aging 
population this proportion is highly likely to increase. 
After the acute phase and the hospital stay, nursing home care is often needed. Using 
hospital data, \ve see that 21 % of mcn and 27 % of women arc discharged dircctly into 
nursing home care. TIlis difference can partly be explained by the higher in-hospital 
mortality of men. In the JI/lrsing home data we see a similar number of men being admitted, 
meaning that they are mainly discharged from the hospital into nursing home care 
directly. For women, however, more were ultimately admitted to nursing home care 
(about 33 % of the hip fractures). Apparently, some of the women return to their homes 
first, but are afterwards transferred to a nursing home. Nursing home stays can be very 
long, but the majority of patients leave the nursing home within 3 months. In our cost 
estimates, we assumed that stays longer than 3 months were not only related to the hip 
fracture, and that pre~existing co-morbidity was important. W/c used the same approach 
dealing with day care cost. 
Other health care consumption is home healthcare and outpatient carc. Hard data about 
those activities \vere scarce and we made an attempt to estimate them using indirect 
information. Their contribution to the total cost of osteoporosis is substantial but 
secondary to hospital and nursing home cost. In 1993, drug use for osteoporosis 
prevention and treatment was also relatively unimportant for the total cost. 
l'JortalitJ' 
Although hip fractures occur less frequently in men, their mortality after a hip fracture is 
more important. \\'C found an in-hospital mortality that is twice that of women. Ivlortalit:y 
was also strongly age dependent and related to concomitant illnesses and in~hospital 
complications. Published follow-up data showed that mortality after hip fracture is 
strongl), elevated in the first few months following the event,2!.U but the available data 
for the Netherlands did not allow a more precise estimate of the duration of dus excess 
mortality. 
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One should be careful not to attribute exclusively all of this excess mortality to hip 
fractures. Patients with a hip fracture more often had concomitant illnesses and a poor 
general condition. This condition in itself can increase the risk of falling and the 
perioperative risk. This situation can also impair the rehabilitation after treatment and 
hamper mobilization. 
lHedical (osts 
In this stud}' we estimated the direct cost associated \\~th fractures at older age. TIle 
majority of these fractures were osteoporosis related, but not all. A clear indication of the 
fact that most of these fractures are osteoporosis related is found in the observation that 
incidence increases exponentially with age. It is not possible to differentiate between 
osteoporotic fractures and non-osteoporotic fractures but we believe that the impact of 
the latter category is small. 
TIle cost of osteoporosis is mainl)' the cost of hip fractures. It is tIus cost we could 
determine most accurately. In comparison, the cost of other fractures and the current 
cost of pharmacotherapy for the treatment and prevention of osteoporosis is low. \"X'e 
used two approaches to estimate the global yearly cost of osteoporosis and fractures in 
the population aged 50 and over. The results of both the top-down and the bottom-up 
approach are comparable, and indicate a yearly cost between € 175 million and € 210 
million. The main difference between both approaches lies in the cost of nursing home 
care (non-hospital inpatient care). Nursing home care was not included in the top-down 
approach. In the bottom-up approach, we assumed that only the first three months of 
nursing home care should be attributed to the fracture, the remainder being due to co-
morbidity and frailty. 
'TIle medication cost of osteoporosis was difficult to ascertain, and the validity of the 
U"fS data is unclear. It was however the only currently available source. It appears that 
the cost of medication was minor, compared to the cost of clinical treatment of the 
fractures. 
\"X'e did not include indirect costs as osteoporosis mainly affects the elderly and their 
production losses can be neglected. 
W/hen comparing these costs with international figures, we found both higher and lower 
estimates. 17 Several studies indicate a cost of USS 7 - 10 billion for the United States,17 
resulting in a yearly cost per capita of € 20 - 30 for osteoporosis and hip fractures. Our 
maximum global cost estimate is equivalent to about € 15 per head of the population. 
The US estimates ho\vever did include the indirect costs that we choose not to include. 
Estimates for France,17 for example, were much lower with a global cost of PF 3.5 
billion (€ 500 million) and a per capita cost of € 9. 
REFERENCES 
I Centr<1al BurC<1U voor de Statistiek (CBS). Postbus 4000, 2270 JM Voorburg. 
2 Swistisch Jaarboek 1994. Voorburg: CBS, 1994. 
22 
1.1 Osteoporosis in the Netherlands: burden of illness 
3 Stichting Informatiecentrum voor de gezondheidszorg, Maliebaan 50, 3508 SC Utrccht. 
4 Institute for Medical Statistics. 
5 'Ilmiszorg Rotterdam. Coolsingel 75, 3012 AD Rotterdam. 
6 CBS, CBS-Publikaties: j\faandstatistiek van de bevolking,Januaf)' 1995. Results Population and 
Household Forecasts 1994. 
7 Burger H, van Daele PL, Alg[a D, et al. The association between age and bone mineral density in men 
and women aged 55 years and o\'er: the Rotterdam Stud),. Bone Miner 1994;25:1-13. 
8 De Laet CEDH, Van Hout BA, Burger H, Hofman A, Pols HAP Bone density and risk of hip fmcture in 
men and women: cross sectional analysis. Bt-I] 1997;315:221-225. 
9 Kanis JA Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: 
synopsis of a \'\'HO report. Osteoporos Int 4 1994;4:368-381. 
10 Erdtsieck RJ, Pols HA, Algra D, Kooy PP, Birkenhager JC. Bone mineral density in healthy Dutch 
women: spine and hip measurements using dual-energy X-ray absorptiometry. Neth] Med 1994;45:198-
205. 
11 Boereboom JiT, de Groot RR, Raymakers )A, Duursma SA. The incidence of hip fractures in The 
Netherlands. Nelh] Med 1991;38:51-R 
12 Seeler DG, Browner \Xrs, Nevitt Me, Genant HK, Scott ]C, Cummings SR. Which fractures are 
associated with low appendicular bone mass in elderly women? 'llte Study of Osteoporotic Fractures 
Research Group. Ann Intern Med 1991;115:837-42. 
13 \'<'eel AEAM, Burger H, De Laet CEDH, Hofman A, Vall Leeuwen )PTM, Pols HAP. Fractures in 
Elderly Men and Women: Incidence and Association with Bone J\fineral Density (submitted) 
14 Melton L3, Chrischilles EA, Cooper C, Lane A \X', Riggs BL. Perspective. How many women have 
osteoporosis?] Bone l\finer Res 1992;7: to05-1O. 
15 Kanis ]A, ;'I.fcCloskey EV. Epidemiology of vertebral osteoporosis. Bone 1992;13:S1-1O. 
16 Black DM, Palermo L, Nevitt MC, et al. Comparison of methods for defining prevalent vertebral 
deformities: the Study of Osteoporotic Fractures. J Bone Miner Res 1995;10:890~902. 
17 Melton L3. Hip fractures: a worldwide problem today and tomorrow. Bone 1993;14:S1-8. 
18 SIG Zorginformatie,]aarboek Ziekenhuizen 1995, ISBN 90-70755~36-X 
19 SIG ZorginforOlatie,Jaarboek Verpleeghuizen 1992, ISBN 90-70755-37~8. 
20 instituut voor Medische Technology Assessment, At l\IJ, van I-Iont BA, Duursma SA. Kosten en 
effeeten van Didronel profylaxe, ii\ITA 93.25. 
21 Schroder I--L\I, Erlandsen M. J\ge and sex as determinants of mortality after hip fracture: 3,895 patients 
followed for 2.5-18.5 years.] Orthop Tralllla 1993;7:525-31. 
22 Boereboom FT, Rarmakers JA, Duursma SA. Mortality and causes of death after hip fractures in The 
Netherlands. Neth) j\fed 1992;41:4-10. 
23 Stuurgroep Toekomstscenario's Gewndheidszorg, Kostenberekening bij Gezondhcidsonderzoek, 
Richtlijnen voor de praktijk, ISBN 90-6224-320-7. 
2·~ Centrale 1Icdische Pharmaceutische Commissie van de ZiekenfondsRaad, Pharmacotherapelltisch 
kompas 1994, ISBN 90-70918-to-2. 
23 

1.2 COSTS OF OSTEOPOROSIS RELATED FRACTURES IN 
THE NETHERLANDS: POSSIBILITIES FOR COST 
CONTROL 
This (hapter is tl lralls/alioll oj al/ mtirle pllblished as: De Lad CEDH, Vall Houl BA, HpJ/till AJ 
Pols HAP. KosleJJ wegms oSleoporolisrhe Jmd/IJ"e1J iu Nededand; l//oge/[ikhedeJ1/-'Oor kosfenbeheersing. 
Ned Tijdschr Gwmkd 1996;140:1684-8 
IN'mODUCflON 
Osteoporosis-related fractures are a major problem for public health, both because of the 
health consequences for the individual patient as for the high costs related to the 
treatment of these fractures. The most serious fracture is the hip fracture. Besides this, 
also wrist fractures and fractures of the vertebrae are considered as osteoporotic 
fractures. n·loreover, most other fractures in elderly people are also, at least partially, 
associated with a low bone mineral density (En'lD).! 
TIle direct medical cost attributed to osteoporosis was estimated at more than 10 billion 
USS (€ 9 billion) in the USA.2 The further aging of the population will cause a strong 
increase of these costs if current policy is maintained. J\foreover, in several countries, 
including the Netherlands/an age-adjusted increase is observed in the incidence of hip 
fractures. 
The aim of this study \vas to evaluate the direct medical costs of osteoporosis-related 
fractures in the Netherlands. Additionally, based on the cost distribution, the potential 
effect of different intervention strategies \vas evaluated. 
DATA AND METHODS 
As a rule, data from 1993 were used in this analysis. 'I11e analysis was restricted to 
fractures of the hip, the forearm and the vertebrae in men and women age 50 years and 
older. The validity of the assumptions was examined and their influence on the costs 
was evaluated by sensitivity analyses. 
Demographic data from the Central Bureau for Statistics were used.4 The incidence of 
hip fractures was estimated based on detailed registration data of hospitalizations 
(Landelijke f..'fedische Registratie, L\fR) registered by the SIG Zorginformatie.5 Dutch 
incidence data for frachlres of the forearm and of the vertebrae were not available. To 
estimate these, incidence data from the USA/ were projected on the Dutch age 
distribution. 
Information on the length of stay in the hospital, on the place of residence after 
discharge and on admissions in a nursing home because of fractures was retrieved from 
registration data and published data of SrG Zorginformatie.7-9. Using linear regression, it 
was investigated hO\v the length of stay in a hospital after a hip fracture was related to 
age, gender and hospitalization in a nursing home afterwards. 
Outpatient care for the treatment of fractures is not systematically recorded in the 
Netherlands. To estimate these costs, we used previously published assumptions.IUTo 
translate the use of health care in costs, Dutch cost accounting guidelines for healthcare 
\vere used. \I 
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RESULTS 
Incidence oj fmc/llres. 
In 1993, 15.107 (3882 in men) hospital admissions because of hip fractures were 
recorded, 96% of which were in persons of 50 year of age and older. These figures 
shO\ved an exponential increase of the number of hip fractures \\.-ith age, for women as 
well as for men. In men, the incidence of hip fractures lagged behind that of women by 
approximately 5 years of age. Based on the comparison with international data we 
estimated the annual amount of fractures of the vertebrae and wrist fractures at 15,000 
and 14,500, respectively (see also section 1.1.2). 
LeJ/g/h of sIt!)' ill a hospital after a hip fmc/ure. 
The median length of stay was 17 days for men and 19 days for women. The average 
length of stay (24,9 and 27,1 days, respectively) was influenced strongly by a relatively 
small group that stayed hospitalized for a long period. TIle longer length of stay of 
women was explained mainly by age. TIle average length of stay increased with age: 0,32 
days/year (95% confidence interval (CI): 0,26-0,37). Patients who went to a nursing 
home after discharge from the hospital, stayed on average 7,9 days longer in the hospital 
(CI: 6,7-9,0) than patients of the same age and gender who went to their own home after 
discharge. After adjusting for age and admission in a nursing home after hospitalization, 
the length of stay of men approximately equaled that of women: women stayed +0,28 
days (-0,96-+ 1,52) longer in the hospital than men. 
AdmissiON ill a lIursing home after a hip fmc/ure. 
Nearly 60% of the patients with a hip fracture returned home after discharge from the 
hospital. 7% went to an elderly people's home and another 7% died in hospital. TIle 
remaining 26% of the patients were admitted to a nursing home after hospitalization. 
TIle proportion of patients that went to a nursing home increased with age: from less 
than 10% of 50-54 year old patients to more than 30% of patients older than 85. \Y,Ie also 
included nursing home admissions due to other fractures in the analysis of the costs. 
TIle median length of stay in the nursing home was 67 days for men and 70 days for 
women. 'I11e average length of stay (238 and 241 days respectively) was, once again, 
strongly influenced by a relatively small group that stayed in the nursing home for a long 
period. J\lore than 60% left the nursing home within three months; more than 70% of 
those returned to their own homes. After 4 months of stay in the nursing home, only 
55% of the patients returned to their own home and after 5 months tIus number was 
reduced to 35%. \'\!hen length of stay was more than one year, more than 80% stayed in 
the nursing home until they died. 
Because of this, we only used the first 3 months in the nursing home in the calculation of 
the costs. This was an arbitrary choice, assuming that those long lengths of stay of some 
patients were connected with a greater need of care and with comorbidity , rather than 
with the fracture itself. 'Ibe cost of day care in a nursing home was calculated in the same 
way. 
26 
1.2 Cost of osteoporosis related fractures in the Netherlands: possibilities for cost control 
.... 
'" ~ , 
0 
.... 
::s 
p;) 
::l 
0 
.~ 
-.~ 
;;S 
70 
60 
50 
40 
30 
20 
10 
0 
Il!I Other fractures 
IT! Hip fractures 
50·54 55·59 60·64 65·69 70·74 75·79 80·84 >84 
Age category 
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Total coff 
Total costs of fracture-treatment in the Netherlands were estimated at about € 190 
million per year. Figure 1 shows the costs of hip fractures and other fractures per age 
group. The contribution of hip fractures in the costs totaled 86,1%. Figure 2 shows the 
contribution of different care providers in the total cost of osteoporotic fractures. 
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SENSITIVITY ANALYSES 
Other fmctllres thaJJ osteoporotic frac/ures. 
To estimate the costs of hip fractures, all hospital admissions because of hip fractures 
were included in the anal)'sis. It is clear that this also included some hospital admissions 
due to pathological hip fractures or fractures due to major trauma, besides those due to 
osteoporosis. 'Ibis may have leaded to overestimating the number of osteoporosis related 
fractures. But, this \vas probably only a low number of cases, because of the strong 
rclation that was observed between the incidence of the fractures with age. \X'e did not 
include in the analysis the hip fractures that, occasionally, did not lead to hospitalization 
and that were treated consenratively. This on the contrary might have leaded to a minot' 
underestimation of the number of osteoporotic fractures. 
Relellflllce oj other than Dutch ilJeidmee data. 
Costs of vertebral fractures that came to clinical attention and forearm fractures were 
estimated on the basis of incidence data from the US, and this may have caused a bias. 
However, the recorded incidence of hip fractures in the Netherlands was very similar to 
the American estimates. The difference in the total estimated number of hip fractures 
was 4% for men and 17% for women (more hip fractures in the USA). Because of this, it 
seems legitimate to use the American incidence data for fractures of the vertebrae and of 
the wrist. i\Ioreover, the cost of these fractures was much lower than that of the hip 
fractures, so the effect of these more uncertain incidence data was less relevant to the 
bottom line than the incidence of hip fractures, that was estimated accurately. If, for 
example, we would usc the considerably higher Swedish incidence figures for the 
fractures of the forearm,12 the annually estimated Dutch fractures of the forearm would 
indeed go up from 14.501 to 22.919, with an estimated additional costs of € 6 million, 
but the contribution of hip fractures in the total of the costs would only drop from 86,1 
% to 83,5%. 
AdmissiolJ to the JIIlrsing home. 
'I11e estimated cost of nursing home admissions represented almost 20% of the total 
cost; day care on the contrary represented less than 1 %. Here, all costs of fractures \vhere 
included and not only those of fractures attributed to osteoporosis. This could lead to an 
overestimation of the cost in the nursing home. In addition, some patients already stayed 
in a nursing home when the fracture occurred. These patients mostly came back to the 
nursing home after their stay in the hospital and again this could have lead to an 
overestimation of the costs. 
The assumption that only the first 3 months of stay in the nursing home \vas connected 
to the fracture was arbitrary, but it was based on the observation that a longer stay \vas 
associated with comorbidity and a greater need for care. In order to value the effect of 
this assumption on the total costs, we varied this arbitrary length of stay in our 
calculations. W'hen we set this limit at 2 months, the cost of admission for full care in a 
nursing home dropped, for all fractures, from € 36 to € 28 million. \,'hen using a limit of 
6 months they increased to € 52 million. 'The contribution of these nursing home 
admissions in the total costs varied thereby from 15,5 to 25,4%. TIlls hardly had any 
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effect on the contribution of hip fractures on the total costs that varied from 86,7 to 
85,2%. 
Olltp(lliml care. 
Cost of outpatient care was based on expert opinion. III 'nus estimated cost represented 
10% of the total costs. Even when the error in estimated cost for all fractures was greater 
than 50% in the same direction, the final contribution changed only from 5,3 to 14,4% of 
the total costs. The contribution of hip fractures changed only from 90,2 to 82,5%. 
COJJcIJlsiollS frollJ Ihe semitivif)' analYses. 
The results of these sensitivity analyses shows that, although there was some uncertainty 
about some data, osteoporotic fractures in the Netherlands cause annually a cost of 
about € 190 million of direct medical costs. Some 85% of this cost could be attributed to 
hip fractures. About 80% of the cost of hip fractures was caused by hospitalization. 
DISCUSSION 
Illcidence. 
The number of hip fractures in the Netherlands is still increasing. There is an increase in 
age specific incidence, and our data for 1993 showed that this increase still continued in 
the Netherlands, although in some countries such as US, the incidence appears to be 
stabilizing. \J At this moment, it is hard to predict whether this trend will continue in the 
future. Additionally, the population is aging. This will, because of the strong relation of 
fracture risk with age, lead to a strong increase in the total number of fractures, even with 
constant disease specific incidence rates. \"'('hen we combined the current incidence rates 
with the population predictions by the CBS,I4 we predict a doubling of the number of 
hip fractures by the year 2050 (see also chapter 1.1). 
TrealllJeJ11 alld cosl cOlllro/. 
The contribution of the oldest patients in the total cost was very striking. Although 
people from 85 years and older constituted only 1,3% of the population (1993), this 
group contributed to more than one third of the cost of osteoporotic fractures. '111e most 
important cause was, besides the higher incidence of hip fractures, the longer length of 
stay in the hospital and the higher incidence of admissions to a nursing home. This group 
of elderly people will increase from less than 200.000 now to 300.000 in 2020 and over 
500.000 in 2050. At that moment, more than 3% of the Dutch population will be 85 
years of age or older. TIus increment in the number of individuals aged 85 years or older 
will have a disproportionate impact on cost. 
['ifore than 85% of the total cost of osteoporotic fractures was caused by hip fractures 
and the contribution of hospital admissions was considerable. Thereforc, besides 
prevention, a morc efficient hospital stay seems to be the most obvious way to control 
costs in the near future. Previously it was argued that, in the Netherlands, many patients 
with hip fractures stay in the hospital too long because the discharge to either somatic or 
psychiatric nursing homes is not organized efficiently. IS These patients stay in a "wrong" 
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and particularly too expensive bed for too long. 'nle optimal length of hospital stay due 
to hip fracture without complications as stated in the mentioned article was 9 days.1s It is 
clear that the median length of stay in hospital due to hip fractures in the Netherlands is 
much longer. 
Our analysis supports tlus argument of hospital discharge problems. Patients, who were 
admitted to a nursing home afterwards, stayed on average almost 8 days longer in the 
hospital than patients who went home, even after adjusting for age and gender. 
111erefore, it appears that those patients stayed in the hospital waiting for a suitable place 
in a nursing home. An average reduction of the length of stay after hip fracture with 1 
day, would in theory produce an annual cost reduction of € 5 million. 
It must be noticed, however, that costs at the end of hospitalization are lower than at the 
beginning, when the patient is being operated upon and when care is more intensive. The 
use of per diem costs could therefore lead to overestimation of the potential gains of a 
shorter length of stay. In a British study, hvo groups of patients with a hip fracture were 
compared, where one group of patients received "hospital at home"-facilities. 1G These 
facilities included home care, physiotherapy at home and ergotherapy under GP 
supervision. Previous studies had shown that this scheme yielded a similar mortality and 
functional rehabilitation as conventional long-term admission in hospital. Almost 40 % 
of the patients in the intervention group were sent home early. For the complete group, 
this lead to a mean reduction of the length of stay by 9,2 days and to an average 
reduction of costs of £ 1015 (€ 1140) per patient for the admission in the hospital only. 
After deduction of the cost of the hospital-at-home facilities this lead to a reduction of £ 
722 (€ 865). 
Prellen/ioll alld (OS/ (oll/rol 
The most obvious way to control costs is to avoid fractures. 11lere is, ho\vever, no ideal 
intervention available, 17 but the structure of the cost of osteoporotic fractures can give 
some indications for an a-priori judgement of the cost-effectiveness of preventive 
measures. 
The effect of measures to prevent falling has not been demonstrated convincingly until 
now. From some intervention shldies in \vhich it was attempted to reduce the tendency 
to fall through a multifactorial approach, it turned out that, although the frequency of 
falling diminished, there was no confirmed effect on the incidence of hip fractures. ,s.2o 
External hip protectors can protect against the direct impact of a trauma on the hip. A 
randonuzed trial in Denmark with patients in a nursing home showed a 50% reduction of 
the number of hip fractures in the intervention group.2! 
Non-pharmaceutical approaches to influence bone strength include lifestyle intenTentions 
such as physical exercise, diet counseling, and the avoidance of smoking and alcohol 
abuse but there is no consensus about the final effect of these schemes on osteoporotic 
fractures. 22-24 
Pharmaceutical prevention often needs to be taken during many years, and it is unclear, 
what happens to the effect after stopping the therapy.251\.foreover, most studies on the 
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pharmaceutical prevention of osteoporosis have been done on relatively ydung, early 
post-menopausal women and often only the effect on vertebral deformities was studied. 
:~\'lore recently, however, clinical trials that also looked at effects on peripheral fractures 
became availablc.2(,,27 
Purthermore. the timing of the prevention is very important for the cost-effectiveness, 
The incidence of hip fractures surpasses I % per year only after the age of 80 years. \'('hen 
intervention is started around the menopause there is a very long period between the 
costs and the subsequent effects. Furthermore. only half of the individuals that are 55 
today will ever reach the age of 80 according to present prognoses, It tnight therefore be 
more realistic to start prevention at a moment that is closer to the age at which hip 
fractures occur frequently. 
Strategies that have other desired effect beside an effect on osteoporotic fractures, such 
as hormone replacement therapy, should therefore be evaluated on their global cost 
effectiveness and not only on their effect on the prevention of fractures,2H 
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1.3 INCREMENTAL COST OF MEDICAL CARE AFTER HIP 
FRACTURE AND FIRST VERTEBRAL FRACTURE: THE 
ROTTERDAM STUDY. 
This chapter is a ,.eplinl rf: De l.Lle! CEDH, VaIJ HOII! HA, Bllrger H, !Weel AlJAM Hq(lIJrlu A, 
Pols HAP. I1Jcremental rosl tilllediral Ctlrt: after hip fmc/lOt: (llld jirs/l'Cllebmi fmrlllre: the Rotterdall/ 
S/lIdj·. Osteoporosis 111/1999 (ill pms) 
INTRODUCTION 
In \'\Icstcrn countries, osteoporotic fractures and especially hip fractures cause major 
morbidity and mortality in the elderly, I and arc associated with substantial public health 
costs due to acute hospital treatment and subsequent rehabilitation.2 Improved life 
expectancy and the demographic evolution will cause the number of hip fractures 
worldwide to increase from around 1.7 million in 1990 to over 6 million in 2050,1 and 
therefore, medical expenditure will increase in the decades to come. In the Netherlands, 
we estimated the cost of osteoporotic fractures at € 190 million (USS 210 million) in 
1993,1 while hip frachlres accounted for 85 % of this cost. 
In some studies it is argued, however, that the importance of non-hip fractures in the 
cost of osteoporotic fractures is underestimated: a US study estimated the health care 
expenditure attributable to osteoporotic fractures in the United States at USS 13.8 billion 
(€ 12.4 billion) in 1995.4 .Moreover, this study concluded that only 60 ryl) of the cost was 
caused by hip fractures, while the remainder was due to fractures at all other skeletal 
sites, including vertebral fractures that came to medical attention. 'nle difference between 
both studies was probably caused by the fact that while our study included only hip-, 
vertebral-, and wrist fractures as osteoporosis related fractures, the US study included, 
based on expert opinion, a large proportion of all non-hip fractures as osteoporosis 
related. 
To assess the cost-of fractures, it is however not sufficient to know the global health care 
expenditure. Some costs, such as for nursing home admissions, may also occur without a 
fracture, and it is therefore necessary to estimate the difference in health care expenditure 
between fracture patients, and similar individuals in which a fracture did not occur. 
Even while a hip fracture is easy to define, and case finding relatively easy. the estimated 
cost for a single hip fracture varies widely from under € 5.500 to over € 36.000,5.1' 
depending upon countrY,flnd timeframe of interest. The cost estimate also depends on 
whether medical cost after fracture \vas simply added-up. or whether incremental cost 
was calculated by comparing the cost to previous health care expenditure. A further 
source of variation is the choice whether to include anI}' medical cost or to take into 
account indirect costs as well. 
Cost estimates of incident vertebral fractures are even less reliable. Vertebral fractures 
often remain asymptomatic, and it was estimated that only a third of vertebral fractures 
spontaneously come to elinical attention. 14·1(, The real incidence of vertebral fractures is 
therefore poorly known, but there is evidence that it increases with age in much the same 
way as hip fractures. H Prevalence shldies indeed show an increase of both prevalence of 
all vertebral deformities, and an increase in severe deformities with age. 1(, 1') Therefore, 
estimates of the total cost depend heavily upon the definition of a vertehral fracture and 
upon the case finding procedures. 'lbere are, however, a few estimates that range from € 
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240 up to € 2.200.6,2.)-21 In a recent review, cost of vertebral fractures was estimated at 
around € 1.100:2 
In this study, we estimate the incremental cost for medical care after hip and 
radiologically defined incident first vertebral fracture in a Dutch elderly population, by 
comparing the health expenditure in fracture patients to the costs generated in a 
comparable control group. \'{,Ie excluded indirect cost. 
PATIENTS AND METHODS 
Jetting 
W/e estimated the cost of incident hip fractures and incident first vertebral fractures in a 
matched cohort design within the Rotterdam Study. TIle Rotterdam Study is a 
prospective cohort study of the occurrence and determinants of disease and disability in 
the elderly. TIle design of this study has been described previollsly.23 The Rotterdam 
Study focllses on neurogeriatric, cardiovascular, locomotor and ophthalmologic diseases. 
The study started in 1990 and all 10.275 men and women aged 55 and over, living in 
Ommoord, a district of Rotterdam, were invited to participate. TIle study was approved 
by the Medical Ethics Committee of Erasmus University .~\'redical School, and 
participants provided written informed consent. By mid 1993, the cohort was completely 
assembled, and from those eligible for participation, 7.983 did participate, bringing the 
overall response rate of this study to 78 %. 
The baseline survey included a home interview for all participants. 'Ibe independently 
living participants were subsequently invited for two visits to the research center for an 
extensive series of clinical examinations and laboratory assessments, Baseline assessments 
in the home interview included self-perceived health and the assessment of the 
impairment of activities of daily living (ADL) using a questionnaire modified from the 
Stanford Health Assessment Questionnaire.18,24 During the visit to the research center \ve 
performed a lateral radiograph of the spine from the fourth thoracic to the fifth lumbar 
vertebra, as described previously. IS Between mid 1993 and 1995, all independently living 
participants were again invited for a follow-up visit to the research center, and at this 
time we performed a second lateral radiograph of the spine using the same protocol. 
I1J(idfllf hip jrar/f(J('f 
Follow-up of hip fractures was achieved through a link with the computer systems of the 
general practitioners of the district and through hospital admission data, covering about 
80 % of the study population. Par all participants not covered by this system, annual 
checks were performed on the complete medical records of their general practitioners. 
Reported fractures were verified by retrieval and review of the appropriate discharge 
reports from the patient record, Participants with an incident hip fracture between the 
beginning of 1991 and the end of 1994 were included as cases. 
I1J(idfllll'frlebml/racfllJ('f 
Vertebral deformities were diagnosed by morphomeu), on the second radiograph 
according to the Eastell method,25 and as modified by Black ct al.2(· As described 
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previously,IS deformities were categorized as moderate or severe.lvloderate deformities 
(grade 1) were defined as a deviation of any ratio of the heights between the -3 and the -4 
SD cutoff value. Severe deformities (grade II) were defined as a ratio below the -4 SD 
cutoff value. 111ese thresholds were obtained in the same study population and were 
published. IS For all participants with a prevalent vertebral deformity on the second 
radiograph, the first radiograph was also digitized and vertebral deformities were 
diagnosed using the same method. W/e defined a first vertebral fracture as at least one 
severe deformity on the second radiograph, without any vertebral deformity on the first. 
l'lalrhed colltro! group 
For every participant with an incident fracture, we randomly choose a participant 
matched at baseline on age (within the same 5 year age group), gender, self-perceived 
health, composite ADL activity score, [S living situation (alone or with partner, and 
independently living or in residential care), and general practitioner. This matching was 
an attempt to make medical consumption at baseline as similar as possible. For the same 
reason, it was a prere<}uisite for the matched control to be alive at the moment of the hip 
fracture, or at the moment of the second radiograph in case of vertebral fractures. 
lHedica! cOllSllllptioJl 
In the Dutch health care system, the general practitioner (GP) is the gatekeeper of the 
healthcarc system. This means that referrals need to be done by the GP, and that the GP 
record is the central repository of medical information about a patient. :Medical 
consumption was assessed by retrieval of the medical records in the general practice. All 
hospital admissions and their duration from 1990 until the end of 1996 were recorded. 
Admission to nursing homes was recorded similarly. \"{/e also recorded all general 
practice, and out-patient visits. Pharmaceutical consumption was assessed by retrieval of 
the computerized records of the central pharmacy of the district, covering all 
participants. 
AJla!ysis 
Unit prices for cost of medical consumption were based on the Dutch guidelines for cost 
calculations in health research for 1993.27 Those guidelines use comprehensive per diem 
prices including medical care and hotel costs: for hospital admissions these were € 351 
per day and € 95 for nursing homes. The price for a GP visit was € 13, the price for a 
medical specialist contact € 90. For pharmaceutical consumption, the net cost to society 
was used. Por hip fracture \ve calculated the cost during the year preceding the hip 
fracture, and compared it to the cost in the 2 years follmving the hip fracture. For the 
control group we did the same, using as reference the date of hip fracture of the 
matching case. Survival was described with K.'lplan nleier survival analysis. 
Since we did not know the exact date of incident vertebral fractures, we compared the 
average yearly cost in the years preceding the first radiograph with the average yearly cost 
in the years follO\ving the second radiograph (until the end of 1996 or until death). To 
account for the period in ben-veen the t\vo radiographs, where important acute care costs 
might be incurred, we also calculated the average yearly cost for this period. 
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Because the distribution of the cost data was extremely skewed, we did not use 
conventional parametric tests for assessing the precision of the estimates. As an 
alternative we used a bootstrap method to calculate the averages and the 95 % 
confidence intervals.2B Cases and controls were sampled as pairs, and for every parameter 
100.000 j\Ionte Carlo bootstraps were calculated. 
RESULTS 
During the follow-up period, 48 hip fractures occurred, and an equal number of matched 
controls were selected. In two cases of hip fracture and in two controls we were not able 
to obtain all the necessary information to calculate medical cost. Th.ereforc, those 4 pairs 
were deleted from the analysis, giving us valid information for 44 pairs (91 %). 
\Y./e detected 45 severe first vertebral deformities, and again selected matched controls. 
Here, we did not obtain all the information on medical consumption for 3 cases, and 
those 3 pairs were deleted from the analysis, leading to valid information for 42 pairs (93 
%). Table 1 presents the baseline characteristics for the four groups. 
Table 1: Ol'mlieJJ! of 
Number 
Women (n) 
Independently living (0) 
.Mean age in years (SD) 
Alive at end 1996 
II/rident hip fmctllres 
fractures 
Cases 
44 
34 
31 
81.6 \1.9) 
22 
Controls 
44 
34 
31 
81.3 (8.2) 
30 
Vertebral fractures 
Cases 
42 
32 
42 
73.1 (7.3) 
38 
Controls 
42 
32 
42 
73.0 (7.3) 
40 
In the year preceding the h.ip fracture, the total cost of medical consumption was similar 
in both groups. Average cost was € 1638 in the h.ip fracture group and € 1511 in the 
control group. In the first year following the hip fracture, the average cost increased to € 
10139 in the hip fracture group and remained at the same level in the control group (€ 
1481). 
Table 2: AI.'erage iJlcrelJlflltal (ost (€) tl tel' hip fmrfflre 
ALL SUBJECrS IN STUDY ONLY SURVIV1NG 
SUBIECTS 
Year before 1st year 2nd year 1,1 year 2nd year 
Pharmac)' 71 -123 46 -42 244 
Hospital :ldmissions 32 6832' 38 6891' 101 
(Orthopedic surgery) 
Other hospital admissions -152 -327 -64 -316 91 
Nursing home 191 2298' 934 2682' 1326 
Physician visits -15 -23 -32 3 2 
Total 127 8658' 923 9218' 1.763 
(95 % CI) (-850-1107) 1(6402-11202) (-651-2953 (6688 - 12141) (-379 - 4604) 
slgtllficant wHhm 95 % confidence limits 
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1.3 Increment.'ll cost of medical care after hip fracture and first vertebral fracture 
Table 2 presents the estimated incremental cost between the hip fracture and control 
groups broken down by area of health care expendihlre. The increased costs were mainly 
incurred during the first 3 months after the hip fracture, the main component being the 
initial hospital stay at the orthopedic ward. The cost difference in those first 3 months 
was € 7280 (5884 - 8740). During the remainder of the first year there was an additional 
cost of € 1378 (25 - 3042) mainly associated with nursing home st.'lys. In the second year 
the average cost in cases was € 2342 compared to € 1419 in controls. Again, this 
additional cost was associated with nursing home admissiolls. 
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Figllre 1: DisftibllliolJ if the COJt (€)ifllledica/ care iJ/ Ihe)'ear qfter hip jrac/fIl'e 
Yearly cost 
Figure 1 indicates the distribution of yearly direct medical costs in cases and controls 
during the first year following the event. It shows that in controls over 65 % of the 
controls had a yearly cost below € l.000 and that cost exceeded € 5.000 in only 10 %. In 
cases, however, cost exceeded € 5.000 in almost 80 % of the cases. 
In this cost calculation, we disregarded the import.'lnt extra mortality after a hip fracture. 
There was indeed an obvious increase in the death rates in the hip fracture patients itl the 
6 months following the event. Figure 2 gives the IG'lplan~i\·fcier survival curves 
comparing the sun,ivai of hip fracture cases with controls. \,'hen we excluded 
participants after the moment they died, the average incremenml cost during the first year 
rose only slightly to € 9218. The main raison for this modest increase was that the 
majority of costs were incurred immediately after the hip fracture, also in people dying 
subsequently. In the second year, however, the cost difference almost doubled, from € 
923 to € 1763, mainly caused by nursing home and phal1nacy costs. 
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For vertebral fractures the cost differences were less pronounced. In tlus population, the 
average cost of medical consumption before the first radiograph was € 1069 for cases 
and € 608 for controls. During the period in between the two radiographs the average 
yearl}' cost was € 1478 for cases and € 1087 for controls. 'Ibe second radiograph was 
taken on average 2.2 years after the first, and the yeady cost aftet:\vards was on average € 
2836 for cases versus € 1877 for control subjects. In the GP records we could find a 
trace of vertebral deformities in only 14 of the cases (33%). Ivloreover, 4 of those were 
only detected after the second radiograph in our study, indicating that these vertebral 
deformities were not detected at the moment of their occurrence. 
Table 3: Ar·em,ge iJ/crelJlflltal (ost (€) after first 1'eI1ebral (rarlllre 
Years before first Years in behveen 
radiograph radiographs 
Pharmacy 25 162 
Hospital adnussions 
(Orthopedic surgery) 
-37 -44 
Other hospital admissions 432' 
Nursing home -13 
Physician visits 54 
Total 461 
(95 % el) (-167 - 1213) 
significant within 95 % confidence linuts 
38 
209 
o 
66' 
391 
(-208 - 1065) 
Years after second 
radiograph 
320' 
136 
452 
11 
40 
959 
(-646 - 2650) 
1.3 Incremental cost of medical care after hip fracture and first vertebral fracture 
Table 3 presents the estimated incremental cost between cases and controls broken dovm 
by area of health care expenditure. The cost difference before the vertebral fracture was 
almost entirely due to hospital admissions. After the second radiograph this difference in 
hospital costs persisted, while the remainder of the increase was mainly associated with 
pharmacy costs and also to a lesser extend with admissions in orthopedic surgery wards. 
The € 320 increment."ll pharmacy cost was not attribut."lble to specific medication, and the 
cost difference was present in almost every drug category. 'fhe most marked increase in 
yearly cost (€ 136) was in the category of the anti-ulcer drugs, and the use of Omeprazol 
and R,1nitidine was responsible for most of this difference, although this was not due to 
volume but to the price levels of those products. Incremental cost was also recorded in 
several other drug categories such as the cardiovascular, hOlmonal, and respiratory drugs 
and also in the non-steroidal anti-illflammatory drugs, but without presenting a clear 
pattern. For the period in between the DoVO radiographs we sec no indication of any acute 
phase costs, apart from a significantly increased cost of physician visits, but these 
represent low costs. But, since we do not know the exact moment of the vertebral 
deformity these costs are more difficult to interpret. 
Figure 3 shO\vs the distribution of average yearly cost in cases and controls after the 
second radiograph. For controls this distribution is similar to that in the hip fracture 
control patients. In cases, however, a large majority had a yearly cost of over € 1.000. 
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Figure 3: Dislliblllioll 0/ the)'ear!y cosl (€Jqf medical care q/terjil'Ji F'ntebralfradllre. 
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DISCUSSION 
l\{ain filJdings 
\Ve estimated that, in this population, a hip fracture caused an extra cost of about € 8600 
during the first year and € 920 in the subsequent year. There was an important extra 
mortality in the 6 months after the hip fracture as other studies reported before.29311 
Taking this excess mortality into account and calculating average cost for surviving 
patients and controls, did not dramatically change our estimate during the first year, since 
most cost was incurred directly after the fracture. But, assessing surviving participants 
only, incremental cost in the second year almost doubles, mainly due to nursing home 
admissions and pharmacy cost. In two other studies that also compared cost before and 
after the event, incremental cost during the first year was estimated at between € 14.350 
to € 17.000 for the US,!3 and € 19.700 for Sweden." This is substantially higher than 
\vhat we found in this Dutch population. The main reason for this difference appears to 
be the cost per day for hospital admissions, which is substantiall}' lower in the 
Netherlands. Estimates from UK studies are generally 100ver,8-1Il but tllese studies only 
focussed on the acute phase costs. Their estimates, however, correspond to our results 
for the first 3 months after the event. 
Costs of vertebral fractures are largely unknown, and cost estimates based on prevalent 
fractures are bound to be biased, since, in practice, those fractures often remain 
undiagnosed. Therefore, estimates vary widely. In our study we determined vertebral 
fractures by comparing radiographs made in a population based cohort, and we found 
that, even before the occurrence of the fracture, the average yearly cost was € 460 higher 
in cases compared to their matched controls. This incremental cost was largely caused by 
hospital admissions and seems to point to preexisting co-morbidity that was not avoided 
by the matching procedure used. 
l\.fost of the vertebral deformities in our study remained undiagnosed. Therefore, it is no 
surprise that the observed incremental cost is only modest. \\'hile the higher cost for 
admissions to orthopedic surgery wards after the occurrence of a vertebral fracture is not 
surprising, the higher pharmacy cost is, especially the observation that there was no 
specific drug category causing this. The single category causing most of this cost 
difference was the category of the anti-ulcer drugs although this was not due to volume 
but to the price levels of those products. Other extra consumption was recorded in the 
groups of cardiovascular, hormonal, and respiratory drugs and in the non-steroidal anti-
inflammatory drugs. The importance of this cost for vertebral fractures becomes, 
however, important since it appear to be a yearly recurrent cost, at least during the first 
few years following the vertebral fracture. 
The finding of this pre-existing incremental hospital cost and the unspecific drug usage in 
patients with incident vertebral fractures may have important implications. \,'hen 
confirmed by additional research, this would mean that the cost-effectiveness of 
strategies to prevent vertebral fractures might be overestimated, since at least part of tlle 
cost \vas pre-existing and will probablr not be avoidable. 
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Strengths alld limitations 
International comparisons of cost arc difficult, because health care is organized 
differentlr in different countries. The average initial stay at the orthopedic ward for 
instance, is only 11 days in S\veden 11 'while it is 26 days in the Netherlands. 1 However, in 
Sweden it is followed by a longer stay at a geriatric ward. [v[oreover, the definition of 
what is included in health care cost and what is not differs from one country to another. 
\'?bile the severity of hip fractures is probably comparable between studies, the severity 
of vertebral deformities heavily depends upon the definition. Here we choose to include 
all severe incident deformities whether or not they caused complaints. 
In this study, we studied incremental cost caused by fractures by comparing health care 
cost directly between individuals with and without a fracture, matching for potential 
determinants of health care consumption, while previous studies on incremental costs 
utilized health care use by the patient in the months before the hip fracture rather than 
using control patients. I\·n This method allowed us to compare costs directly, but also to 
take into account the excess mortality in the hip fracture group, compared to the control 
group. For hip fractures, the matching appears to have achieved its purpose, since 
average cost before fracture was roughly equal between cases and controls. For vertebral 
fractures however, there was, even before any fracture, a cost difference of € 460. This 
was possibly caused by underlying co-morbidity that was not avoided by the matching, 
and it clearly underlines the need for a control group when assessing the cost of vertebral 
fractures. Since the exact date of the vertebral deformity was impossible to determine, we 
accounted for those costs by analyzing the complete period in between the two 
radiographs, and we did not find indications of any substantial acute phase cost. 
In this study we only included direct medical costs, and the average cost was small, 
compared to overall average health care costs for individuals of the same age in the 
Netherlands:11 This is because we included only relatively healthy and mostly 
independently living individuals. \Yle also investigated only incremental cost after a first 
vertebral fracture, and this study gives no information on the cost consequences of 
multiple vertebral fractures. lvforeover, \ve included a large proportion of vertebral 
deformities that never came to clinical attention, and this has to be considered when 
extrapolating these results to other populations. In calculating the medical consumption 
we did not include health care costs such as home care and home help, paramedical care, 
ambulatory physiotherapy, equipment costs and transportation cost. Prom Dutch health 
expenditure data,J! we estimated that these costs only account for about 15 % of all 
health care costs in this age group. Indirect cost due to lost production was not included 
as we felt this was irrelevant in this elderly population, but this is an important reason 
\vhy our estimates are low. 
The most important limitation, however, is that this study for assessing the cost of 
incident fractures by direct comparison of patients with a control group was relatively 
small, and although the approach appears feasible, the results should be interpreted with 
caution, as is obvious from the relatively wide confidence intervals. Further investigation 
is needed, especially to validate our finding that co-morbidity might be an important 
determinant in the cost of vertebral fractures. The observation of the increased and 
unspecific drug consumption is intriguing, and to our knowledge no other study has 
included this individual pharmaceutical consumption in a cost analysis of fractures. 
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COllclllJ;OIlS 
In this study, ,"ve used a novel approach for assessing the cost of incident fractures by 
direct comparison of medical expenditure in fractures patients with that in a matched 
control group. \'\!hile, for hip fractures, our results largely confirm previous cost 
estimates both in the Netherlands as in other countries, the results for vertebral fractures 
are surprising. Hip fractures cause an important cost and excess mortality, and 
prevention of hip fractures would probably avoid those. For vertebral fractures we could 
not detect important acute care costs, but we did observe a higher medical expenditure 
even before the occurrence of the fracture, while an important part of the additional 
incremental cost after fracture was caused by unspecific use of pharmaceutical drugs. 
11us appears to point to co-morbidity, and it is therefore unlikely that prevention of 
vertebral fractures will eliminate all the incremental cost. \'\/hen confirmed, this finding 
would have important implications for the evaluation of the cost effectiveness of 
preventive strategies. 
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PART 2 
MODELING THE RISK OF HIP FRACTURES 

2.1 BONE DENSITY AND RISK OF HIP FRACTURE IN 
MEN AND WOMEN: CROSS SECTIONAL ANALYSIS 
This (hapfer WflJ Pllb/ished as: De uri CEDH, Vall HOII! BA,Bmger H,Ho/lJlol1 A, Pols HAP. 
BollC dwsity and fisk 0/ hip /mrlm'C jn men find WOIJ/f1J: troIS sedional tllla/ysis. BiH] 1997,' 315:221-5. 
INTRODUCTION 
TIle number of people with fracture of the hip is increasing rapidly and by the year 2050 
may exceed 6 million a year worldwide, up from 1.6 million in 1990,1 The aging of the 
population is the most important reason for this increase. In addition, the age specific 
incidence of hip fractures has also increased in several countries, including the 
Netherlands.1.2 Hip fractures are a major cause of mortality and disability in elderly 
people and an important burden for the health services in many countries.-1 
As most hip fractures occur in women, most attention has focused on bone loss in 
women, predominantly around the menopause. Less is known about the rclation of hip 
fractures with bone loss later in life, and the high incidence of hip fracture in older men 
is largely neglected.4 
Detailed quantitative knowledge about the effect of age and bone density on the absolute 
risk of hip fracture is necessary to evaluate the potential benefit of interventions aimed 
exclusively at bone density. The association of low bone mass with an increased risk of 
hip fracture is well documented.5 The strong increase of risk with age and the bone loss 
associated with age are also evident/i but the effect of both determinants together is 
poorly understood. This information could be obtained directly from follow up studies, 
but the numbers and time required make those studies difficult to accomplish. 
Combination of data can, however, lead to indirect estimates of the absolute risk 
comparable "vith the approach used previously to estimate the lifetime risk 
of hip fracture. 7 
In the present study we combined cross sectional data on bone mineral density from a 
population based sample of elderly men and women living independently with incidence 
data on hip fracture from a national registry in the Netherlands. In combination with 
data from the literature, this allowed us to estimate the effect of age and bone density on 
the risk of hip fracture in men and women. 
METHODS 
Distribution 0/ bOHe lJI;mral dellSi!)' 
The Rotterdam study, started in 1991, is a prospective follow up study of the occurrence 
and determinants of disease and disability in elderly people. The design of this study has 
been described.8 The study focuses on four primary topics of research: neurogeriatric 
diseases, cardiovascular diseases, locomotor diseases, and ophthalmological diseases. All 
10275 men and women aged 55 and over living in a district of Rotterdam were invited to 
participate. The study was approved by the appropriate medical ethics committee, and 
participants provided written informed consent. From those eligible, 7983 participated, 
bringing the overall response rate of this study to 78%. 
47 
Osteoporosis and fracture prevention 
The baseline survey included an initial home interview followed by two visits to the 
research centre for a series of clinical examinations and laboratory assessments. Those 
baseline assessments included dual energy x ray absorptiometry scans of the femoral 
neck. 
:~\'Iethods of measuring bone mineral density and data on bone density in a subsample of 
1762 subjects have been reported.') The present study used the data on femoral neck 
bone density from the total study population. This site was chosen because of the 
growing consensus that prediction of fractures is best done with site specific 
measurements.] People in nursing homes (11%) did not visit the research centre and thus 
were not eligible for bone density measurements. 
\Y..'e present the results for men and women separately. using the age on the day of the 
bone density measurement. The bone density distribution by age and sex is presented in 
5 year age classes; additionally it was analysed continuously by linear regression. This 
regression model was extended with quadratic and cubic terms to detect a possible non-
linear association between age and bone density. As obesity is well known to affect bone 
density.')'w and as in this study body mass index seemed to be related to age, it was added 
to the regression model as a potential confounder. TIle results are presented with 95% 
confidence intenTals. 
Disln"blliioll of hip frac/llres 
'l1le SIC (Foundation for Health Care Information) is a national registry that collects 
various data related to health care. II All admissions to hospital in the Netherlands are 
included in this registration as is most of the information from nursing homes. In the 
Netherlands virtually all patients with a hip fracture are treated clinically. TIlerefore. 
hospital data give accurate information about the incidence of hip fractures. 
Data for hip fractures in 1993 (IlIlema/iollal Classijlra/ioll 0/ Diseases, ninth revision (ICD-9) 
code 820xx) were collected from the detailed SIG hospital registration data. TIley were 
combined with Dutch demographic data for 1993 from the Dutch Central Bureau for 
Statistics.12 The data were aggregated in one year age classes and a best fitting function 
estimated with the SPSS cunTe fitting facility.lJ 
Probability oj hip ./radllre 
The relative risk for hip fractures, expressed as relative risk per SD decrease in bone 
density measured at the femoral neck. was estimated by Cummings et al to be 2.6 (95% 
confidence inten'al1.9 to 3.6) in women. 14 Combining this relative risk with data on 
incidence and bone density made it possible to estimate the probabilities of hip fracture 
by age. sex, and bone density. The mathematical details are given in the Appendix A. \Y..'e 
used the same relative risk estimate for men. \Y/e also estimated the isolated effects of 
aging and decline in bone density related to age and calculated confidence intervals for 
these separate effects by using the 95% confidence inten'als of the relative risk per SD 
decrease in bone density. 
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2.1 Bone density and risk of hip frachlre in men and women: cross sectional analysis 
RESULTS 
DistribNfiol1 oj bone mineral deusiry 
Table 1 shows the overall characteristics of the study population. From the 7086 people 
eligible, bone density data were obtained for 5814 (82%). 111is response rate remained 
above 70% up to the age of 85 years; in people aged over 85 the response dropped to 
54%. Men were slightly younger than women (mean 67.6 (SD 7.6) years v 68.5 (8.3) 
years). The age at menopause was the same in all age groups (48.9 (5.2) years). 
The bone density values. stratified by age and sex. were normally distributed, and the SD 
\vas almost constant over the age categories. Bone density declined linearly. and 
introducing quadratic and cubic terms did not improve the model. The apparent decrease 
in bone density at the femoral neck was 0.0046 (95% confidence interval 0.0040 to 
0.0051) g!cm2!year for women and 0.0031 (0.0024 to 0.0038) g!cm2/year for men. 
Correction for body mass index changed those values only slightly (0,0050 g/cm2/year 
for women and 0.0028 g/cm2/year for men). 
Table 1: lHeall (JD) heigh~ JJ!eigh~ borf)' mass index, (/~/d bOlle mineral delJsity qfelderfy people, 
Rotterdam. 
Men \VOlllcn 
No Height Weight DMJ BMD No Height Weight BMI 
em k 1m Icml ) em k kim 
'49 117.2 (6.8) SO.9 (m7) 25,7 (29) IL917 (0.B3) 613 IM.l1(6.2) 7n.n(II.U) 26.1 (3.9) 
572 176.0 (6.5) BO.5 (11.3) 2{,.0 (3.2) O.!jgB (0.121) 730 163.1 (6.1) 70.6 {I 1.2) 26.5 (J.9) 
>47 175.1 (6.4) 78.7 (10.4) 25.7 (29) 0.866 (O.B!) (,SO 1626 (6.1) 71.3 (10.9) 27.0 (.1.9) 
418 174.1 (6.3) 78.4 (10.5) 25.9 (j.O) 0.865 (0. US) '"0 161.0 (6.2) 69.')(10.9) 21.0 (4.U) 
301 1720 (63) 75.S (9.8) 25.6 (2.9) n.855 (0.145) 433 158.S ({,.2) (,7.9 (11.2) 26.9 (4,2) 
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2446 174.9 6,8 78.8 10.8 25.7 ].0 0.876 0.13 JJ68 161.7 6_5 1i<).9 11.1 26.7 4,0 
DislJibllfiol1 of hip fmrtHres 
In the Netherlands in 1993 there were 15 107 registered hospital admissions for hip 
fractures in a population of 15 million, a quarter of which occurred in men. The one year 
incidence of hip fracture (per 100000) increased from around 40 at age 55-59 to about 
3150 over age 95 in men and from around 40 to about 4450 in women. In each age 
group, the incidence of hip fracture in men was equivalent to that in women 
approximately five years younger. Figure 1 shO\vs the one-year cumulative incidence of 
hip fractures by age and sex with the fitted curves; details of these functions are given in 
Appendix B. 
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Probability of hip fmc/lire 
From the preceding results we estimated the probability of hip fracture by age, sex, and 
bone density (Appendix B). Figure 2 represents the association of the incidence of hip 
fracture with bone density at the femoral neck for different ages in men and women. 
Comparing an 80 year old woman with average bone density with a 60 year old woman, 
we found a relative risk. for hip fracture of 13.6. \X'hen we separated the effects, age 
contributed 7.1 (5.7 to 8.8) to this relative risk, and age related decline in bone density 
contributed 1.9 (1.5 to 2.4). For men the relative risk was 12.7; the contribution of age 
was 8.2 (7.1 to 9.5) and of age related decline in bone density was 1.6 (1.3 to 1.8). 
The rnagnitude of the relative risk per SD change in bone density affected the slope of 
the risk function (fig 3), \"\'hich shows the curves for the central estimate (2.6) together 
with the curves at the lower and upper limits of the 95% confidence interval (1.9 to 3.6). 
As the incidence of hip fracture specific for age remains constant the risk of low bone 
density becomes higher, and the risk of high bone density becomes smaller when we 
assume a higher relative risk. The opposite happens at the lower confidence limit. 
Fig 2 One year cumulative incidence of hip fracture by femoral neck bone density at ages 
60, 70, and 80 in women and men 
50 
2.1 Bone density and risk of hip fracture in men and women: cross sectional analysis 
0 4000 0 0 80 0 3500 Mean (-2SD - + 2SD) 0 
..-< 
..... 
<l) 3000 ---Women 
l$ 2500 .··0··. Men 
~ 2000 .-<:) 
.9 '. 
§ 1500 70 1000 <:) 
. 
.s 500 60 
=S 0 
0,4 0,5 0,6 0,7 0,8 0,9 1 1,1 1,2 
Femomi neck bone density 
Figure 2: Onej'ear (/{IIIII/alit'e illcidtllce cf hip fraclllre 0'fillloral/leck bone dtllsity al ages 601 70 
alld80. 
0 
0 9000 o~ 
0 8000 0 
..-< 
Mean (-2SD - + 2SD) 
..... 7000 
<l) 
l$ 6000 --Women 
<l) 
:5! 5000 - - - - Men 
<:) 
.9 4000 
~ 3000 ., 
.... 
<:) 2000 
.s 
=S 1000 0 
0,4 0,5 0,6 0,7 0,8 0,9 1 1,1 1,2 
Femomi neck bone density 
Figure 3: Glle )'ear (/fllm/alire illcidtllce cf hip frac/llre inlJleJJ (wd WOlJltll aged 80 wilh a relatit'e fisk 
(per SD decrease fflflllloral1leck bone densiD') cf2.6 and 95% cOlljidtllce lilllils 1.9 alld 3.6. For 
telllral esfliJlale (2.6) solid and dOlled lines oluJap 
51 
Osteoporosis and fracture prevention 
DISCUSSION 
After the age of 60 the incidence of hip fracture is consistently 10\ver in men than in 
women of the same age. n'ren have about the same risk of hip fracture five years later 
than women. Though the age related decline in bone density is larger in women, the risk 
of hip fracture \vhen age and bone density arc considered together is remarkably similar 
in men and women. The five year difference in the age specific incidence of hip fracture 
behveen men and women can, in this study, be explained by the different bone density 
distributions at those ages. 
Though the risk for hip fracture increased 13-fold from age 60 to age 80 in both men and 
women, the age related decline in bone density explained merely a doubling of this risk. 
'Ibe rest of the increased risk is explained by other determinants of risk that have been 
accounted for by using age as a surrogate and that are approximately equal in men and 
women. Previous research identified several skeletal and extraskeletal determinants. IS 
'I1lOugh bone density is 'Oat the main component of the increased risk of hip fracture in 
old age, risk would be substantially reduced if the age associated decline in bone density 
behveen the ages 60 and 80 could be excluded: a 36% reduction in men and 48% in 
women. Recent clinical trials indicate that part of this risk reduction might be 
achievable:16,17 
ASSIlIllPfio1JS 
The stronger effect of age on risk of fracture in general and of hip fracture in particular 
has been obsenTed in women, HI but previous studies were based on relatively small 
numbers of fractures. Our design allowed us to use the information from more than 15 
000 hip fractures in the analysis. The data presented here, however, were derived from 
several sources, which involves some assumptions that need to be examined. \"'(,Ie 
assumed that the distribution of femoral neck bone density in the Netherlands 
corresponds to the distribution in this study. Even though our sample was population 
based, it could have been influenced by selection bias: healthy people could have been 
overrepresented. 'I1le high response rates indicate that this effect was probably small. 
j\.[ore importantly, the sample included only people who were living independently. TIle 
more [rail patients in nursing homes, presumably with lower average bone density, were 
excluded, resulting in an underestimation of the age associated decline of bone density. 
Fewer than 9% of elderly people aged under 80 were in qursing homes, but this 
proportion rose greatly at higher ages. This means that the validity of the data seems 
assured up to the age of 80, but that the effect of the age associated decline in bone 
density will probably be somewhat higher than estimated in the older age categories. The 
age associated decline in bone density that we found was of the same magnitude as in 
other cross sectional, population based studies, although the absolute levels are slightly 
higher.1'J-21 
Finally, cohort effects cannot be excluded as the bone density data used in this study are 
cross sectional. If present, these cohort effects would affect the estimated rate of bone 
loss but not the risk function. 
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Other liJk indirators 
In the analysis, age was used as a surrogate marker for several risk indicators, including 
propensity to fall, types of fall, muscle strength, and bone quality. \Yle used the 
distribution of bone density and the age related decline in bone density without 
correction for height, weight, or for the age at menopause as we were interested in the 
combined effect of these determinants. :Moreover, the confounding effect of body mass 
index was small, and in women the age at menopause was unrelated to age at fracture. 
Choice of relative risks 
\\le assumed the relative risk of2.6 per SD to be the same at all ages, and we also 
assumed this relative risk applies to the Netherlands. This relative risk estimate influences 
the slope of the association between incidence of hip fracture and bone density but it 
does not alter the level of those curves, as is clear from figure 3. It could, however, 
influence the contribution of the age related decline in bone density to the risk of hip 
fracture. But, even at the upper confidence limit, this merely doubles the risk over 20 
years of aging. It was previously shown in women that bone mineral density predicted 
fractures equally well at different ages up to the age of 80.22 Additionally, in a recent 
meta-analysis the relative risk estimate remained at 2.6 while the confidence interval 
narrowed slightly (2.0 to 3.5).5111is same study also indicated that the estimates of 
relative risk for different measurement and fracture sites seem to be comparable in 
different parts of the world. 
As no relative risk based on large samples was available for men we assumed the same 
relative risk in men and women, as others have suggested,2.3,24 and as was confirmed in a 
recent follow up study of bone density measurements in 752 men in Australia.as That 
study estimated the relative risk for hip fractures per SD lower bone density at the 
femoral neck at 2.9 (1. 7 to 5.0). 'This seems compatible with our tl priori assumption of 
no difference. \X/hen we applied this point estimate of 2.9 the results changed only 
slightl)'; the contribution of aging (age 60 to age 80) became 7.8 (6.1 to 10) and that of 
bone density decline 1.6 (1.3 to 2.1), supporting our conclusions. 
COl/clI/fiol1s 
The risk of hip fracture, when expressed as a function of bone density and age, is 
remarkably similar in men and women, and the difference in age specific incidence of hip 
fracture can be explained completely by the different distribution of bone density in men 
and women. Our results also shO\v that the contribution of age associated decrease in 
bone density to the exponential increase of the risk of hip fracture with age is limited. 
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APPENDIX A 
To obtain the incidence of hip fracture specific for age, sex, and bone mineral 
density (Hr.'ill) \ve combined the BlvlD distribution in this population based sample, 
the observed incidence of hip fracture specific for age and sex in the 
Netherlands, and the relative risk for hip fractures per SD decrease in the 
femoral neck bone density as described by Cummings et al. 14 \'{!hen we assume a 
constant relative risk per SD decrease of Bn-lD, the age, sex and Bn'ill specific 
incidence for hip fractures is given by: 
(1) 
where page,sex denotes the incidence for people with mean Hf'..'ill for that age and 
sex, where a is the relative risk per SD decrease in Bi'vID, and where z is the BMD 
difference from the age and sex specific mean BMD expressed in SDs. 'I11e 
distribution of hip fractures b)' BMD in people of the same age and sex will then 
be given by the product of the risk of hip fracture specific for B1'fD given above 
and the BMD distribution in this same population, which we know is normal. The 
distribution of cases is therefore given by: 
The total incidence of hip fracture can be calculated by the integration of this 
distribution over the whole range of z. The incidence of hip fracture specific 
for age and sex is thus given by: 
As the age and sex specific hip fracture incidence is known from population 
data, we can calculate 
From (1) and (2) it follows that: 
P"ge.l.et,fJ,lfD 
(3) 
In practice this means that, to obtain the incidence of hip fracture for people 
with mean Bl\'lD, the observed incidence specific for age and sex needs to be 
divided by a correction factor C, given by: 
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c 
C equals 1 when a equals 1.1n all other cases C is larger than 1. \\'hen a=2,6, 
as is the central estimate in this article, the correction factor C equals 
1.578541. (At the lower confidence limit (1.9) the correction factor is 1.228739 
and at the upper lintit (3.6) it is 2.271399.) 
APPENDIXB 
The one year cumulative incidence of hip fracture (per 100000) in this article 
is estimated from population data. The best fitting curves are power functions 
given by: 
and 
TIle relation of femoral neck Bi\lD (gl cm~ with age is best described by a linear 
function: 
BMD" .. '.mm = 1.08586-0.0031·age 
and 
BMD age,wnmell 1.121284 -0.00456·age 
\\lith the conditions of normality and homoscedasticity fulfilled, and by assuming 
a relative risk of 2.6 per SD decrease of BMD at the femoral neck, the one year 
incidence of hip fracture (per 100 000) is thus given by (3): 
Page,mell,BJID 
and 
P age,WOn!fll,BJlD 
(
9.3 ·10-15 . age''''') . 
1.578541 
(
5.9.10-15 . age'.0731) . 
1.578541 
I.OS586--o.cX)31 • age-BMO 
2.6 0.135 
1.I212S4--o.{)()4S' age-BMD 
2.6 0.134 
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2.2 HIP FRACTURE RISK ESTIMATION IN ELDERLY MEN 
AND WOMEN: VALIDATION IN THE ROTTERDAM STUDY 
This chapler Jlias pllblished as: De uel CEDH, V{III HOII' BA,Bmger H,HojIl/(11/ A, IF'eel 
AEA-,-'J,Po/s HAP. Hip Fmc/lire Prediction il1 ElderlY i.\1m and IVoJJlm: Va/idatioN ill the 
RotterdalJl Stlldy. ] BOlle Miller Res 1998; 13:1587-1593. 
INTRODUCI10N 
In \"'{'estern societies, hip fractures cause major morbidity and mortality in the elderly,l 
Consequently, they generate substantial costs due to acute hospital treatment and 
subsequent rehabilitation.2.3 Improved life expectancy and the demographic evolution will 
cause the number of hip fractures worldwide to increase from abollt 1.7 million in 1990 
to over 6 million in 2050,1 To target prevention at those with the highest risk, it is 
important to be able to predict hip fractures. 
Although the inunecliatc cause of a hip fracture is mostly a fall, their occurrence is closely 
associated with osteoporosis.4 Osteoporosis is defined as a condition characterized by 
low bone mass and micro-architectural deterioration of bone tissue, with a consequent 
increase in bone fragility and susceptibility to fracture. 5 TIle conventional method of 
estimating bone mass is by bone densitometry. TIle \';todd Health Organization defines 
osteoporosis as a bone mineral density (HMD) of 2.5 standard deviation (SD) below the 
mean for young adults.6 
It is, however, important to distinguish between B~·fD as a tool for defining osteoporosis 
and B~'ID measurement as a tool for fracture risk prediction.7 TIle association of En'ID 
with subsequent hip fracture has been demonstrated in several studies with an estimated 
relative risk, for women, of 2.6 per SD decrease in femoral neck B~\'ID.4,g \'\Iith this 
relative risk estimate, the registered hip fracture incidence in the Netherlands, and the 
Bn<fD distribution from a Dutch population-based sample, we derived a theoretical one-
year hip fracture risk function by age and femoral neck BMD for men and women,') In 
the present study we validated this tool for predicting hip fracture incidence rates in a 
prospective follow-up study. Additionally, we calculated the risk of hip fracture per SD 
decrease in femoral neck Bl."lD for both men and women. 
METHODS 
Jlllrfy participants 
\Y,Ie previously estimated the one-year cumulative risk of hip fracture by age and BMD, 
based on Dutch hip fracture incidence data, the distribution ofBl\'ID in a sample of 5814 
men and women aged 55 years and over, and on data from the literature.'} In the present 
study, we validated this risk estimate in the Rotterdam Study, a population based 
prospective cohort study of the occurrence and determinants of disease and disability in 
the elderly. The Rotterdam Study focuses on neurologic, cardiovascular, locomotor and 
ophthalmologic diseases. The study started in 1990 and all 10275 men and women aged 
55 and over, living in Ommoord, a district of Rotterdam, were invited to participate. The 
study was approved by the Medical Ethics Committee of Erasmus University Medical 
School, and participants provided written informed consent. From those eligible for 
participation, 7983 did participate, bringing the overall response rate of this study to 78 
%. The design of this study has been described previously. III 
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The baseline survey included an initial home interview followed by two visits to the 
research center for a series of clinical examinations and laboratory assessments. Baseline 
assessments included dual energy X-ray absorptiometry scans of the femoral neck in the 
independently living participants, using a Lunar DPX-L densitometer. :Measurement 
procedures have been reported previously.11 
Risk estimatiolJ 
For each participant, wc calculated the one-ycar cumulative risk according to the risk 
function, as an individual risk estimate. The equations used for this purpose are given in 
the appendix. Participants with an incident hip fracture prior to BMD measurement were 
excluded from the risk classification. Based on the same risk functions, a nomogram 
indicating the one-year hip fracture risk by age and Bf'iID was constructed for men and 
women. To avoid that these nomograms would only be useful to users of Lunar 
machines, we also converted those risk functions to other brands of densitometers. 111is 
conversion was done using the conversion algorithms provided by Genant et al.,12 and 
the resulting equations can also be found in the appendix. 
Hip fmc/lire follow'lip 
Pollow-up for hip fractures was achieved through a link with the computer systems of 
the general practitioners of thc district and on hospital admission data, covering about 80 
% of the study population. For all participants not covered by this systcm, annual checks 
were performed on the complete mcdical records of their general practitioners. Reported 
fractures were verified by retrieval and review of the appropriate discharge reports from 
thc patient record. Follo\v-up started eithcr at January 1, 1991 or at the time of the 
baseline interview whcn this was later. Follow-up ended either at death, at the time of the 
first hip fmcture, or February 29,1996. 
Ana/pis 
To asscss the performance of the risk function, we divided the population with a valid 
BMD measurement into categories by gender and risk. TIle individual onc-year risk 
estimate was categorized as either low « 0.1 %), moderate (0.1 - < I %) or high P-: 1 %). 
These cut-off levels were arbitrary but based on clinical common sense: a one-year risk of 
0.1 % approximately corresponds to the risk for an average women at the age of 60, (9) 
while a 1 % risk approximately corresponds to the risk for an average 80 year old 
women. Incidence rates of first hip fracture were then calculated for each of these 
categories. To account for the events occurring in participants \\--ithout a B!'t'ID 
measurement, hip fracture incidence was calculated separately for those living in 
institutions for residential care and for community dwelling persons without HMD 
measurement. 
To assess the effect of age, we subdivided these risk-categories into ten-year age groups. 
To avoid categories without outcome events, we combined for tIus analysis by age the 
low and moderate risk categories into a single category. For categories where follow-up 
time was less than 100 pyrs, we did not to calculate incidence rates since those results 
were considered too unreliable. 
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Finall)', we calculated the age-adjusted relative risk per SD decrease in B:i\ID using Cox's 
proportional hazards model. All point estimates arc presented with their 95 % confidence 
intervals (el). 
RESUlTS 
Base/ine fisk c!assijirat;oll 
Figures 1 and 2 represent, as a nomogram, the one-year hip fracture risk by age and 
B.i'vID calculated from the risk functions, for men and women respectively. The shaded 
areas depict our Dutch reference HMD distribution (g/ cmZ), while the curves connect 
points of equal risk at all ages. TI1e curves are very similar in men and women, as we 
described before,'} while the average Hi\·ill is higher in men than in \vomen at every given 
age, and the decrease of Hi\{D with age is slower in men. 
Complete follow-up was achieved for 7046 persons (2778 men) with an average follow-
up time of 3.8 years. In 5305 of those (2227 men), we also had a valid B:r.lD 
measurement at baseline, and the BMD distribution by age is shown in Table 1. Based on 
bone density, age and gender, we classified everybody at baseline in risk categories 
according to the risk functions: 2360 individuals were categorized as low risk, 2567 as 
moderate risk and 378 as high risk. For 1741 individuals no baseline Hi\JD measurement 
was available: 614 lived in residential care, and 1127 lived independently. From the 
independently living, 487 did not come to the study center, the others had no BMD 
measurement because of technical reasons, mostly caused by machine downtime. 
7:"1ble 1: AI/emge BAlD at base/illc (SD) I!)' age and gendo: 
Age \Vomcn Men 
< 60 0.862 (0.130) 0.916 (0.133) 
60-69 0.825 (0.132) 0.878 (0.128) 
70-79 0.778 (0.128) 0.861 (0.141) 
" 80 0.747 (0.130) 0.827 (0.143) 
Obserwd hip frac/lfre ;lIddeJIfe 
FoUO\v-up totaled 26771 person-years (10333 for men), and 110 first hip fractures were 
obsenred, 23 of them in men. 111e observed hip fracture incidence rate for the whole 
population was 4.1/1000 pyrs (3.4-5.0). Obsen'ed incidence in the low risk group (2 
fractures) was 0.22/1000 pyrs (0.05-0.S7). In the moderate risk group (27 fractures) the 
incidence was 2.7/1000 pyrs (1.8-3.9) and in the high risk group (25 fractures) the 
obsen'ed incidence was 18.4/1000 pyrs (12.4 - 27.2). In the group without H~'1D 
measurement incidence in residential care (36 fractures) was 19.7/1000 pyrs (14.2-27.4). 
In the independently living participants \vithout HMD measurement (20 fractures) the 
overall incidence was 4.5/1000 PYRS (2.9-7.0). Figure 3 presents these obsen'ed hip 
fracture incidences for men and \Vomen separately. 
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Figure 3: Obse11!ed hip jrarlllfe illcidmfe 0' fisk category find gel/der. 
Table 2 gives an overview of the baseline classification according to the risk function, by 
gender and ten-year age groups, and the number of hip fractures that occurred during 
follow-up. As expected from the nomograms, the high risk group is more prominent at 
older ages and more important in women than in men. At ages over 80 almost nobody is 
still in the low risk group, but an important proportion of the independently living 
population can be considered, a priori, at only moderate risk, especially in men. Table 3 
lists the observed incidence rates for all categories, and the point estimates confirm the a 
priori risk classification. However, in this analysis by age, the confidence intervals arc 
much wider, reflecting the smaller number of events and follow-up time per category. 
'The observed age-adjusted relative risk for hip fractures was similar in men and women. 
'lbe relative risk was 2.5 for each SD decrease in femoral neck HMD (1.8 - 3.6) in 
women. In men this relative risk \vas 3.0 (1.7 - S.4). 111ese relative risks were not 
statisticall)' different (p~O.65). 
Table 2: Risk dassificatiol1 at btlseiim l?y age find gtl/der (Humber of obse11'ed hip fiwc/llres). 
'Vonten Men 
~ 
«S 
u 
Age Low Mo<..\er.He High ImLJ.i,". Res. CllC Toul Loll' risk Mo,,knlc Jligh ImL Liv. Rt:5. Cue Total 
<G() 472(0) 74 (1) 75 (1) I (0) 622 (2) 371 (0) 
(,0·69 591 (1) 661 (1) 9 (U) 2m (2) 8 (0) 147f. (4) 667 (1) 
70·79 85 (0) 736 (tI) 141 ('J) 2(.4 (4) 58 (3) 1284 (21) 161 (0) 
>80 7 (0) 148 (4) 154 (12) 161 (11) 416 (21) 886 (54) 6 (0) 
Tot~l 1155 (Il 1619 (11) 304 (21) 7u7 (18) 4!H(30) 4268 (81) 1205 (I) 
Ind. Liv: Independently hvmg, but no Ui\,ID measured 
Res. Care: Residential care, no BMD measured 
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15 (1) 46 (U) 432 (1) 
365 (2) 1 (0) 155 (1) 5 (0) 1193 (4) 
478 (6) 2'J (U) 147 (1) 26 (1) 841 (8) 
'Xl (1) +t (4) 72(0) 100 (5) 312 (IO) 
948 (10) 74 (4) 420 (2) BI(6) 2778 e2J) 
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T:'lbJe 3: Obsm'cd incidence rales / 1000 p)'rs fry age andgmder (95 % CI). 
Women Men 
Age Low and High Ind. Liv. R~,,;. elf~ Owr.ill Lowmd High Ind. 1.;\ .. 
modcutc modeute 
< 60 0.5 3.5 . 0.8 0.7 0 
(0.07·3.4) (0.5.25.0) (0.2.3.4) (0,1-4.9) 
(,U-(,<) 0.4 , 23 , 0.7 0.8 1.6 
(O.I~I.(') (0.6.9.2) (0.:'>·1.8) (0.3·2.4) , (0.2.11.6) 
70-79 .u \6.6 3.6 17.1 5.2 24 1.8 
(1.8.6.0) (8.6.31.8) (1.4-9.6) (5.5-5:'>.lI) (3.6.7.6) (1.1.5.4) , (0.3.126) 
280 65 22.5 19.1 21.5 18.1 29 27.7 0 
(24-17.3) (128-39.6) (1U.6-3-t6) (14,7--'1.3) (B.9-23.7) (0.4-2O.6) (10.4-73.7) 
Tow 1.6 18.8 6.4 20.5 5.3 L3 1(,.3 L3 
(1.0·26) (123.28.9) (4.U-Hl.1) (14.J-29.3) (4_3-(5) (0.8-24) (6.1-43.4) (0.:'>-5.1) 
* inCidence rates not calculated when observation ttme IS < 100 PYIS 
Ind. Liv: Independently living, but no Bt-.-1D measured 
Res. Care: Residential care, no Hi\'ID measured 
DISCUSSION 
Alain findings 
Rts. elfC O\'cnill 
0.6 
(0.1·4.4) 
09 
, (0.3-24) 
25 
, (1.:\-5.0) 
!B.(, 10.2 
(7.7.H.6) (5.5·1~W) 
16.6 22 
(7.5.J7.0) (1.5.3.4) 
In the community dwelling individuals, the high risk group consisted mainly of 
individuals aged 70 years and older, predominantly women. 'lbe observed incidence rates 
and their precision demonstrate that the risk function accurately predicted hip fracture 
incidence in dle various risk subgroups in men and women. The low and moderate risk 
groups taken together, identified a large proportion of the study group with 100v hip 
fracture incidence, even at ages over 80. However, a smaller group of individuals with 
high hip fracture incidence starting at age 70, could be identified. 
Participants living in residential care institutions had a hip frachIre risk similar to the 
highest risk category. This is in agreement with previous findings of high hip frachIre 
incidence rates in nursing homes and institutions for residential care. IJ,14 Both in 
residential care and in the high risk category, the obselved incidence was slightly lower in 
men. TIlis was probably due to the different age distribution, with men being, on average, 
younger within each group. 
The relative risk for hip fracture per SD decrease in m',,{D observed in this study 
confirms previous estimates. \\lhile for women tIus estimate was based on large studies,4,11 
the estimate for men \vas only based on a small sample. IS. For thc dcrivation of the onc-
year cumulative risk function, we assumed that the relative risk was equal in men and 
women. Our present findings confirm the validity of this assumption. 
The risk evaluation in this shldy was based on a one~year risk estimate and, although 
follow-up amounted to almost 4 years, prediction on a longer term is important for 
therapeutic decisions. Prediction over a longer time period is, however, dependent on 
assumptions about the n:~JD evolution. If we assume linear decline, as \ve found in our 
cross-sectional study, we can estimate long term risk by extrapolation of the current 
BlvfD level on the nomogram. There are, however, indications for a more rapid BMD 
decline at older ages, ](;,17 and, if so, future risk \vould be underestimated. Additionally, it is 
unclear how well an individual BMD measurement correlates with bone density in the 
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future, and long-term risk prediction is dependent on assuming a high correlation. IS 
Follow-up studies over a longer period are needed to answer this question fllore 
precisely. 
Genemlizabili!J 
The risk function was developed based on Dutch data, and its applicability in other 
populations might be limited if either the hip fracture incidence or the bone density 
distribution were different. But, comparing Dutch hip fracture incidence data with recent 
international data,19,21) they appeared remarkably similar to incidences in Sweden, Scotland 
and Switzerland and slightly lower than in US Caucasians. There have also been 
indications that B?vfD distributions might be different in several European countries, but 
those estimates were based on small samples.21 .22 In this large sample, however, the bone 
density distribution was almost identical to that in US \vomen,:n after correction for 
scanner type. 12 This suggests that the application of the risk function is not limited to a 
Dutch population, although additional validation in other populations remains desirable. 
Even while the number of hip fractures in men was small (23 fractures), we believe this is 
an important first attempt to validate risk estimates in a male population. \Y./e are not 
aware of any comparable study where an a priori risk was validated in a follow-up design 
in males, but especially here, additional validation remains necessary. 
To facilitate the usability by users of other brands of densitometers, we have provided 
converted equations in the appendix, while the converted nomograms are available from 
the authors. These conversions, obviously, do not change the risk classification itself, but 
only affect the absolute levels of Bi\'lD, and the associated risk curves. 
Po/eJltial iilJlitatio1Jf 
Although population based, there was self-selection in the participation to the study. 
Even \vith the high response rates, this might cause selection bias towards more healdly 
individuals. TIlere might also be concern about potential misclassification. Since the cases 
that were reported were well documented, this rnisclassification would most likely result 
in an underreporting of fractures. Both phenomena would lead to a lower hip fracture 
incidence than expected from Dutch overall hip fracture incidence rates. However, a 
comparison of our results with national incidence rates, only indicates a slightly lower 
incidence than expected: 110 hip fractures versus 132 expected. This is equivalent to 83 
% (69 % - 100 %) of expected hip fractures, suggesting that those effects were probably 
small. It is, moreover, unlikely that this selection would influence the validity of the risk 
function. 
BJ\{D was not measured in some independently living participants because they did not 
come to the study center, and this could, in theory, again lead to selection bias towards 
more healthy individuals. \'\fhen Bi\<fD was not measured for technical reasons, selection 
bias seems unlikely, and this applied to the majority of participants. In any case, the 
observed hip fracture rate in this group \vas very similar to the overall incidence for the 
same gender. 
66 
2.2 Hip fracture risk estimation in elderly men and women: validation in the Rotterdam Study 
The validation was done in broad risk and age categories, which was necessary to acquire 
enough follow-up time to obtain stable results. In figures 1 and 2 we have indicated one-
year risk levels up to 10 %, corresponding to the clinically relevant observations. In this 
study, there where only 3 women exceeding this 10 % risk and 2 of them suffered a hip 
fracture during follow-up. Although this would correspond to an incidence rate of 
203/1000 pyrs (51-813), we believe this result should not be over-interpreted. \Y/e 
analyzed the effect of age by 1 O-year age categories, and although we are aware that the 
baseline risk is very different within those categories, taking smaller age-categories would 
have frustrated any validation effort. 
For the original derivation of the risk functions we used the baseline B:rvlD data from the 
same reference group as where the risk function was validated afterwards. Since the hip 
fractures in tllls studies were observed afterwards and prospectively, we do not perceive 
this as a problem. An alternative would have been to use reference data from the 
manufacturer, but since those data were not based on Dutch data we preferred to use our 
own. 
Finally, the risk function generated a one-year cumulative risk, while the outcome 
measure of this study was incidence rates. \'{fith the expected and observed incidence 
rates, the difference between those two measures is negligible. 
CONCLUSION 
\'{'e conclude that hip fracture rates can be predicted accurately, from age and B:MD, in 
both meri and women. In prevention programs, \ve need a tool for risk stratification of 
the population. This follow-up study showed that our risk function is a valid instrument 
for that purpose. 111e majority of hip fractures (61 out of 110) occurred either in the high 
risk group or in the residential care group, even though these groups accounted for 
barely 14 % of the studr population. In addition, we found a similar relation of femoral 
neck B:rvfD with hip fracture in men and women. 
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APPENDIX 
Although both the derivation of the risk function by age and femoral neck bone density, 
and the reference data were described previously,,) and are included in the previous 
chapter we felt it necessary to include them here. Additionally, this opportunity was used 
to expand the usability, by converting the risk functions developed from measurements 
on a Lunar DPX-L machine to other brands of bone density equipment. 
In the Rotterdam Study, we observed a linear decline of bone density with age in men 
and women. The average bone density at all ages, measured with a Lunar DPX-L 
densitometer, was given by: 
1.121284 - 0.00456· age 
and 
1.08586 - 0.0031' age 
B1\'ill was normally distributed at all ages with an overall standard deviation (SD) of 
0.134 in women and 0.135 in men. 
Using the conversion algoritlul1s of Genant et al12 we converted these regression 
formulas to: 
a f3 * age 
using the appropriate values from table 4. 
TabJe 4: RiskflllJrtioIJ MllleS for IlIlIat DPX-L, Hologic QDR-2000 and Nodand XR261Hmk ii 
dmsilolJlelers 
I Lunar DPX-L Hologic QDR 2000 Norland XR26 Mark II 
\'\fomen ~Ien Women Men Women Men 
a 1.121284 1.08586 0.9293393424 0.89977896 1.040553924 1.00651146 
~ 0.00456 0.0031 0.00381216 0.0025916 0.00438216 0.0029791 
SO 0.134 0.135 0.104024 ",q}~~8~ .,~." 0.125074 0.126035 
. -- -"--~~-.- - -
Using this conversion on the HMD data from women in our cohort, the rclation of B:MD 
with age became almost identical to the NI--IANES III data.23 Unfortunately, no such 
widely accepted reference data are available for men. 
Por the derivation of the risk function, we used Dutch nationwide hip fracture 
registration to estimate the hip fracture incidence function by age and gender, and 
additionally, we used the assumption of a 2.6 relative rjsk per SD 100ver femoral neck 
bone density. Under those assumptions,') the one-year cumulative risk is given by: 
Pdxe,lI"omm,B.llD (
5.9.10-15.age9_07JJ) (t-{l'<1g~-IUm 
.26 SD 
1.578541 . 
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and 
(
9.3.10-15.ageS_s-m) a-p'uf',e-8JID 
.2.6 SD 
1.578541 
again using the appropriate values from table 4. 
Figures 1 and 2, adapted for use with either Hologic or Norland densitometers are added 
at the end of this chapter. 
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2.3 HIP FRACTURE PREDICTION IN THE INDIVIDUAL 
INTRODUCTION 
The association of bone mineral density (B:~'ID) with subsequent hip fractures has been 
demonstrated in several studies, and in a meta~analysis the relative risk for women was 
estimated at 2.6 for 1 SD decrease in B1lD measured at the femoral neck.! Previously, 
we showed that, for groups of individuals, the hip fracture risk can be estimated 
accurately by age, gender, and Bfi,ID,l using the risk functions that we developed based 
on Dutch data.) \"X'e also showed that the same relative risk estimate can be used for 
men/ and that men and women have the same risk for hip fractures at the same age and 
Bj\fD level. J 
For general prevention purposes predictability of fractures for groups of individuals is 
important. It is, however, less easy to predict which individual will suffer a hip fracture in 
the future. 
Since it is part of the definition of osteoporosis, Bi\rD can be used for the diagnosis of 
osteoporosis, and as such it will give an indication of individual risk, but it is not 
necessarily a good test to predict hip fractures in individuals, ie prognosis.4 The \\'orld 
Health Organization defines osteoporosis as a bone mineral density (Bi\.fD) of 2.5 
standard deviation (SD) below the mean for young adults. TIle number of SD's from this 
average for young adults is called a T-score.5 Bi\1D results can also be expressed as a Z-
score. A Z-score corresponds to the number of SD from the age and gender specific 
average. 
In this chapter, we evaluate the performance of our risk functions as an individual 
prognostic test for hip fractures within a large population based follow-up stud}t, and 
compare it to the mere prediction by age and gender, and to the usc of the conventional 
T -score and Z-score thresholds. 
wlETHODS 
For the risk estimation we used the risk functions for men and women that were 
described previously;' and that yield a one-year hip fracture risk estimate based on 
gender, B.MD and age. The study was conducted \vithin the Rotterdam Study, a 
population based prospective cohort study of the occurrence and determinants of disease 
and disability in the elderly.(' For participants in whom Bi\JD at the femoral neck was 
measured at baseline (Lunar DPX-L densitometer), we calculated the one-year 
cumulative risk according to the risk functions, as an individual and continuous risk 
estimate. Those participants \vere subsequently followed-up for the occurrence of hip 
fractures during on average 3.8 years. Details of procedures and partial results have been 
reported elsewhere (see also chapter 2.2).2 
The performance of the risk function as an individual prognostic test was assessed by 
calculating the ROC area under the curve, and the sensitivity and specificity at various 
risk thresholds. To evaluate the additional value of the Bl'.'lD measurement, we compared 
this with the performance of a test using just age and gender for risk prediction in the 
same group of participants. 'nlis was done by comparing the ROC area's under the 
curves, and by calculating the positive predictive value (PPV) at different risk thresholds. 
Additionally. we compared sensitivity and specificity of the risk score to the sensitivity 
and specificity of aT-score'::::: -2.5 and of a Z-score .::::: -I. Por the Z-scores, we used our 
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previously published Dutch reference data,) and for the T-score we used the same 
absolute value (0.675) in both men and women, based on Dutch reference data.7 The 
argument for choosing the same value for men was first proposed in chapter 1.1 and 
further validated by our finding that hip fracture risk is similar in men and women at the 
same age and Bi\-ill level:' 
The ROC area under the curve and its precision was calculated using the ROCFIT 
program.I\,') The precision is presented as 95 % confidence intervals (CI). 
RESULTS 
Complete follow-up was achieved for 5305 participants (2227 men). In this group we 
observed 54 hip fractures during an average follow-up time of 3.8 years. Table 1 gives an 
overview of the risk estimates in 10-year age classes and the observed number of hip 
fractures. 2 
Table 1: Ollcj'ear lisk eslliJJalc al baseliue l?Y age (wd gmder (lJllJJlber oj obsert'ed hip fmc/llres). 
\Y/omen Men 
Age <0.1% 0.1 -< 1 % >1% Total <0.1% 0.1-<1% > 1 % Total 
< 60 472 (0) 74 (1) 546 (1) 371 (0) 15 (1) 386(1) 
60·69 591 (1) 661 (1) 9 (0) 1261 (2) 667 (1) 365 (2) 1 (0) 1033(3) 
70·79 85 (0) 736(11) 141 (9) 962(20) 161 (0) 478 (6) 29 (0) 668(6) 
~ 80 7 (0) 148 (4) 154 (12) 309(16) 6 (0) 90 (1) 44 (4) 140(5) 
Total 1155 (I) 1619 (17) 304 (21 3078(39 1205 (1) 948 (10) 74 (4 2227(15) 
Sensitivity and specificity at various threshold values of the risk estimate, in men and 
women, are shown in figures 1 and 2. 'Ibose figures show that, at a threshold risk 
estimate of 0.5 % one-year risk, sensitivity and specificity are around 80 % in both men 
and women. 
1J 100% ......... ______ 
ffi ~80% t---------~~~~----------c=========,_---~'- ,-------"--7L-/--.......... -""" .... ______ -II-SenSiti~tyl, __ 
.- .g 60% ,- / ......... I .I .~ 'u " -Specificity; ~ ~ 40% +---/-r'~--~""',,-..----'=~==~-
~ ~20% t--~/~----------------.~~----~~~~-
0% 
o 0,1% 0,5% 1% 2% 3% 4% 5% 
Risk Threshold 
Figure 1: Swsilil1i!)' alJd specificity al tJaliolls fisk thresholds in wO/Jlm. 
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100% .-.... ~ ... .. 
"0 • 
lij ~80% 
• 
.Sensili\Hy 
. ~:!! 60% • 
> :t: ... --Specificity 
.- () • • t:: C1I 400/0 
---'" c- • ~ Ch 20% • ~ 
. - - . -
0% T 
0 0,1% 0,5% 1% 2% 3% 4% 5% 
Risk Threshold 
Figure 2: Se1JsilitJiI)' (wd specificity (It mfiollS fisk thresholds in/JIm, 
The overall ROC area under the curve for men and women combined was 0.86 (0.81 -
0.91), \\!hen B.MD was excluded, using only age for risk prediction, the area under the 
curve decreased to 0.79 (0.73 - 0.85). For women the area under the curve was 0.85 (0.79 
- 0.91) versus 0.81 (0.74 - 0.87) for age alone, and for men 0.87 (0.79-0.95) versus 0.74 
(0.60 - 0.88). 
In another representation of the same data, we compared the PPV of both tests. \X!hen 
no test is used, considering everybody at risk, dIe PPV is equal to the cumulative 
incidence for the total population. In women, this prior probability of a hip fracture, 
considering everybody at risk, was 1.3 0/0, while the sensitivity was obviously 100 0/0, 
\X/hen we introduce testing, the aim is to increase this PPV while retaining acceptable 
sensitivity, By increasing the risk threshold of the test, the sensitivity decreases. But, at 
the same time the PPV increases. Figure 3 demonstrates tIus effect of changing the risk 
threshold level on the PPV and the sensitivity in women, TIle solid curve represents the 
risk function, including age and B.~JD, while the dotted curve shows what happens using 
only age as a risk indicator. On the graph we have indicated the corresponding ages: the 
area where the curves of both tests diverge, corresponds to the age of 75 years and older. 
In men, the prior probability was 0.7 0/0, At all ages the probability of a hip fracture was 
lower than in women of the same age. As shown in figure 4, also in men the curves 
diverge in the area corresponding to the ages of 75 years and older. However, at ages 
above 80, results became unreliable. 
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indi(ates the ,isk jimrtio1J i"dudi1lg BiHD al/d age, lJ!hile the dolted lim represmtf the lISe of OJlIY {?ge tIS 
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Subsequentl}', we compared the sensitivity and specificity of the risk function with the 
performance of using the conventional '1'- and Z-scores. Figures 5 and 6 show the 
threshold values used in women and men. They show that in \vomen the use of the T-
score or Z-score thresholds, yields the same absolute n:~'fD value around the age of 70, 
After that age, a T-score of -2.5 corresponds to a higher B:~'ID value than a Z-score of-
1, and at later ages, a large proportion of women have BivID values lower than aT-score_ 
of -2.50 
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Figure 6: Absoillte BMD (g/ m/) tbresholds (LffJlar DPX-L) ill lJ/eIJ. 
\"'{Ie compared the sensitivity and specificity of the risk score, as shown in figures 1 and 2, 
to the performance of the conventional T and Z-scores in lO-year age classes. In figures 
7 and 8 this is shown for women, and in figure 9 and 10 for men. l11ese figures show 
that both in men and in women, sensitivity and specificity of the use of nr.'ID alone, not 
taking into account age, is good at low ages, but much lower at higher ages. Specificity 
remains acceptable at higher ages, but sensitivity drops to 50 % or lower. In interpreting 
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these figures, it should also be remembered that the number of hip fractures at the ages 
below 70, is extremel), low. 
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Figure 7: Jemitil-'i(y alld specificity a/llmiollS ages for T-scol? ~ -2.5 in JJ10lJleJJ. 
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DISCUSSION 
l'.[aill reSllits 
The choice of an optimal threshold is a trade~off between the cost and effects of the 
proposed intervention and the cost of missing a hip fracture, As a prognostic test, both 
the sensitivity and specificity of our risk function, incorporating both Hi\lD and age, were 
around 80 % at a risk threshold level of 0.5 % one-year risk, regardless of age. The 
conventional T- and Z-scores, including only Bn'ID, performed satisfactorii}' at ages up 
to 70, when the risk of hip fracture is trivial, both in men and women. At ages over 70, 
however, when hip fractures really become a problem, their performance is bad. 
The risk function also performed better than age on its own, as demonstrated by the 
ROC area under the curve, A ROC area under the curve, hmvever, describes the overall 
performance of a test at all thresholds, and does not provide information about the 
performance at specific thresholds. Our analysis showed that the better performance 
suggested by the ROC area under the curve, was due to a better performance from age 
75 omvard. In women this trend \Vas stable, but in men the results became unreliable at 
ages over 80, due to the small number of elderly males, and therefore, the small number 
of events. 
Implications 
Conventionally, the results of BMD measurements are expressed as T-scores or Z-
scores. They give an indication of the relative BMD level of that person, but in fracture 
prevention, we really need a tool for estimating the fracture risk of an individuaL The risk 
functions that we evaluated in this stud}" appear to be a valid instrument for this, and the 
nomograms \ve presented else\vhere,z can assist in a better interpretation ofB:i\1D 
measurements taking age into account. 
A threshold of 0.5 % annual risk appeared in this study to be a potentially interesting 
cutoff value, offering both high sensitivity and specificity, for the short term risk 
estimation, From the nomograms we can read that this risk thresholds corresponds to 
the risk of a 77 year old women with average BMD, but also to a 70 year old women with 
a T-score of -2,5, W'omen with high Br.,fD only reach this risk level at later ages, 
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Our risk functions, and their performance were validated over a period of almost 4 years, 
and for estimating the individual short term hip fracture risk, including the measurement 
of BnJD was only superior to age alone after the age of 75. At ages under 60, a low B1\{D 
had appeared to have both high sensitivity and specificity for predicting hip fractures, but 
past that age the performance of the B1\ .. ill thresholds alone dropped dramatically This 
does not necessarily mean that BMD measurement at those ages is useless in clinical 
situations. 
\\;'hen wc \vant to predict who will have a hip fracture when they will be older, we need 
to assume that individuals with low BMD for their age and gender, will remain on that 
same relative level in the future. Under this assumption, long term risk can be estimated 
by extrapolating their future BMD level. But, currendy, litde is known about the long 
term B1'ill cvolution, since most studies of age related bone density decline are either 
cross-sectional or have limited follow-up time. The few long term studies available 
indicate indeed that the correlation of B~lD measurements declines with time. III In the 
last part of this thesis, we will use modeling techniques to study the effects on the long-
term risk, of different assumptions about correlation ofBMD measurements over time. 
Concllfsion 
Absolute Brvill thresholds have limited value when age is not included in the assessment 
of hip fracture risk. The risk functions including age and Bn'ill give more clinically 
relevant information than the commonly used T-scores and Z-scores. A threshold level 
of 0.5 % one-year risk had, in this study, both a high sensitivity and specificity, and is 
therefore, potentially, an interesting and clinically relevant cutoff point. However, 
confirmation and validation in other populations is desirable. 
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PART 3 
MODELING PREVENTION 

3.1 ESTIMATING LIFETIME RISK OF HIP FRACTURE IN 
WOMEN 
INTRODUCTION 
To target prevention of hip fractures at those with the highest risk, it is important to be 
able to predict hip fractures and to estimate the lifetime risk. The direct cause of a hip 
fracture is mostly a fall, but their occurrence is closely associated with osteoporosis.! 
Although it has been shown that bone mineral density (BlvID) can be used for estimating 
short term hip fracture risk,I.3 less is known about the long-term risk. Ideally, we would 
like to have long-term data from follow-up studies to assess the long-term evolution of 
B:~\'ID and its predictive power for hip fracture incidence. Currently, we do not have 
those data, and we would have to \vait unacceptably long before \vc \vauld obtain them.4 
Ivfodeung cao, in those cases, be a solution, provided that there are reasonable 
assumption that can be made. 
In this chapter we describe two models that were developed to assess the lifetime risk of 
hip fracture in the population at large at different ages, and at the conventional BlvID 
thresholds as defined by T-scores and Z-scores. 
THE STRUCTURE OF THE MODELS 
Two separate models were used to estimate lifetime risk for hip fracture. TIle first model, 
that will be referred to as the 'illdividlfallJlodel' estimates the lifetime risk for a person with 
a given age, gender and B1{D. This model is a lifetable-based spreadsheet, where a start 
age and a start BMD are defined. Every year, the probability to die and the probability of 
a hip fracture are calculated. Only the occurrence of first hip fractures is considered in 
the analysis. 
The second model, that will be referred to as the 'poplflntiolllJlodel' basically performs the 
same analysis, whereby every year (or at other time intervals) the risk for a hip fracture or 
death is calculated, but rather than describing age and BMD as fixed starting points, the}' 
are entered as distributions. At the beginning of each simulation a virtual person is 
created with an age and Bl'vID drawn from those distributions. Then this person is 
followed through the model till he or she dies. At each time interval the model calculates 
the age, BMD and subsequently the risk of events. From these risk distributions, either a 
hip fracture, death or no event, are randomly drawn. After the death of a virtual person, 
this is repeated for the next. The final results are the averages from the whole simulation 
nlll. Figure 1 graphically depicts the basic structure of both models. 
81 
<- )steoporosis and fracture pren'lltion 
Figure 1: Bafic ftmdJl1lJ if the lJIodels. 011 the lift fide, the illput is difined (If either a fixed age al/d 
BiHD ~lIdil)idllallJlode!) or af a dhiJiblltioJ/ oj age (wd Bl1JD ill the populatiolllJlodel. 011 the dght 
side, the JlfllJlber 0/ e/!wtf) and the I/lOlJleNt Jllhm th~y O(Cllr in time are couNted. 
During the simulation the virtual person ages, and future B.~'ID is calculated. , \Xlhile the 
calculation of future age is straightforward, estimating future B11D is less obvious. One 
possibility is to use the cross-sectionally measured Bi\ID decline observed in a population 
and to apply this to the start BMD, assuming that the bone density at time 0 is perfectly 
correlated with bone density at time t, assuming the same rates of bone ioss in different 
individuals. The few longitudinal studies that are available, however, show that this 
correlation is less than 1, partly due to different rates of bone loss and partly due to 
random error. 5-7 
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Assuming that the correlation coefficient p that is less than 1, the average HMD at time t, 
given the baseline Bn-'ID ex) at time t, is given by: BMD{1\'(Tage = fl/ + p :!..Lex - flo), 
<To 
where Iln is the average Hi\ill for the population at baseline age, an the SD at baseline 
age, and at the SD at age+t, Assuming homoscedasticity, as found in the Rotterdam 
study, this becomes simply: BMDamage = fl, + P (x- flo). The standard deviation of 
B:~'1D at time t is given by SD = 0'/ ~l- p2 . 
\'<'hile testing the appropriateness of the bivariate normal model to describe the 
uncertainty of future B~\'ill) \ve observed important regression-to-the mean phenomena 
when using low correlation coefficients, and extremely low baseline nrvID values. Under 
those circumstances (I-score < -3.5 at age 55 and p < 0.7) we even observed small 
increases of average B:~'ID with age. Since this only happened under extreme 
assumptions, we will limit the use of this model to more common Hi\lD thresholds. 
In the population model, a baseline Bl\'ID is randomly assigned for every individual from 
the distribution of Bi\fD at that age. Then, based on the applied correlation coefficient 
and the assigned baseline BMD, a EMD value at time t is drawn from the calculated 
distribution. \Ve assumed a linear evolution of En'ill from the baseline value to this new 
value at time t, After time t, this linear decline is further extrapolated into the future. 
In the individual model this distribution of future Bn-'ill was implemented in a similar 
way, using @Risk software as a simulation add-in tool for the spreadsheet,s 
PARAlvlETERS FOR THE MODEL 
Simulation rhamrtnistirs 
In the individual model \ve calculated the lifetime risk at different ages and for several 
clinically relevant HMD thresholds. \'<'e did dus first assuming perfect correlation and 
then for correlation coefficients lower than 1. 
To determine the lifetime risk at different ages for a population, we started with cohorts 
of equal ages in all the simulations with the population model. Those virtual persons 
were then assigned a B:~'ill drawn from the bone density distribution at that age. To 
aclueve high precision of the lifetime risk estimate, the model was run on cohorts of 
1.000.000 women, leading to extremely small confidence intervals. 
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Baselim B1HD alJd alla!ysis thresholds 
The input femoral neck BMD distribution at all ages was based on the distributions given 
in chapter 2.1.') \Y./e also used these distributions to calculate Z-scores at every age for the 
simulations in the individual model. As thresholds in the individual model, we used 
respectively aT-score = -2.5, and Z-scores equaling -1 and O. 
Average values for young adult women were obtained from a Dutch study, also using a 
Lunar DPX-L densitometer. lII \,(/ith those reference values, aT-score = - 2.5 
corresponded to a B.~'lD level of 0.675. This value was very similar to the threshold value 
in the machine specific USA Reference population. 11 In that population, a T-score of-
2.5 corresponded to a B:~JD level of 0.681. 
Hip /raflllre risk 
The risk functions based on age, gender, and femoral neck ENID are described in chapter 
2.1.') These theoretical one-year risk functions were validated over a period of almost 4 
year in a large cohort from the Rotterdam Study as described in chapter 2.2.12 \Y/e 
extrapolated those risk functions into the future, and we assumed them to remain valid 
through life. 
l\lortft/il)' 
.~'I'1ortality was based on Dutch cross-sectional mortality data for 199313. Mortality was 
modeled as a continuous function with the SPSS curved fitting function. H Best fitting 
was an exponential function, aIld the one year mortality risk in women by age (/1000) 
was given by: d
ag( = 0.008 * e(O.Il."ge) 
Estimating/lltllre B1HD 
In a first analysis, we assumed perfect correlation of baseline Bi\,ID with BMD later in 
life. To determine future BMD, we used a linear decline based on the cross-sectionally 
measured B:r."ID decline with age described in chapter 2.1.') Subsequently we tested the 
effect of non-perfect correlation ofBf..'fD measurements using correlation coefficients 
lower than 1. \Y/e changed the correlation of baseline Bn'ill with En'ID 20 years later 
between 0.6 and 1 corresponding to the orders of magnitude of previous estimates of 
this correlation.5-1 The rate of decline of Bf..'ID was assumed to be linear over those 20 
years and the same rate of decline was further extrapolated into the future. 
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RESULTS 
The illdivMllal model 
TIle calculated lifetime risk of hip fracture for women at different ages and with various 
BlvID thresholds, assuming perfect correlation of Bn'ID measurements is shown in figure 
2. It was remarkabl}' similar at all ages when Z-scores were used: at every age the lifetime 
risk was about 11% in \vomen \vith average Bfl/ill, and about 25% in \vomen with Bn'ill 
at - lSD for that age. 
However, when T-scores were used as thresholds, the lifetime risk was higher at younger 
ages for the same T-score. reflecting the fact that a T-score is a fixed cutoff level of 
B~'[D. The Bi\ID thresholds correspond to the threshold values used in chapter 2.3 and 
they are discussed in more detail there. As shown in 6gurc 5 of that chapter, aT-score ::::: 
-2.5 and a Z-score ::::: -1 become equal around the age of 70 in women. ll1ercfore, risk 
estimates based on both scores will cross at that age. Lifetime risk before this age was 
higher when the T-score threshold was used, afterwards the opposite happened. 
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Figure 2: Life tillle ,isk for Np fm{t{{re for IJ'OIJIefJ at d{fjermt ages awmlillgpnjerl {onelatioll. The 
estimates/or B1HD thresholds J1'fre obtailU'd with the j"dil'idflalmodel, the al'emge lisk Wt/S estilllated 
with the populatioll lIIode!. 
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The previous calculation assumed perfect correlation between B11D measured at one 
moment in life, and bone density measured later. Figure 3 shows the effect on the 
lifetime risk at age 55 of less than perfect correlation, assuming correlation coefficients p 
ranging from 1 to 0.6. When a correlation coefficient lower than one was assumed, we 
found that the lifetime risk calculated previously, was overestimated in women with low 
baseline Bn,rD. 
\V'hen the T-score was -2.5, the estimated lifetime risk at age 55, that was 33 % assuming 
perfect correlation went down to 24 % when correlation was 0.6. \X'ith a Z-score = -1 at 
age 55, the estimated lifetime risk declined from 24 % to 20 %. 
In women with average and high baseline BMD, however, the previously estimated 
lifetime risk assuming perfect correlation, appeared underestimated. For women with 
average BMD, estimated lifetime risk \vent up from 10.9 % to 14.3 %. 
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Figllre 3: Lifetime n"sk at age 55 for d{j)erent bmeiine leNls ofBiHD alld differellt /el.'e/s of 
forre/ation. The estilJlates for RMD thresholds were obtained with the indifJI·dlla/ model the anmge lisk 
was estill/ated with the population model. 
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Figure 4 shows the same analysis for lifetime risk estimated at age 70. \,</e observed 
similar effects, but with a smaller magnitude, since there is less uncertainty about future 
HMD when B~,,1D is measurcd later in lifc. 
As mentioned earlier, Z-score = -1 and T-scorc = -2.5 correspond to almost the same 
absolute B:L\'ID lcvel at age 70. Therefore, lifetime risk estimates are vcry closc at this age. 
The estimate for Z-scorc, assuming perfect correlation is 24.S % while the estimate for 
T-score is 23.S %. W/hen correlation coefficient 0.6 is assumed these estimates go down 
to 21.6 % and 21.5 % respectively. 
In women with average and high baseline B:~'1D at age 70, the lifetime risk was again 
underestimated, but less pronounced than at age 55. For women with average BnJD, 
estimated lifetime risk \vent up from 11.2 % to 12.4 %. 
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Figure 4: Lifetime n'sk (If age 70 for dtfferent baseline lerels ofBi'ID and diJjerent Iet/fls of 
(orrelatioN. The estimates for BiHD thresholds were obtained with the liJdil'id/lal model, the anmge n"sk 
JMS estimated JJlith the pop/dation mode/. 
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The popJ(lafio1J model 
The population model estimates the lifetime hip fracture risk for a population with a 
n:r...fD distribution corresponding to the distribution of the Dutch population at that age. 
'lbe lifetime risk at different ages, and assuming perfect correlation of Bl\'fD 
measurements over time is given in figure 2 as the average risk curve. At age 55 the 
average lifetime hip fracture risk is estimated at l3.3 %, slightly higher then the risk for 
an individual with average BMO, due to the combination of an exponential increase of 
risk with lower BnlD, together \vith a normal distribution of this Bf..'ID. TIlls lifetime risk 
remained stable when estimated at later ages. TIlls is due to the exponential increase of 
both the incidence of hip fractures and death, as competing risks. Onl}' at ages over 80 
the lifetime risk decreases slightly. 
The average lifetime hip fracture risk at ages 55 and 70, but assuming less than perfect 
correlation is included in figures 3 and 4 as the average r.isk curve. At the age of 55, the 
average lifetime risk, previously estimated at 13.3 %, went slightl}' up to 14.4 % as shown 
in figure 3. TIus phenomenon was due to the exponential increase of risk with lower 
Bn'ID. Therefore, the effect on lifetime risk in people with lugh baseline Bi\tID loosing 
more bone than expected outweighed the lower than expected risk in people with a low 
n:MD at baseline, but loosing less than expected. 
\"'{/hen we estimate lifetime risk at age 70, we observe similar phenomena, but smaller in 
magnitude. 'TIle population lifetime risk assuming perfect correlation was estimated at 
13 .. 4 % and it remained at the same level with decreasing correlation. 
DISCUSSION 
lUain findings 
Assuming perfect correlation of BMD now and in the future, the average lifetime lup 
fracture risk at age 55 was estimated at 13.3 %, a risk comparable to previous estimates of 
the lifetime risk by other groups. is-iS Moreover, this lifetime risk remained stable 
regardless of age. Only at ages over 80 this lifetime risk decreased slightly. Also when z-
scores are used to evaluate BMD, the lifetime risk remained similar at all ages. The reason 
for both phenomena is that, although hip fracture risk increases exponentially with age, 
this phenomenon is matched by a similar exponential increase of mortality, and the ratio 
of hip fracture risk and mortality risk is relatively stable through aging. 
A T-score on the other hand, is a fixed threshold value, and therefore the lifetime risk is 
much higher when T-score is low at a younger age. The consequences of this and the 
discussion about whether a T-score or a Z score is to be preferred for screening purposes 
\vill further be addressed in the chapter 3.2. At ages around 70, both scores have the 
same absolute meaning in this population and with the reference values used. 
\"'{'hen non-perfect correlation of Hi\ID over time was assumed, we conclude that the 
lifetime risk in women labeled at high risk \vas overestimated. On the contrary, in women 
considered at low risk, the lifetime risk was underestimated. This is most prominent 
\vhen screening occurred at younger ages. At age 70 this phenomenon is still present, but 
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much less pronounced. This, again, might have important consequences, since it means 
that the performance of screening at an early age will be overestimated when this 
declining correlation is not considered. 
The lifetime risk at age 55 for the population at large was found to be 13.3 % assuming 
perfect correlation. But assuming a lower correlation, this lifetime risk increased slightly. 
Apparently, the underestimated risk in women at 100v risk outbalances the overestimated 
risk in women at high risk. 
Strengths l11Jd limitations 
One of the main limit'ations of 'any modeling study lies in its assumptions. The relation of 
hip fractures with age and bone density was derived theoreticall}', but validated in a 4-
year follow-up study. But, this distribution of bone density related to age \vas only 
observed in a cross-sectional way. This might lead to observation biases. Ideally, we 
would prefer long term longitudinal bone density data. In the future, studies such as the 
Rotterdam Study are expected to provide those. 
'I11e use of a correlation coefficient to express the uncertainty about the long-term 
evolution of Bf..,ID has not been validated and might indeed present some problems at 
extreme BMD values, as indicated in the methods section. \,\'hether this is caused by a 
bias in observational cross-sectional studies caused by surplus mortality in persons with 
lower BMD or whether the bivariate normal model is not completely suited for 
describing the relation of BMD density measurements remains to be investigated in long-
term follow-up studies of bone density. However, with the Bl\'ID thresholds used here 
this problem appears to be minor compared to the uncertainty surrounding the 
correlation coefficient itself. 
C01Jr/tlsio1JS 
\Y.le estimated lifetime risk of hip fracture at several ages. At all ages this risk is around 
13.3 %, and it only declines slightly after the age of 80. But, \vhen taking into account the 
uncertainty about future rates of bone loss, this lifetime risk estimates appears slightly 
underestimated. \'('hen using specific Bf..,ID thresholds for risk estimation, the lifetime 
risk is overestimated at low Bl."ID values, but underestimated at average or high B:MD . 
. Measuring B:MD later in life partly circumvents these problems, since the uncertainty 
about future B10fD diminishes. 
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3.2 MODELING INTERVENTIONS 
INTRODUCTION 
In the previous chapters we have developed models to estimate short-term and long-
term hip fracture risk by age and bone mineral density. The aim of interventions on 
osteoporosis is to reduce dus fracture risk. In this chapter, we will usc the previously 
described models to study the dynamics of interventions on osteoporosis and fracture 
prevention, with a special focus on their potential cost-effectiveness. Designing a cost-
effective intervention means that we not only need to select the most suited treatment 
but also the right target population and the age at which intervention result is optimal. 
l",Iany treatments have been proposed for osteoporosis, ranging from general healthy 
living recommendations such as diet, exercise and smoking cessation, over the use of 
pharmaceutical drugs such as calcium or vitamin D supplementation, hormone 
replacement therapy (HRT), bisphosphonates, up to thc usc of hip protectors. But, in the 
most optimistic scenarios, the hip fracture risk reduction is not larger than 50 %, and 
most often it is smaller. 1 For most intenrcntions it is also unclear what happens with the 
effect after treatment cessation, although it is assumcd that there will be an offset of 
effect in the following years, and in some cases such as HRT it is likely that lifelong 
trcatment is needed. 1 
In a perfect world, we would like to possess long-tcrm data from clinical trials to assess 
the long-term effectiveness of different intelventions. If we want to study the effect of 
carly intervention on long-term hip fracture risk therc arc, however, long delays between 
the start of the intervention and the occurrence of the event, so unacceptably long 
follow-up \vould be needed to reach conclusions.2 ~{odeling allows for the simulation of 
reality but should be used with caution. It is important that the assumptions used are 
reasonable and supported by the best available evidence. 
Recently there has been some debate about whether osteoporosis should bc targeted to 
the whole population, a public health approach, rather than to high risk groups.3,4 
Attractive as it may seem at first, it seems unlikely tllat this type of intervention, unless 
very effective and inexpensive, could ever bc cost-effective.5 111ereforc, it can be 
expected that the focus of osteoporosis \vill. at least for a \vhile, be on a high-risk 
approach where individuals at high risk will need to be identified, 
An important predictor of hip fracture risk is bone mineral density (I3l\lD), leading the 
\,{fHO to define osteoporosis as aT-score < _2.5.6 But, the short- and long-term hip 
fracture risk is very much dependent upon the age at which this T-score is reached as \ve 
showed in part 2 of this thesis, 7.~ and in chapter 3.1. Nevertheless, this threshold has 
evolved into an intervention threshold in many guidelines around the world, regardless of 
9·12 
age. 
In this chapter \ve will compare the effect of a population approach without screening 
with a screening approach. \'{fe will also assess the effect of age at intervention on 
effectiveness and the potential cost-effectiveness of hip fracture prevention in women. 
As an example of a screening approach we will usc the conventional bone density 
thresholds. Rather than focus on specific therapies, we choose a generic approach where 
we compare theoretical intenrcntions leading to a preset risk reduction, without 
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specifying whether this was obtained through a pharmaceutical or any other intervention. 
Additionally we will address the uncertainties about the duration of effect after treatment 
cessation. In doing so, \ve will try to clarify the dynamics of intervention scenarios in hip 
fracture prevention. 
METHODS 
The mathematical model used for the intervention modeling was a purpose written 
model described in chapter 3.1 as the 'populatioJJ model'. \Vie used this model to estimate 
the lifetime risk for hip fracture at different ages with changing assumptions about the 
correlation between B.MD measured at one moment and Bn1D measured 20 years later. 
In this chapter, we will use the same model to assess the effect of theoretical preventive 
interventions in various situations of screening and non-screening and at different ages. 
The model was fitted with exactly the same parameters as described in chapter 3.1. Each 
of the intervention scenarios was compared with the baseline scenario of no intervention. 
Baselille !eel1mio! 
In the baseline scenarios we estimated the lifetime risk for hip fracture in a cohort of 55-
year-old women that were followed up for a lifetime without any intervention. The 
results for these baseline scenarios were described in chapter 3.1. 
IJ1ter1!entiolls 
\Vie assumed hvo theoretical interventions: 
Intervention 1: lifelong treatment having lifelong full effect 
Intervention 2: a 5-year treatment period with full effect, followed by a linear decline of 
the effect over a period of 5 year after treatment cessation. 
For each of these hvo interventions we assumed 2 different effectiveness assumptions, so 
that each intervention lead to a hip fracture risk reduction of either 20% or 50% during 
the period of its full effect. 'l11ose levels of risk reductions were arbitrary, but chosen to 
correspond to clinically relevant risk reductions. \'\'1ith risk reduction !O\ver than 20 %, 
intervention would probably not be envisaged, unless the treatment is both save and 
inexpensive. A risk reduction of 50% corresponds to the highest estimates to date of 
intervention effectiveness. 1 
The interventions were all assumed to have an immediate effect. Using this approach also 
implies that we assume that intervention effectiveness was equal at all ages. 
Targetillg tbe iuterl!f11tiollS 
Wle modeled the effect of timing by starting the theoretical intervention at different ages. 
For each of these ages we either applied the intervention directly to everybody without 
screening, or only to a high-risk group. 
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As examples of risk thresholds we used either aT-score < -2.5 or a Z-score < -1. The Z-
score was calculated from Dutch age specific HMD distribution data.7 Average values for 
young adult women were obtained from a Dutch study. \3 As described previously in this 
thesis, a T-score of - 2.5 corresponded to a Hr.'ID level of 0.675 measured on a Lunar 
DPX-L densitometer. 14 
It was assumed that screening \vas followed immediately by treatment when appropriate. 
Since \ve assessed the effect of preventive strategies on the occurrence of a first hip 
fracture, we did not allow the model to start intervention when a hip fracture had 
occurred previously. 
Correlation of B1HD oifer tillle 
For each of the interventions, we assessed the effect of the uncertainty of future Br ... 1D 
evolution, given a baseline value. First the interventions will be analyzed assuming perfect 
correlation. Next, we will assess the effect on treatment effectiveness and cost-
effectiveness assuming a lower correlation, as described in chapter 3.1. For the purpose 
of this analysis we will present the results for a correlation coefficient p = 0.6. 
NIJlllber of treatlllent J'WI'S 
In the lifelong treatment scenarios, treatment years were counted as the number of years 
until the occurrence of either death or a hip fracture, \\/hen 5 year of treatment was 
assumed, this was counted as 5 years unless either death or a hip fracture occurred 
before. 
To achieve high precision for the baseline scenarios (no intervention with either perfect 
correlation or with p = 0.6), these were run on cohorts of 5.000.000 women, leading to 
extremely small confidence intervals (Cl) for the parameters of interest. The intervention 
scenarios were run on cohorts of 250.000 women. It was felt that when, after this 
number of sirnulations, results did not become precise and statistically different from no 
effect, they were probably irrelevant anyway. \\fhen the effect is not statistically different 
from no effect after 250.000 simulations, it will not be shown in the tables. \\'hen the 
lower limit of the 95 % CI was lower than half the point estimate or the upper limit over 
double the point estimate this will be indicated in the tables. 
PreseJltatiolJ of the reSlllts 
The main results will be presented as proportion of first hip fractures avoided and 
treatment years per hip fracture avoided. Additionally, we will describe the number 
needed to screen to avoid one hip fracture, as a measure of the screening burden, 
First we will present the results for both interventions assuming perfect correlation of 
Bi\,ID over time. Subsequently, we will present the results for the same intervention, now 
assuming that the correlation of B:~.fD over 20 years time is only 0.6. 
In a sensitivity analysis the originalS-year offset of treatment period was modified to 0 
and to 10 year linear decline of the protective effect after treatment cessation. 
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RESULTS 
I. Bf/seline sCeJJarios (110 il1/erJ!e1Jliou) 
In the baseline scenario we estimated the lifetime risk for a cohort of 55 year old women 
at 13.3%, assuming a Hr.'ill distribution equal to the Dutch population of that age, in the 
absence of intervention, and assuming the same linear B1JD decline for every participant. 
\X'hen lower correlation coefficients were assumed for these rates of loss, this lifetime 
risk estimate increased slightly, to 14.4 % as was shown previously in chapter 3.1. 
TIlerefore, in each of the intervention scenarios, the intervention was compared to what 
would have happened \vithout intervention with the same correlation coefficient 
assumption. Full results of the baseline scenarios can be found in chapter 3.1. 
2. III/erJ!elllioll assJIIIJingpeiferl correialion 
Inten rentiOJ11: lifeJoIlg treatment 
In the most optimistic scenario, we assumed lifelong treatment and lifelong effectiveness, 
perfect correlation ofB.~'I'1D over time and a 50 % risk reduction. \,(/ith the no-screening 
approach, when the total cohort would receive this intervention at baseline (age 55), 44 
% of first hip fractures would be avoided in this population, compared to the situation 
without intervention. TIle intervention with a 20 % risk reduction resulted in a 16 % 
reduction in hip fractures. \'{Ihen intervention occurred at a later age, the proportion of 
hip frachIfes avoided declined, as can be expected with lifelong effectiveness. TIus is 
illustrated in figure 1. 
When screening was used, the proportion of hip fractures avoided in the population 
declined markedly, but the effect of age became more complicated. For the Z-score 
threshold, the proportion hip fractures avoided declined with age, but with the T -score 
threshold it first increased until the age of 75, with a subsequent decline. \X'hen 
intervention occurred at older ages, the difference between the screening and the-no 
screening strategies became smaller. In dus intervention simulation, and in all other 
simulation in this chapter, the curves for Z-scores and T-scores come together at the age 
of 70 since, as we showed in chapter 2.3, both scores represent the same absolute B~'ID 
level at that age. 
Since intervention 1 involves lifelong treatment, treating at age 55 involved many 
treatment years. "'ith 50 % risk reduction, treating everybody at age 55 meant that we 
needed almost 500 treatment-years to prevent one lup fracture. For the 20 % risk 
reduction this went up to almost 1300 treatment years. Treating at later ages, or 
introducing screening reduced the number of treatment years to avoid a hip fracture. 
These effects are shown in figure 2, The full results for both outcome measures arc listed 
in table 1. 
'I11e number needed to screen to avoid one hip fracture (50 % risk reduction) decreased 
for the T-score from 100 at age 55 to 40 at age 85. For the Z-score it was around 50 at 
age 55 and remained at that level. After the age of 70 is slowly increased to about 70 at 
the age of 85. 
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Table 1. Resl/I/s for in/en'en/ion 1 E!Y lenl oj Jisk redl/ction and age (Iiftlollg /rf(1IJmnl and peifect 
cOITe/alioN 0/ bom dens;ty). 
Treatment years to avoid one Proportion of hip fractures avoided 
hip fracture 
Ag< 55 60 65 70 75 80 85 55 60 65 70 75 80 85 
no screening 
50% 467 397 318 257 199 152 115 44% 42% 41% 37% 32% 24% 15% 
20% 1292 995 885 673 512 500 371 16% 17% 15% 14% 12% 7% 5% 
T-score<-2.5 
50% 196 165 139 113 92 75 53 7% 10% 12% 14% 14% 12% 9% 
20% 436 464 349 483 264 222 163 3% 4% 5% 3% 5% 4% 3% 
Z-score<-l 
50% 225 174 146 107 85 63 41 14% 15% 14% 14% 11% 8% 5% 
20% 558 619 405 327 229 209 144+ 6% 4% 5% 4% 4% 2% 1% 
, , 
upper 95 Yo CI hmH exceeds double of this esUmate 
Table 2. Reslli/s for il1/en'fIJh'olJ 1 ry le1'el ojtisk redlfctiolJ and age (lifilol1g /rf(1/meJJ/ and assl/ming a 
bom demity (om:iatiolJ ojO.6). 
Treatment years to avoid one hip 
fracture 
Ag< 55 60 65 70 75 80 
flO screening 
50% 462 385 321 252 186 150 
20% 1282 1088 781 670 507 428 
T-score<-2.5 
50% 251 189 159 117 116 72 
20% 473 425 477 307 310 234 
Z-score<-l 
50% 295 216 152 100 81 63 
20% 600 440 382 695 360 156 
" 
, 
upper 95 Yo CI hmlt exceeds double of tillS estimate 
- lower 95 % CI limit is lower than half tills estimate 
Proportion of bip uactures avoided 
85 55 60 65 70 75 80 85 
114 41% 40% 38% 35% 32% 23% 14% 
306 15% 14% 15% 13% 12% 8% 5% 
66 5% 7% 8% 11% 11% 13% 7% 
135 3% 3% 3% 4% 4% 4% 4% 
45 10% 10% 10% 12% 11% 9% 6% 
98 5% 5% 4% 2% 3% 4% 3% 
Intervention 2: 5-year treatnlent period 
W'hen using intervention 2, assuming a 5-year treatment period during which full effect is 
obtained, followed by a linear decline of the effect over a period of 5 year after treatment 
cessation, the results changed dramatically. 
Figllfe 3 shows the proportion of hip fractures prevented in the population with a 50 % 
effective inten'ention. Treating the whole cohort at age 55 would result in the prevention 
of onl}' 2 % of the hip fractures in that population. Applying this same intervention at 
later ages increased the effectiveness of this intervention, and the optimal age for 
effectiveness was around 80 years of age, when 12 % of the hip fractures in the 
population could be prevented. 
In this scenario, we assumed treatment during only 5 years. 'fllerefore, the total number 
of treatment years -was obviously much lower. Figure 4 shO\vs the years needed to treat to 
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"void one hip fracture. As in the intervention 1, dle intervention is most cost-effective in 
terms of treatment years per hip fracture prevented at later ages, but this effect is much 
more pronounced than in the previous scenario. The full results for both outcome 
measures are listed in table 3. 
The number needed to screen to avoid one hip fracture (50 % risk reduction) decreased 
only below 250 at the age of 70 for both scores. From there on it quickly decreased \vith 
age, arriving at 70 for the T-score and at 100 for the Z-score at age 85. 
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~ T -score < -2,5 
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------------------
55 60 
--
.,.. ~ .'------
r ..... ............ . 
,.,.".. . 
~:#~ .. 
~ 
-,-----,----,-----,---------, 
65 70 75 80 85 
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Figure 3: ProPOItiOJJ rf hip fractures prt/!t1Jted in the pop"/tltiolJ JJlith inten'entioll 2, assmlling 50 % 
dsk redur/ioH (5j'ear treatlJlmt and peifect cOfTe/atiolJ rf bOHe densi()'). 
500 -No screening -, 
'" • - T -score < -2,5 ~ \ \ ~ 400 \ - Z-score < -1 ~ , ~ 
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Figure 4: j'Vulllber 0/ treatlllmt Jed,'" meded to aroid ONe hip fracture nith il1ten'ention 2, tlSSIfIl1ing 50 
% lisk reduction (5j'ear trea/lllmt and peifect correlation of bone dow!;'). 
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Table 3. RemIts for illtm'fJItioll 2 0' lad 0/ ,isk redlfction flIId age (5j'ear treatment tlnd peifect 
correlalion 0/' bone densl!>~. 
Treatment years to avoid one hip 
fracture 
Age 55 60 65 70 75 SO 85 
no screening 
50% 2050+ 1266 575 344 231 151 96 
20% 2256 1055 767 450 235 
T-score<-2.5 
50% 380+ 229 177 106 75 59 
20% 500± 278 196 129 
Z-score<-l 
50% 497+ 233 167 99 63 38 
20% 299+ 189 204 98 
+ upper 95 % CI limit exceeds double of tIllS esUmate 
lower 95 % Cllimit is !O\yer than half this estimate 
Proportion of hip fractures avoided 
55 60 65 70 75 80 85 
2%- 3% 6% 9% 11% 12% 11% 
1%- 3% 3% 4% 5% 
1%- 2% 3% 5% 6% 5% 
2%- 2%- 2% 
1%- 2% 3% 4% 4% 3% 
2%- 2%- 1%- 1%-
Table 4. Reslllts for iniorelliion 2 0' lerelo/'Iisk reduction tlnd tlgf (5 )'ear treaflJlell1 tlnd assllming a 
bone dellsity (oJ7eialioll 0/'0.6). 
Treatment years to avoid one hip 
fracture 
Ag' 55 60 65 70 75 80 
no screening 
50% 2045+ 1373 884 381 237 134 
20% 1877 752 505 418 
T-score<-2.5 
5CWo 504 198+ 152 181 59 
20% 250' 294+ 102 
Z-score<~1 
50% 422+ 298 181 97' 67 
20% 344+ 197+ 128 
, 
+ upper 95 Va CI limit exceeds double of this estimate 
- lower 95 % CI lim..it is lower than half tlus estimate 
Proportion of llip fractures avoided 
85 55 60 65 70 75 80 85 
98 2%- 2% 4% 7% 10% 13% 10% 
269 2%- 4%- 5%- 4% 4% 
54 1%- 2%- 3% 3% 8% 6% 
121 2%- 2%- 5%- 3%-
37 1%- 1% 2% 4%- 4% 4% 
62 1% 2%- 2%· 3%-
3. IJllerpmtions assJlming a 100J1tr correlation coefficienl for fllillre BtUD wall/lion (p = 0.6) 
\\"'ith the population approach (no-screening), the differences with the baseline scenarios 
were negligible and within the margins of variation, as could be expected. The 
effectiveness of the screening approaches, however, decreased, notably for early post~ 
menopausal interyentions. At older ages, this effect became smaller. Therefore, this 
effect is only observed in intervention 1, were the efficiency of the screening approach 
was lower up to the age of 70, In intervention 2, the efficiency of early post-menopausal 
interventions \vas 100v anyhO\v, so differences were obscured, 'nle results for both 
scenarios for a correlation coefficient of 0.6 are shown in tables 2 and 4. 
For intervention 1, the number needed to screen to avoid one hip fracture (50 % risk 
reduction) decreased for the T-score from 130 at age 55 to 40 at ages 80 and 85. For the 
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Z-score it was around 70 at age 55 and decreased to 50 at the age 70. After the age of 75 
is slowl}' increased to about 60 at the age of 85. For intervention 2, the numbers only 
decreased below 250 after the age of 70 and its further pattern was similar to that of 
intervention 2 assuming perfect correlation. 
4. SellSitiliity anafysis assllll/illg d[fferent ~/}set ~( treatlllent periods in interpeJltion 2 
For intervention 2, we assumed that after the 5-year treaunent period, the protective 
effect gradually declined over a period of the 5 following years (the offset of treatment 
period). To assess the importance of this assumption, we changed in a sensitivity analysis 
this baseline scenario to an offset of treaUnent period of 0 and 10 years. 
\\then we increased the offset of treatment period to 10 years, the age of optimal 
effectiveness was slightly younger than in the baseline scenario (between 75 and 80) and 
more hip fractures were prevented. Similarly, assuming a lO-year offset of treaUnent 
period decreased the number of treatment years needed to avoid one hip fracture at 
every age. \'{'hen inuneruate loss of effect was assumed the opposite happened. The 
effect on the proportion of hip fractures prevented in the population and on years to 
treat to prevent one hip fracture is illustrated in figures 5 and 6 for the scenario of the 
population approach (no-screening), 50 % risk reduction and perfect correlation of bone 
density over time. 
20% 
"0 
$l 5 15% 
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Figure 5: Ejfed of {hal/gil/g Ihe ~[/sel ~(tn!{l/JJItIII ~fje{1 all Ihe propo!tioll of hip fmdllres ptrl!mted ill 
the poplI/alion wilh intfl1'm/ion 2, aSffllJling 50 % !7sk redll{tion and JJlithollt sorming (5j'ear 
treatlllellt and pe~ff{/ fOnda/ion of b011e df1Jsi!J). 
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DISCUSSION 
i.lIa;" findillgs 
In this modeling study, we concluded that in a population approach and in the most 
optimistic scenario oflifeiong effectiveness (intervention 1) and 50 % risk reduction, 44 
% of hip fractures could be avoided by applying this intenTention to everybody at the age 
of 55. This means that in some people hip fractures would indeed be prevented early on 
by the intervention, but occurred later in life. However, with 500 treatment years to avoid 
one hip fracture this would probably only be an option for an intervention that is both 
very effective and inexpensive. Applying this same intenTention at later ages improved 
the cost-effectiveness balance, as expressed by treatment years needed to prevent one hip 
fracture. At the age of 70, only 250 treatment years \vmIid be needed to avoid one hip 
fracture, while we would still be able to avoid 35 % of hip fractures. 
In a screening scenario, the effectiveness (number of hip fractures avoided) was better 
for the Z-score threshold approach before the age of 70 and better for the T-score 
threshold above that age, reflecting the fact that the more people arc selected the more 
hip fractures can be avoided. The number of treatment years to avoid one hip fracture 
was much lower in the screening than in the population approach, but cost-effectiveness 
differences between both screening approaches were slight. However, the cost-
effectiveness was again much better when treating at later ages. 
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\':'ith intervention 2, assuming a more realistic scenario of treaUUent during 5 years, 
followed by a gradual decline of effect during the next 5 years, effectiveness of 
intervention increased with age reaching an optimum around the age of 80, both in the 
population and in the screening approach. Again, cost-effectiveness \vas much better in 
the screening than in the population approach and improved with age. 
In both interventions the cost-effectiveness difference between the screening and the 
population approach became relatively small at ages over 80. \\?hen screening would be 
an important cost, or unfeasible, the population approach might become the best 
alternative for women over 80, depending upon the burden of the proposed intervention. 
From the sensitivity analysis, changing the offset of treatment assumptions, it became 
clear that these are important parameters. W'hen residual effect would last for 10 years 
after treatment cessation, more hip fractures would be prevented by intervention at a 
younger age, and the cost-effectiveness balance would improve. The opposite occurred 
when effect stopped immediately after treatment cessation. 
\Vhen \ve introduced the assumption that BMD evolution over time was not perfectly 
predictable, the effectiveness and cost-effectiveness of the population approach were not 
affected, but it did negatively influence the effectiveness and cost-effectiveness of the 
screening scenarios at younger ages. Past the age of 70, however, the effect of this 
assumption became negligible. Ifwe intend lifelong treatment starting at a peri-
menopausal age, this assumption has important consequences. If, however, we propose a 
5-year treatment similar to intervention 2 starting after the age of 70, the effect becomes 
unimportant. 
'I11e number needed to screen to avoid one hip fracture varied between 50 and 100 
shortly after menopause in intervention 1, a lifelong treatment that could correspond to 
lifelong HRT. However, when short-term treatment is what \ve have in mind, the 
number needed to screen stayed well above 250 before the age of 70. 
Strengths (Iud jill/i/d/ions 
As indicated before, the main limitation of any modeling study lies in its assumptions. It 
is important to underline that the interventions that were modeled here were theoretical. 
Rather than focllssing on specific therapies, we choose a generic approach where we 
compared theoretical interventions leading to a preset risk reduction, without specifying 
whether this was obtained through a pharmaceutical or through any other treatment. Wle 
tested these interventions at various ages and in screening and non-screening conditions 
thereby implicitly assuming that intervention were equally effective at all ages. This is 
probably not true for all types of interventions. However, it is plausible that different 
interventions could be conceived at different ages, such as HRT early postmenopausal, 
specific bone resorption inhibitors later on, and hip protectors at old age. 
Ultimately, this study was intended to show the dynamics of intervention in a cohort of 
women. Therefore, effectiveness and cost-effectiveness were expressed as proportion of 
hip fractures avoided and treatment years needed to avoid a hip fracture. In a real cost-
effectiveness analysis we would need to discount both costs and effects, However, this 
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would only help to reinforce the conclusion that intervention should be postponed until 
older ages. 
Cour/lIsio!1S 
In modeling the dynamics of osteoporosis interventions, we observed that lifelong 
treatment of the entire population starting at an early post-menopausal age with a 
theoretical intervention with 50 % risk reduction for hip fractures, and assuming lifelong 
effectiveness, \vould prevent 44 % of first hip fractures in women. Apart from being 
unrealistic, however, this intervention \vould also be extremely expensive. Testing more 
realistic scenarios with a shorter treatment period and declining effect, it became evident 
that early posunenopausal intervention is both less effective and especially less cost-
effective in terms of years needed to treat to prevent a hip fracture. From ages 70 
onwards, however, the effectiveness and cost-effectiveness of such interventions 
markedly improved for persons at high risk After the age of 80, a population approach, 
treating everybody with an effective intervention and without screening, might become 
cost-effective. 
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PART 4 
DISCUSSION AND SUMMARY 

GENERAL DISCUSSION 
Since tile number of elderly is increasing and the elderly arc becoming older, there is 
growing attention for the prevention of those diseases that typically affect elderly people. 
There is a need for the definition of not only effective, but also cost-effective strategies 
for the prevention of those diseases and notably for osteoporosis, as indicated by various 
organizations within the Dutch health care (CnO, NHG, Gezondheidsraad, 1Jinistry of 
Health),l.2 However, there is a variety of options that have not yet been properly assessed 
regarding their associated costs and benefits. 
\Y.le showed that osteoporosis and fractures are an important burden to society. Of the 
fractures related to osteoporosis, the hip fractures arc the most important public health 
problem. TI1ey invalidate patients physically and psychologically and they induce high 
costs. \Y.le estimated the yead}' cost of osteoporotic fractures in the Netherlands at € 200 
million, and this cost was for 85 % related to hip fractures. 'This thesis therefore focuses 
on the prediction and prevention of hip fractures. A study conducted in the United States 
attributed a larger proportion of the total cost to fractures other than the hip, .1 but this 
study considered a large proportion of all fractures as osteoporosis related, while we only 
included vertebral, wrist an hip fractures. HO\vever, even in this US Shlcl)" the cost of 
fractures \vas mainly determined by hip fractures. 
Since hip fractures are related to important direct medical cost and excess mortality, the 
prevention of hip fractures \vould probably avoid those. The yearly number of hip 
fractures in this country is rising and based solelr on the demographic evolution (CBS). 
we predicted that, without intervention, the number of hip fractures will double by the 
year 2040. One might even expect a sharper increase when we take into account the fact 
that the incidence of hip fractures, corrected for age, increased significantly in the 
Netherlands during dle last 20 years. 
Hip fractures in the Netherlands almost always lead to a hospitalization, and the average 
length of stay was 26 days in 1993. This appears to be too long, and we concluded that 
the most direct way for cost reduction was to accelerate the discharge from hospital by 
either providing adequate facilities at home or by making the transfer to a nursing home 
easier. 
Compiling numbers and costs from national registration gives a good overview of the 
total medical consumption after a fracture has occurred. It is, however, also important to 
know the real incremental cost in fracture patients. l1lcrefore, we compared cost with 
and without a fracture. In the follow-up phase of the Rotterdam Study we did this for hip 
and vertebral fractures, using a nested case-cohort design. This pilot study confirmed the 
high cost of a hip fracture (around € 10.000 during the first year). For vcrtebral fractures, 
on the contrary, we found no evidence of important acute care cost but we observed a 
yearly incremental cost of € 1.000. Part of this incremental cost, however, was pre-
existing and might therefore be caused by co-morbidity. 'TIle additional incremental cost 
was mainly caused by the lise of pharmaceutical drugs. It is therefore unlikely that 
prevention of vertebral fractures will eliminate aU the incremental cost. TIllS was, 
however, only a small study and it needs to be repeated in a larger population. 
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At this moment there is no coherent strategy for fracture prevention, and in daily life 
osteoporosis and fracture prevention is mainly carried out through sporadic individual 
case identification in general practice and specialist care. But, at the same time, there is a 
growing awareness of osteoporosis in the general public, partly generated by information 
from the pharmaceutical industry, and there is no guarantee that this growing awareness 
and demand from the general public \vill automatically lead to optimal intervention. 
For the prevention of osteoporotic fractures it is important to know who are at risk as 
well as which preventive strategy is most effective and cost-effective for different risk 
categories. In the modeling of fractures and fracture risk we concentrated on the 
predictive value of bone mineral density (Bi\-fD) and age. A limitation, however, was that 
there are currently almost no prospective data about the long term evolution ofB~'ID 
within individuals, and the bone mineral density data in our prediction models were 
measured cross-sectionally. Therefore, we needed to make assumptions about this 
individual evolution, evaluating different correlation coefficients. The Rotterdam study 
will, over time, provide these follow-up data on BMD evolution and fractures, allowing 
more detailed estimates for the incidence of those fractures in the Netherlands, and its 
relation to BMD. 
HMD is, however, not the only element involved in fractures. The observed and 
relatively modest decline in bone density with age can not fully explain the exponential 
increase of hip fracture incidence with age. This shows that also other factors arc 
important contributors to the fracture risk, including bonc quality but also non-bone 
specific determinants. A trauma, most often a fall from standing height, is the direct 
cause of the fracture. Propensity to fall increases \vith age due to a variety of reasons such 
as a decrease in mobility, the use of sedative drugs, visual impairment etc .. The impact of 
those non-bone-density-related factors have, in the current models, been taken into 
account by using age as a surrogate. 
These other risk indicators could, of course, be contemplated for fracture prediction. 
Some of these have indeed been included in risk scores developed around the world, and 
also in our own study population.4,5 They include risk indicators such as visual 
impairment,low body \veight, smoking, use of walking aids, drug usage and also co-
morbidity in general. But, as is clear from our validation studies, both in subgroups as in 
the individual, the performance of age, gender and B1vID is already quite high, making it 
very difficult to improve the predictive value of those functions substantially. Risk can 
well be estimated for groups of individuals, but since a fracture also remains a chance 
event, it will most likely remain difficult to predict in which individual and when it will 
occur. 
\Y/e do not expect that adding other fractures will change our overall conclusions, but we 
will add them into the model, since they too will be affected by prevention and they too 
are associated with increased costs and impairment of quality of life, No nationwide data 
are available, but we recently obtained estimates of the incidence of non-hip peripheral 
fractures and their relation to B1,[D from the fracture follow~up within the Rotterdam 
study.6 The incidence of vertebral fractures is, however, more difficult to evaluate, since 
these fractures often do not come to clinical attention. But, since we have estimates of 
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the prevalence of vertebral fractures from the first cross-sectional phase of the 
Rotterdam Stud}" where the spinal radiographs were analyzed,7 we were able to estimate 
incidence, taking into account the increased mortality risk when a vertebral fracture is 
present,S In the future we will obtain the cumulative incidence of vertebral fractures by 
comparing spinal radiographs made at baseline in the Rotterdam stttdy with radiographs 
made at later return visits, Currently, the third round of return visits in the Rotterdam 
Study is being completed, which will lead to an average follow-up period of 6 years. 
Over the years, the Rotterdam Study will continue to offer a unique opportunity to study 
the combined risk indicators and outcomes in the same population and in both men and 
women. Although these additional risk indicators were measured at baseline, additional 
follow-up time and more events are needed before more precise estimates can be 
obtained. 
The current models perform well, and the simulated incidences were equal to the 
observed incidence in the Netherlands as, obviously, they should. The estimated lifetime 
risk was also similar to previously published estimates, although the methods to arrive at 
it were different. OJ Since the risk equations are based on Dutch data, they can be used to 
effectively help in reviewing the Dutch osteoporosis guidelines, where this model can be 
used to simulate any proposed interventions, Additionally, we feel confident that they 
can also be used for other populations, fitted with local data when needed and available, 
1Jany pharmaceutical treatments have been proposed to prevent osteoporotic fractures 
with various evidence of effectiveness:4 calcium or vitamin D supplementation, hormone 
replacement therapy (HR1), bisphosphonates, calcitonin, and recenti}' also the "selective 
estrogen receptor modulators" (SERJ\l's), Other strategies have focused on lifestyle 
intenrentions, the removal of risk factors in the home or on interventions to reduce the 
propensity to fall by training, or by the avoidance of sedative drugs. Yet another strategy 
is the use of extewal hip protectors in individuals at high risk, such as nursing home 
patients. 
But, \vhatever the choice of the intervention, the important question that remains is 
when to intervene and in whom, Overall one-year hip fracture incidence only rises above 
1 % after the age of 80 for women and 85 for men. \,{'hen the moment of intenrention is 
at or soon after the menopause, we can expect that even with an effective therapy, the 
expected benefit is so far off that the compliance with medication \vill be poor. This isslle 
is furdler complicated by the problem that, even when data about short-term 
effectiveness may be readily available, long-term effectiveness data are lacking. 
Additionally, effectiveness data oftcn concern intermediate endpoints such as bone 
mineral density rather than the tlharder" endpoints sllch as fracture incidence. It is 
therefore preferable, if possible, to bring the preventive intervention nearer to the 
adverse outcome, 
In ollr modeling studies, we observed that even a very effective intervention, with 50 % 
risk reduction and assuming lifelong effectiveness, would not prevent more than 44 % of 
first hip fractures in \vomen when the whole population were treated at an early post-
menopausal age, 11lis was due to the fact that prevention, on average, leads to a 
postponement of the occurrence of a hip fractme, but not always to the avoidance of it. 
Assuming more realistic scenarios, with shorter treatment periods and with declining 
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effect after discontinuation of treatment, it became evident that early postmenopausal 
intervention is both less effective and therefore surely less cost-effective. 
\V,/e also observed that a T-score lower than -2.5 in early post-menopausal women, 
represents an extremely high lifetime risk, and we should probably design strategies to 
detect those women at an early stage as was also advised by the 'Gezondhcidsraad'.2 At 
ages past 70 years, however, a large proportion of women will have a T-score below this 
threshold. TIlis means that the current definition of osteoporosis is possibly not the best 
threshold for treatment. As an alternative we suggest our one-year risk estimate taking 
into consideration both age and B:~\'ID. At a risk threshold of 0.5 % this estimate had 
both a high sensitivity and specificity for predicting hip fractures in the 4 following years. 
At those higher ages screening followed by selective treatment of women at high risk 
might become the most cost-effective option. After the age of 80, however, our 
modeling experiments indicate that treating everybody with an effective intervention and 
without screening might be more cost-effective than a screening approach. 
Current guidelines for the prevention of osteoporosis are relatively vague, I reflecting the 
uncertainties. Recently the rGezondheidsr<ladr advised to investig<lte different prevention 
scenarios.2 Those scen<lrios should not only define how to treat, but especially who and 
\vhen. To support this decision making, information about the balance between costs and 
effects - from a societal point of view - is needed. Given the time horizons that need to 
be considered, a model is the illost productive instrument to bring together knowledge 
and uncertainties about the epidemiology, and about the expected costs and benefits of 
various preventive strategies. Currently, the CBO guideline for osteoporosis is being 
revised and, \\~th our models, we \\'111 try <lnd contribute to the assessment of the cost-
effectiveness of the strategies proposed, both in the definition of the target population 
and strategies for case finding, as in the evaluation of the interventions chosen. 
The overall picture of fracture prevention is indeed complex. Optimal and cost-effective 
strategies will probably be combinations of several types of interventions, each focllsed 
on a specific target population with specific risk indicators. 'I11e aim of our research was 
to provide the tools to design such strategy. The questions that we put forward at the 
start of this research were simple but important: who should be treated, and when and 
how should this be done? \"'('ith the models we developed in this thesis, we provided the 
framework to answer those questions for every proposed intervention. 
FUTURE RESEARCH 
In this thesis we developed basic models to analyze costs and effects of prevention and 
treatment of osteoporosis. Since the prevention of osteoporosis, and its cost-
effectiveness \\~ll also be influenced by the impact of interventions (e.g. HRT scenarios 
or the usc of SERlvf's) on other diseases such as cardiovascular disease and cancers, these 
need to be included in a more global model. Wle need to cl<lrify whether these diseases 
occur independently, allO\,~ng for simple models, or whether their occurrence is related 
either directly, or through the same risk factors. There might, for example, be a positive 
relation between fracture risk and heart disease reflecting estrogen exposure during a life. 
There might also be an inverse relation between the risk of fracture and that of breast 
cancer as has been suggested in the literature. III The data from the Rotterdam Study will, 
in the future, be used to study these relations. 
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Around the world there are a few prospective cohort studies that are comparable to the 
Rotterdam Study, and that also study osteoporosis and some of the other outcomes of 
interest. Only one of those other cohorts also includes men. At this moment, we are 
preparing to collaborate with some of those large cohort studies, to try and cross validate 
our findings. \"X'hen successful, this cross validation would greatly enhance the 
generalizability of the results. 
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SUMMARY 
In this thesis on the cost-effectiveness of osteoporosis and fracture prevention, the first 
part deals with the burden of illness and the cost of osteoporosis in the Netherlands, 
both in terms of morbidity and mortality as in financial terms. In the second part models 
for estimating the short-term hip fractures risk are developed. TIle last part is devoted to 
simulation models that estimate lifetime hip fracture risk and the effect of theoretical 
interventions. 
PART 1: BURDEN OF ILLNESS OF OSTEOPOROSIS 
Osteoporosis and related fractures are a major source of morbidity and health care costs 
both today as in the foreseeable future (chapters 1.1 and 1.2). TIle most seriolls fracture, 
the hip fracture, occurs frequently in the Netherlands, and its incidence is increasing with 
time. The incidence increases exponentially with age, and men reach the same hip 
fracture incidence at a 5 year older age than women. 
The total number of hip fractures will inevitable rise if no serious preventive efforts are 
undertaken. Based solely on the demographic evolution, we predict that, without 
intervention, the number of hip fractures will be around 30.000 by the year 2040. One 
might even expect a sharper increase when we take into account the fact that the 
incidence of hip fractures, corrected for age, has increased significantly in the 
Netherlands during the last 20 years. 
nIortality associated with hip fracture is strongly age dependent and related to 
concomitant illnesses and in-hospital complications. In a case cohort stud}' (chapter 1.3), 
we were able to directly confirm the finding that after a hip fracture mortality rates are 
elevated in the first few months following the event, but return to normal after about 6 
months. Although osteoporosis and hip fractures are often thought of as related solely to 
women, mortality rates after a hip fracture are much higher in men.(chapters 1.1 and 1.2) 
In-hospital mortality is twice that of women, but it remains unclear \vhether this is related 
to co-morbidity in men or to other factors. 
The average hospital length of stay after a hip fracture was 26 days in 1993, and this was 
much longer than necessary from a medical point of view. From the data, we concluded 
that notably persons waiting for a nursing home admission stayed in the hospital for too 
long. 'Iberefore, we concluded that, besides prevention, a .more efficient hospital stay and 
discharge strategy is the most obvious way to control costs in the near future. 
Nursing home care was often needed after the acute phase of the hip fracture. \Ve 
detected that 21 % of men and 27 % of women were discharged directly towards nursing 
homes. This difference could partly be explained by the higher in-hospital mortality of 
men, but also to the fact that, at the age when hip fractures occur, more women live 
alone than men, and they are therefore more in need of olltside help. Although nursing 
home stays were sometimes very long, the majority of patients left the nursing home 
within 3 months. 
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Precise incidence rates for non-hip fractures could not be obtained for the Netherlands 
at the start of this research, and we derived those from international data. Since the focus 
of this thesis was on cost and personal illness burden, this uncertainty for non-hip 
fractures was not perceived as a major problem. Later on, however, we were able to 
confirm those data with data from the Rotterdam Study. W'rist and vertebral fractures 
(when diagnosed) are most frequently treated in an outpatient setting. Based on the 
literature it was estimated that about one third of the vertebral fractures came to clinical 
attention. 
\y"'e estimated the direct cost associated with fractures at older age. The majority of these 
fractures were probably osteoporosis related, but not all. \Y/e concluded that the cost of 
osteoporosis is mainly related to hip fractures. \V'e used two approaches to calculate the 
yearly cost of osteoporosis and fractures in the population aged 50 and over in the 
Netherlands in 1993. The results of both the top-down and the bottom-up approach 
were comparable, and indicated a yearly cost between € 180 million and € 210 million. 
TIle main difference between both approaches was the cost of nursing home care that 
was not included in the top-down approach. Indirect costs were excluded since 
osteoporosis mainly affects the elderly and their production losses can be neglected. 
The contribution of the oldest patients in the total cost was very striking. Although 
people from 85 years and older constituted only 1,3% of the Dutch population (1993), 
this group contributed to more than one third of the cost of osteoporotic fractures. The 
most important cause was, besides the higher incidence of hip fractures, the longer 
length of stay in the hospital and the higher incidence of admissions to a nursing horne. 
\Y,./ith an aging population this situation may worry health policy planners. 
\V'hen comparing the cost in the Netherlands with international figures, we found both 
higher and lower estimates. Several studies indicated a cost of USS 7 - 10 billion for the 
United States resulting in a yearly cost per capita off 20 - 30 for osteoporosis related 
fractures. A more recent study estimated the cost in the US for all osteoporosis related 
fractures at almost USS 14 billion, but this study included a large proportion of all 
fractures as osteoporosis related. Our maximum cost estimate is equivalent to about € 15 
per head of the population in the Netherlands. The US estimates however did include the 
indirect costs that we choose not to include. 'l1le estimates for France, hO\vever, were 
much lower \vith a global cost of FF 3.5 billion (€ 500 million) and a per capita cost of € 
9. 
In a case cohort study \vithin the Rotterdam Study, we estimated the incremental health 
care consumption and its associated cost directly (chapter 1.3). For hip fractures, the cost 
estimate of € 10.000 for the first year largely confirmed our previous cost estimates in the 
Netherlands and those made for other countries. But, the results for vertebral fractures 
were unexpected. For vertebral fractures we could not detect important acute health care 
costs, but we did observe a yearly incremental cost of€ 1000. Almost half of this 
incremental cost, however, was present even before the occurrence of the vertebral 
fracture, while an important part of the additional incremental cost after the fracture was 
caused by use of pharmaceutical drugs, mostly anti-ulcer drugs. 11us appears to point to 
co-morbidity, and it is therefore unlikely that prevention of vertebral fractures will 
eliminate all the incremental cost. 
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PART 2: MODELING THE ruSK OF HIP FRACI1JRES 
For the modeling of fractures (chapter 2.1), we concentrated on the predictive value of 
bone mineral density (Bi\ID), \vhile the impact of other, non-bone density related risk 
indicators were accounted fC?r by using age as a surrogate indicator. 
B~'1D is the indicator that is most commonly used to determine fracture risk, especiaU}' 
arVID measured at the femoral neck. BMD at the hip appears to be more strongl), related 
to the risk of hip fracture than bone density measured at other sites. In the literature, the 
age-adjusted relative risk for hip fracture was estimated at 2.6 per SD decrease in bone 
density at the femoral neck in women. W/e were able to confirm this estimate in the 
Rotterdam study, not only for women but also for men. 
From dus relative risk, combined with Dutch incidence data and BMD distribution from 
the Rotterdam Study, we theoreticallr derived risk functions by age, gender and HMD to 
calculate one-year cumulative incidence. 
Subsequentl}' we conducted a validation study within the Rotterdam Study, to test the 
performance of these theoretically derived risk functions for lup fracture risk prediction 
(chapter 2.2). The majority of hip fractures (61 out of 110) occurred either in the high 
risk group or in the residential care group, even though these groups accounted for 
barely 14 % of the stud}' population. In the community dwelling individuals, the high risk 
group consisted mainly of individuals aged 70 }'ears and older, predonunantl}' women. 
TIle low and moderate risk groups taken together identified a large proportion of the 
study group with low lup fracture incidence, even at ages over 80. HO\vever, a smaller 
group of individuals with high hip fracture incidence starting at age 70, could be 
identified a priori by using the risk function. 
Therefore, we concluded that we can accurately estimate hip fractures risk in population 
subgroups. The risk functions performed well for the prediction over a period of 4 years 
in both men and women. Longer follow-up will be needed to validate those risk 
functions for use over longer time periods. 
As an additional tool to estimate hip fracture risk in daiJ}, routine, \ve constructed, based 
on the risk functions, a nomogram to derive the hip fracture risk based on age, gender 
and B~'1D measured at the femoral neck. Although our risk functions were developed 
with data from a Lunar machine we have also converted them for use \vith other brands 
of bone densitometers. 
For the prediction of hip fractures in the individual (chapter 2.3), absolute B1\,ID 
thresholds appear to have limited value when age is not included in the assessment of hip 
fracture risk. Our risk functions including age and B1\·ID gave more clinically relevant 
information than the commonly used T-scores and Z-scores. A threshold level of 0.5 % 
one-year risk had, in this stud}', both a high sensitivity and specificity, and is therefore, 
potentially, an interesting and clinically relevant cutoff point. 
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PART 3: IvlODELING PREVENTION 
In two models, we evaluated Ii fetime risk of hip fracture extrapolating risk from the 
previous fracture risk models, and assuming BMD decline with perfect correlation over 
time. The average lifetime risk in women aged 55 was estimated at 13.3 %, comparable to 
previous estimates by others. Subsequently, we evaluated the performance of specific 
threshold values of Bi\:fD for predicting long term and lifetime risk. \'Vhen Z-scores were 
used to evaluate the B1\'lD, the lifetime risk remained similar at all ages. The reason for 
this is that, although hip fracture risk increases exponentially with age, this phenomenon 
is matched by a similar exponential increase in mortality rates. The ratio of hip fracture 
risk and mortality risk is almost stable through aging. A T-score on the other hand, is a 
fixed threshold value, and therefore the lifetime risk was much higher when T -scores are 
low at younger ages. 
Subsequently, we assumed that the BMD decline is not the same in every individual and 
that the correlation between BMD now and BMD in the future is not perfect. \'fhen 
taken into account, average lifetime risk increased slightly, with decreasing correlation. 
\Vle also concluded that the lifetime risk in women considered at high risk is seriously 
overestimated when this phenomenon is disregarded. On the contrary, in \vomen 
considered at normal or at low risk, the lifetime risk is underestimated. 'I11is, again, might 
have important consequences, since it means that the benefits of screening at an early age 
will be overestimated when this phenomenon is not considered. 
\v.,'e simulated the effect of theoretical interventions leading to a risk reduction of 20 % 
and 50 % respectively. In this intervention simulation study, we found that in the most 
optimistic scenario of lifelong effectiveness and 50 % risk reduction, only 44 % of hip 
frachlres would be avoided by applying this intervention to everybody at the age of 55 
(the population approach). However, with 500 treatment years to avoid one hip fracture 
this would only be an option for a very inexpensive intervention. 
Applying this same intenrention at later ages improved the cost benefit balance 
considerably. \v.,'ith the same intenrention at the age of 70, ani}' 250 treatment years 
would be needed to avoid one hip fracture, ·while we would still be able to avoid 35 % of 
hip fractures. 
As examples of a screening approach we used the Z-score and T -score thresholds. NIost 
hip fractures were prevented using the Z-score before the age of70 and by using the T-
score threshold past that age, reflecting the fact that the more people are selected the 
more hip fractures can be avoided. Cost-effectiveness was much better for the screening 
approaches than for the population approach but the difference between both screening 
approaches was small. However, the cost-effectiveness was again much better when 
treating at later ages. 
\'{fhen the more realistic scenario of treating for 5 years, followed by a linear offset of 
effect during the next 5 years was assumed, effectiveness of intervention increased with 
age reaching an optimum around the age of 80, both in the population and in the 
screening approaches. The effect of treatment shortly after menopause was almost 
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In both inten'entions, the cost-effectiveness difference between the screening and the 
population approach became relatively small at ages over 80. \Vhen screening would be 
an important cost, or when using it would be impractical such as for nursing home 
residents, the population approach is likely to become the best alternative for women at 
those ages. 
From the sensitivity analysis it became clear that the offset of treatment assumptions are 
important parameters. \\!hen residual effect would last for 10 years after treatment 
cessation, more hip fractures would be prevented by inten'ention at a younger age, and 
the cost-effectiveness balance would improve. The opposite occurred when effect 
stopped immediately after treatment cessation. 
Assuming a less than perfect correlation did not influence the effectiveness or cost-
effectiveness of the no-screening approaches, but it did negatively influence the 
effectiveness and cost-effectiveness of the screening scenarios at younger ages. After the 
age of 70, however, this effect became negligible. Again, this is an argument for screening 
and inten'ention at later ages. 
Overall, the cost-effectiveness of fracture prevention appears better in screening 
approaches than in the population approach, although this difference becomes srnaller 
late in life. The cost-effectiveness is also improved when inten'ention occurs at later ages. 
Therefore, optimal and cost-effective strategies will probably be a combination of several 
types of interventions, each focused on specific target populations with a specific risk 
profile. The aim of our research was to provide the tools to design such strategy. The 
questions that we put f01ward at the start of this research were simple: who should be 
treated, and when and how should this be done? W1ith the models we developed in this 
thesis, we provided the framework to answer those questioIls for every proposed 
inten'ention. 
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In illt proefschrift over de kosteneffectiviteit van de preventie van ostcoporose en 
fracturen, is het eerste dee! gcwijd aan de ziekte1ast van ostcoporose in Nederland. In het 
tweede ded worden modellen onn.vikkeld om het korte termijn risico op heupfracturen 
te schattcn. In het derde dee! worden deze modellen gebruikt om het lange termijn risico 
op ceo heupfractuur en het effect van theoretische intcrvcnties op elit risico te simuleren. 
DEEL 1: ZIEKTELAST VAN OSTEOPOROSE IN NEDERLAND 
Osteoporose en aan ostcoporose gerelateerde fraeturen zijn ceo be1angrijke oorzaak van 
ziekte en van kosten, zowcl vandaag als in de nabije toekomst (hoofdstukken 1.1 en 1.2). 
Dc meest ernstige fractuur, de heupfractuur, komt veel voot in Nederland cn de 
incidentie crYan neemt nog steeds toe. De incidentie stijgt exponentieel met de leefcijd, 
en de incidentie bij mannen bereikt vergelijkbare \llaarden op een 5 jaar hogere Jeeftijd 
dan bij vrouwen. 
Indien geen prcvcncieve acties worden ondernomen zal het totaal aantal hellpfracturen 
nog verder toenemen. \"X'anneer we enkcl rekening houden met de demografische 
evolutie zullen rand 2040 jaarlijks 30.000 heupfracturen optreden in Nederland. \X'anneer 
we bovendien de trend extrapoleren dat in Nederland de leeftijdsspecifieke incidencie van 
heupfracturen de laatste 20 jaar sterk is toegenomen kan dit aantal nog scherper stijgen. 
Aan hellpfracturen gerclatcerde sterfte is sterk leeftijdsafhankelijk, en bovendicn 
afhankelijk van co-morbiditeit en complicacies die optreden na een chirurgische 
interventie in het ziekenhuis. In ccn case-cohortonderzoek (hoofdstllk 1.3) hcbben we 
aangetoond dat de sterftekans verhoogd is gcdurende 6 maanden na de hellpfractuur, 
maar daarna tcrugkeert naar normale waarden. Alhoewel osteoporosc en heupfracturen 
meestal beschou\vd \vorden als een aandoening van vrouwcn, is de ziekenhuismortaliteit 
na een hellpfractuur bij mannen twee keer zo groot (hoofdstllkken 1.1 en 1.2). De reden 
hiervoor is onbekend. 
Dc gemiddelde duur van de opnanle in het ziekenhuis bedroeg 26 dagen in 1993. Dit lijkt 
een £link stuk langer dan noodzakelijk vanuit medisch oogpunt. Uit de gegevensanalyse 
bleek dat vooral die personen die uiteindelijk naal" een verpleeghuis gingen veel te lang in 
het ziekenhuis verbleven. Een voor de hand liggende conclusie is dat, naast preventie, 
ook een tijdigc voorbereiding van het ziekenhllisontslag kan bijdragen tot het 
terugdringen van de kosten in de:; nabije toekomst. 
Na de acute fase van de heupfractuur was er dikwijIs behoefte aan vcrpleeghuiszorg. Bij 
mannen ging 21 % en bij vrouwcn 27 % na de ziekenhuisopname direct naar hct 
verpleeghllis. Dit verschil wcrd deels verklaard door de hagere sterfte bij manncn, maar 
oak door het feit dat op deze leeftijd veel meer vrouwen aileen leven dan mannen en 
daarom ook meer behoeftc hebben aan hulp van buitenaf. Alhoewel het vcrblijf in hct 
verpleeghuis in sommige gevallen erg lang was, kon de meerderheid van de patienten 
tach binnen 3 maanden terug naar Imis. 
Nauwkeurige incidcntiegegevens van andere dan heupfracturen waren niet beschikbaar 
voor Nederland en voor ons onderzoek hebben we deze geextrapoleerd vanuit 
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Amerikaanse gegevens. Vermits de klemtoon van elit proefschrift lag op de kosten en het 
persoonlijk lijden ten gcvolge van osteoporose, beschouwden we de mindere 
betrouwbaarhcid van deze gegevens wet als een belangrijk probleem. Bovendien konden 
we, achteraf, deze schattingcn valideren aan de hand van gegevens uit ERGO. 
Polsfracturen en \vervelfracturen worden meestal poliklinisch behande1d, en uit de 
literatuur kondcn we afleiden dat sleehts ongeveer een derde van de vertebrale fraeturen 
ook echt onder de aandacht komt van een arts. De resultaten van ons ease-
eohortonder:wek bevestigden dit. 
\'Ile hebben een sehatting gemaakt van de kosten gerelateerd aan het optreden van 
fracturen op oudere leeftijd. De meerderheid van deze fmeturen was waarsehijnlijk toe te 
sehrijven aan osteoporose. \Y/e kwamen tot de eonclusie dat de kosten van osteoporose 
vooral bepaald worden door de heupfraeturen. \Y./e kozen twee benaderingen om de 
jaarlijkse kosten van osteoporose en fracturen te berekenen in de bevolking ouder dan 50 
jaar, en beide benaderingen gaven vergelijkbare c.ijfers. De schatting van de kosten voor 
de verzorging van fracturen, voor het jaar 1993, lag tussen € 180 miljoen en € 210 
miljocn. Het be1angrijkste versehil tussen beide benaderingen was dat de kosten van 
verpleeghuizen wet meegenomen waren in de laagstc schatting. Indireete kosten werden 
oak niet meegenomen, vermits osteoporose en daaraan gerelateerde fracturen 
voorkomen bi; een oudere bevolking waar de praduetieverliezen verwaarlaasbaar zijn. 
Het aandeel van de oudste paticntcn in de totale kosten was erg opvallend. Alhoewe1 
personen van 85 jaar en ouder maar 1.3 % uitmaken van de Nederlandse bevolking 
(1993), droeg deze groep voor meer dan een derde bij aan de kosten van osteoporotische 
fracturen. Dc voornaamste reden hiervoor was, behalve een hogere heupfraetuur 
inc.identie, het langerc vcrblijf in het ziekenhuis en de grotere kans op opname in een 
verpleeghllis. nlet een snel verollderende bevolking is dit fenomeen verontrustend. 
\\{anneer we onze schattingen van de kostcn vergeleken met internationale gegevens 
vonden we zowe1 hogere als lagere schattingen. Versehillende onderzoeken rapporteren 
voor de Vcrenigde Staten jaarlijkse kosten van USS 7 - lO miljard, wat per capita 
overeenkomt met € 20 - 30 voor osteoporose en gerelateerde fracturen. Een recent 
onderzoek schatte de kosten van osteoporose in de Verenigde Staten zelfs op USS 14 
miljard, maar elit onderzoek beschouwde een bclangrijk ded van aile fraeturen als 
gerelateerd aan osteoporose. Onze maximale schatting komt overeen met een per capita 
kost van ongeveer € 15, maar de Amerikaanse schattingen bevatten oak de inelireete 
kosten die wij buiten beschouwing hebben gelaten. Schattingen voor Frankrijk waren 
lager, met een globale kostprijs van € 500 miljoen, per capita € 9. 
In een case-cohortonderzoek binnen het ERGO-onderzoek (haofdstuk 1.3) hebben we 
ook rechtstreeks het verschil in medische consllmptie en kosten onderzocht tussen 
patienten met een fractuur en vergelijkbare personen zander fractuur. Voor 
heupfracturen vanden we bijkomende kosten van € 10.000 voor het eerste jaar, hetgeen 
grotendeels onze vroegere schattingen bevestigde. De resultaten voor wervelfracturen 
waren cchter onverwacht. Alhoewel \ve gcen bclangrijke acute meelische kosten konden 
detecteren, vonden we tach een jaarlijks kostenverschil van ongeveer € -1000. Bijna de 
helft van dit kostellverschil was echter al aanwezig in de jaren voor het optreden van de 
wervelfractuur. Van de bijkomende kosten na de fmctuur was een belangrijk decl toe te 
schrijven aan het gebruik van geneesmiddelen, vooral van maagzlIUfsecretieremmers. Dit 
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lijkt te wijzen op co-morbiditeit. en het is daarom onwaarschijnlijk dat de preventie van 
wervclfracturen ook alle bijkomende kosten zal verrnijden. 
DEEL 2: MODELLEREN VAN HET RISICO OP EEN HEUPFRACTUUR 
Voor het modellercn van het risico op cen heupfractuur OlOofdstuk 2.1). hebben we ons 
geconcentrccrd op het voorspellend vermogen van botmineraaldichtheid (B:r.,.'fD). De 
invloed van anderc. nict aan de botclichthcid gerelateerde indicatoren wcrd in 
beschouwing genomen door leeftijd te gebruiken als een surrogaatindicator. 
Hi\,lD is de meest gebruikte indicator voor het risico op fracturen. en vooral de B:r..JD 
gcmeten ter hoogtc van de femurhals blijkt sterk gerelateerd te zijn aan het risico op een 
heupfractuur. In de internationale literatuur wordt het, voor de leeftijd gecorrigcerde, 
relatief risico op een heupfractuur bij vrauwen geschat op 2.6 per standaard deviatie 
vermindering van de Hi\,lD gemeten aan de femurhals. Binnen het ERGO-onderzoek 
konden we deze schatcing bevestigen, ruet alleen bij vrouwen maar ook bij mannen. 
illet dit geschatte relatieve risico, Nederlandse incidcntie gegevens en de Bn'ill verdeling 
binnen het ERGO cohort hebben we thcorctische risicofuncties afgeleid die het cen-jaars 
cumulacieve risico op een heupfractuur geven naar leeftijd, geslacht en Hj\'fD. 
Vervolgens hebben we, binnen het praspectieve deel van het ERGO-onderzoek, deze 
functies gevalideerd ten aanzien van hun voorspellend vermogen voor heupfracturen 
(hoofdstuk 2.2). De meerderheid van de heupfracturen (61 van de 110) kwamen 
inderdaad voor bij de hoogrisico groep, ofwel hij de gei'nstitutionaliseerde deelnemers in 
verpleeg- en verzorgingshuizcn, oak al maakten dezc grocpen samen maar 14 % uit van 
de onderzoekspopulatie. Bij de niet-gcYnstitutionaliseerde declnemers bestond de hoog 
risico graep vooral uit personen van 70 jaar en ouder, en ook vooral uit vrouwen. De 
groepen met een laag of gemiddeld risico identificeerden een belangrijk ded van de 
bevolking waarbij we een lage incidentie van heupfracturen vaststelden, zdfs op de 
leeftijd van 80 jaar en ouder. Een kleinere groep van personen met een haag risico op 
een heupfractuur kon correct gedetccteerd worden met onze risicofuncties. 
Hieruit condudeerden we dat rut risicomodel accuraat de incidentie van heupfracturen 
kan voorspellen in deelgroepen van de bevolking. De risicofunctie werkte adequaat oyer 
een periode van 4 jaar, zowel bij mannen als bij vrouwen. Een verdere follow-up is nodig 
om het voorspcllcnd vermogen over langere periodes te valideren. 
1\ls extra instmment om het risico op een heupfractuur in tc schatten in de dagelijkse 
praktijk, hebbcn we op basis van onze risicofuncties een nomogram gcmaakt waarap 
gemakkelijk is af te lezen wat het een-jaars risico is gebaseerd op Iceftijd, geslacht en 
BMD. Deze tisicofuncties werden ontwikkeld met gegevens yan cen Lunar DPX-L 
densitometer. \Y/e hebben ze oak geconvertcerd voor gebruik met andere densitometers. 
Ben vast afkappunt voor de BMD lijkt wcinig waarde te hebben om bij individuen een 
heupfractuur te voorspellcn wanneet de leeftijd buiten beschouwing blijft (hoofdstuk 
2.3). Onze risicofuncties die zowclleeftijd als BMD gebruiken geven meer klirusch 
relevante informatie dan de in de praktijk gcbruikelijke T - en Z-scores. Een afkappunt 
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van 0.5 % ccn-jaars risico resulteerde in zowel een hoge seositiviteit als een hoge 
specificititeit, en illt is daarom potentieel eeo interessante en klinisch relevant afkappunt. 
DEEL 3: HET MODELLEREN VAN PRRVENTIE 
In twee aparte modeilen hebben we het 'life-time' fisico op heupfracturen gemodeileerd 
uitgaande van de genoemde risicofuncties met de aanname dat de B:~ ... ID lineair afneemt 
met de leeftijd en met een perfecte correlatie in de tijd. Het gemiddelde 'life-time' fisico 
voor cen 55-jarige vroU\v \verd geschat op 13.3 %, vcrgelijkbaar met vroegere schattingen 
van andere onderzoekers. \Vfe hebben bovendien het belang geevalueerd van specifieke 
Bl'vJD afkapwaarden voor het 'life-time' risico. \\fanneer Z-scores werden gebruikt bleef 
het 'life-time' risico op een heupfractuur gelijk op aile leeftijden. De reden hiervoor is dat, 
alhoewel het risico op een heupfractuur exponentieel stijgt met de leeftijd, dit 
tegengegaan wordt door cen vergelijkbare stijging van de sterfte met de leeftijd. Hierbij is 
de verhouding tussen het risico op een heupfractuur en het sterftefisico stabiel over aile 
leeftijden. Een T -score daarcntegen is een vaste afkappunt en daarom was het 'life-time' 
risko veel hager bij een lage T -score op jonge leeftijd. 
Vervolgens namen we aan dat de daling van de Bl\.JD niet gelijk is bij aile personen en dat 
de corrclatie tussen BI\,ID nu en Bl'vfD in de toekomst ruet perfect zal zijn. \Vanneer we 
dit fenomeen in beschoU\ving namen steeg het 'life-time' risico licht hij dalende 
correlatie. \Y/e kwamen bovendien tot de conclusie dat het 'life-time' risico op een 
heupfractuur behoorlijk overschat wordt hij vrouwen met cen hoog risico wanneer we dit 
fenomeen niet in beschouwing nemen. Bij vrouwen met een gemiddeld of een laag risico, 
daarentegen, wordt hct risico onderschat. Het voorspellend effect van screening op een 
vroege leeftijd zal dus overschat worden indicn we hiermee geen rekening houden. 
\Y./e simuleerden theoretische interventies die aanleiding geven tot een risicoreductie van 
respectievclijk 20 % en 50 %. Bi; het simuleren van deze interventies vonden we dat met 
het meest optimistische scenario dat 'life-time' interventie koppelt aan 'life-time' 
effectiviteit met 50 % risico reductie, slechts 44 % van de heupfracturen vermeden kan 
worden, ook al wordt deze intervcntie aan iedereen gegeven vanaf 55 jarige leeftijd (dc 
bevolkingsstrategie). Om dit te doen zijn echter 500 behandelingsjaren nodig voor elke 
vermeden heupfractuur, wat aileen een optie kan zijn voor een bchandcling die erg 
goedkoop is. 
\,'anneer we dezclfde interventie op latere leeftijd toepassen verbetert de 
kosteneffectivitcit aanzienlijk. Op de leeftijd van 70 jaar 7,ijn er voor de preventie van een 
heupfractuur slechts 250 behandelingsjaren nodig, tenvijl tach nag 35 % van de 
heupfracturen vermeden kan worden. 
1\ls voorbeeld van cen mogelijke screerungsstrategie gebruikten we afkappunten voor de 
Z-score en de T-score. Hct grootste aantal heupfracturen werd vermeden door gebruik te 
maken van een Z-score voor de leeftijd van 70 jaar en door gebruikt te maken van de T-
score na die leeftijd. Dit reflecteert uiteraard het fcit dat rand de Jeeftijd van 70 jaar beide 
afkappunten correspondcrcn met dezelfde Bl\'ID. De kosteneffectiviteit van screening 
was veel beter dan voor de algemene interventie zonder screening, maar toch was ook 
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hier de kosteneffectiviteit veel betcr op hogere Iceftijd. Het verschil in kosteneffectivitcit 
tussen bcide screeningsbenaderingen was gering. 
1vlet het meer rcalistische scenario waarbij uitgegaan wordt van een behandelingspcriode 
van 5 jaar die gevolgd wordt door een periode van 5 jaar waarbij het effect van de 
behandeling uitdooft, steeg de effectiviteit van de interventie met de lceftijd en bereikte 
een optimum rond de lecftijd van 80 jaar. Zowel bij de algcmene bcvolkingsbenadcring 
als in het screeningsscenario werd dit optimum bereikt op dezclfde leeftijd. Het effect 
van deze interventie kort nn de menopauze was zclfs verwaacloosbaar. Opnieuw nam de 
kosteneffectiviteit toe met de leeftijd en was deze beter in de screeningsscenarios dan in 
de algemene bevolkingsbenadering. 
Bij alle bestudeerde interventies werd het verschil in kosteneffectiviteit tussen de 
screenings- (hoogrisico) en de algcmene bevolkingsscenarios rclatief klein na de leeftijd 
van 80 jaar. Het valt daarom te verwachten dat, indien de kosten voor screening hoog 
zjjn, of wanneer screening moeilijk te organiseren is zoals voor verpleeghuisbewoners, 
een interventie zonder screening bet beste alternatief is op deze leeftijd. 
Uit de gevoeligheidsanalyse bleek dat de assllmpties over de uitdoving van het 
beschermend effect belangrijk zijn. \\'anneer wc veronderstellen dat het effect 10 jaar 
aanwezig blijft in plaats van 5 jaar, worden mecr heupfracturen vermcden en ligt het 
optimum van de interventie op een iets jongcre leeftijd. W'anncer daarentegen het effect 
onmiddellijk stopt bij het staken van de inten'entie worden er minder fracturen 
vermeden en moet er zo laat mogelijk behandeld worden. 
\Vanneer we ervan uitgaan dat het verIoop van de BlVID bij het verouderen niet perfect 
voorspeld kan \vorden verandert er niets aan de efficieotie van de algemene 
bevolkingsintenTenties, maar de efficientie van de screening beoaderingen vermindert 
sterk, vooral op lagere leeftijd. Dit is opnieuw een argument am screening en interventie 
llit te stellen tot latere leeftijden. 
De preventie van fracturen is indcrdaad ingcwikkeld. Over het algemeen lijkt een 
scenario waarbij een hoogrisico groep behandeld wordt kosteneffectiever dan een 
bevollcingsbenadering, maar het verschil tussen beide benaderingen \vordt klein op 
hogere leeftijd. De kostencffectiviteit van interventies vcrbetert ook \vanneer ze wordt 
toegepast op latere Iecftijd. Een optimale, en hopelijk kostencffcctieve strategie, zal 
waarschijnlijk cen combinatie zijn van verschillcnde intenTcnties die elk gericht zijn op 
een specifieke doelgroep met een eigen risicoprofiel. Het belangrijkste doel van dit 
onderzoek was het olltwikkelen van hulpmiddelen am dezc strategic te ontwerpen. Bij 
het begin van dit onder7.oek hadden \ve een cenvoudige vraagstclHng: wie moet 
behandeld worden, en wanneer en hoc moet dit gebeuren? ~let de door ons ontwikkelde 
modcllen hebbcn we bet kader geschetst am deze vragen te beantwoorden voor elke 
inten'eorie die overwogen wordt. 
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DANK\'(IOORD 
Het is 20ver, het bockje ligt cr, en dat is zeker oiet alleen mijn vcrdienste. i\1ijn oprechte 
dank gaat uit nant allen die hicman, direct of indirect, hebben bijgedragen. r..Taar, hoewel 
ik hiermee het gevaar loop iemand te vergeten, wiI ik tach graag enkclc personen heel 
specifiek bedanken. 
Huib (,grate Huib,), tacn ik je vOOf het eerst ontmoctte begreep ik dat je iemand bent die 
voorzichtig maar vastheraden naar het doel kan gaan. Je hebt me op je eigen typischc 
marner overtuigd om dit onderzoek tc docn. lk ben blij dat ik al die jarcn met jou heb 
kunnen samcnwcrken en dat we daarbij oak vricnden zijn gewordcn. Ik hoop dat deze 
samenwerking nag lang duurt en dat jc me daarbij blijft aansporen de biologic oak af en 
toe cen kans te geven tc midden van het computergewcld. 
Bert. toen eind 1994 de onderzoeker van dit onderzoeksproject vertrok vroeg jij mij of ik 
gdnteresseerd was om het over te nemen, oak al wist je dat ik niet op zoek was naar dit 
soort werk. Ik zci uitcindelijk toch ';a' en ik heb er nooit spijt van gehad. 
Ben, onze samenwerking begon moeilijk maar ik heb redelijk snel je gebruiksaanwijzing 
gevonden en na een paar maanden verliep het uitstekend. Ik heb ontzettend veel van jou 
geleerd en je hebt me bellOed voor ontclbare £Iaters. 
Frans. vanaf het begin was je bij dit project betrokken als promotor, maar uitcindelijk heb 
je Ben naar voren geschoven. Het werd inderdaad een beetje dringen, en ik stclde het erg 
op prijs. Sinds ik bij jou werk, heb ik wei ondenTonden hoe goed je bn delegeren. 
John. from the beginning of my work in the field of Osteoporosis your name \vas 
familiar to me from scientific literature. Later on I have come to know you more 
personally and I have learned a lot from our discussions. I am honored that you have 
accepted to be a member of this promotion committee. 
Robert, als voorzitter van het UPT Verouderingsvraagstukken was jij officieel mijn 
werkgever. Je hebt je al die jaren erg betrokken getoond bij het goede verloop van het 
onderzoek, en het contact met onderzoekers van andere faculteiten was stimulerend. Ik 
ben blij dat je nu oak bij de promoue zelf betrokken bent. 
Paul en Huib ('kIdne Huib'), mijn twee kamergenoten bij het begin van dit project. Jullie 
hebben me ingewijd in de geheimen van de epidemiologic van osteoporose en ik weet dat 
ik uren van jullie tijd heb verbruikt met mijn ontelbare vragen. Jullie hebben natuurlijk 
ook wraak genomen door op het enige moment in die drie jaar dat we moesten verhuizen 
samen te vertrekken naar Australie voor een Cotlgres. Maar ik had na 8 jaar bij IBn-f veel 
ervaring met het verhuizen en ik heb de gelegenheid gebruikt am ontzettend veel troep 
weg te gooien. Ge1ukkig heeft niemand die ooit gemist. 
Paul ging na 1 jaar al weg, maar Buib was 20 vriendelijk te blijven tot ik oak wegging. 
Gedurende die tijd was het erg prettig am met jou de meest absurde ideecn te bedenken, 
ze meestal oak weer te vcrwerpen, maar heel af en toe kwam er tach iets bruikbaars uit. 
Bedankt oak dat je bij dat kIeine grocpje Rotterdamse BV's hoorde,' zodat we niet aIleen 
in de witte toren deze gesprekken hebben gevoerd. Overigens oak nag onze 
gezamenlijke dank aan dr. nIoortgat en aan dr. De Koninck voor hun creatieve hulp. 
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Angelique, jij hvam pas later bij het clubje en bovendien had je in het begin erg veel werk 
buiten de afdding. Ik vrees dat het in die beginperiode soms lastig voor je was waoneer 
Huib en ik weer eens heftige gesprekken voerden, maar je hoorde er al sncl helemaal bij. 
Ik vind het erg leuk am met jOll samen te werken. 
:r\ilarianne, jou heb ik pas laat beter leren kennen. Nu we aan dezelfde projecten werken 
en daarbij dezelfde kastelen bezocken heb ik jouw manier van werken erg leren 
waarderen, en oak het feit dat je me, in de aanloop naar dit proefschrift, zoveel met rust 
hebt gelaten en zovee! in mijn plaats hebt gedaan. Ik hoop dat we nag lang en goed 
kunnen samenwerken op het terrein van de 'suggestions for further research'. 
Anu, Alejandro, Alexei, Rueben, Jama, Sara, and the other NIHES fellows, the year we 
spent together at the ~{aster of Science course is unforgettable. Especially for an older 
boy, this direct contact with a bunch of eager young people that were fascinated by the 
same scientific spirit was a unique experience. Now, when everybody is spread out over 
the \vorId again, we are still good friends. Thanks to the Net. 
Hanne, Peter, Pascale en l ... larc, mijn ex-collega's bij Lasion. Toen ik daar vertrok wisten 
jullie oak dat het zeker niet omwille van de collega's was. Het was een sprong in het 
onbekende en jullie hebben me, ieder op jullie eigen manier, prima ondersteund bij dit 
proefschri ft. 
Een speciale dank gaat verder uit naar J\-1aiwenn. Dankzij het voorbecldprogramma dat 
zij schreef in Turbo-Pascal kon ik een vliegende start nemen bij het programmeren van 
de simulatiemodellen. Patrick en Hilde leenden me de antieke schrijfmachine die ik nodig 
had am de standaardformulieren voor deze promotie in te vullen. 
Beide paranimfen werden a1 genoemd, maar tach nag cens extra bedankt dat jullie dit 
voor mij willen doen. 
Erna, met jou heb ik dit wilde idee am een leuke en goedbetaalde baan in te rullen voor 
een onzeker hestaan in de wetenschap voor het eerst besproken. Wle wisten toen niet 
waar we beiden, nu meer dan 7 jaar later, zouden staan, maar de vcle gesprekken die ik 
met jOll hierover gevoerd heb, hebben me enorm geholpen am de juiste keuze te maken. 
Ik hoop dat je hier vandaag aumvezig kan zijn. 
En dan is er natuurlijk het gain, en dat hceft me erg goed geholpen am ailes tach maar 
te relativeren. Hannah kan het nag niet :w goed verwoorden, maar toen ik Lisa trots 
vertelde dat een artikel van mij gepubliceerd was in de B.i\lj vroeg ze me nuchter, HEn ... , 
ben je nu berocmd ?" 
Rita, bcdankt voor je geduld, en voor al de rest. 
Mijn moeder is helaas veel te vroeg gestorven. Ze zou ape trots zijn ge\vcest. 
1 BV: 'Bon Vivant'. AranaA,Rotterdam 1994. 
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